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I. Erratum 
 
The aim of this erratum is to summarise the inconsistencies between data presented in 
this PhD thesis and the raw data that it is based upon. References to tables and figures 
in the PhD thesis will be made in the form of “Thesis Table” and “Thesis Figure” to 
avoid confusion with tables shown in this erratum. File names mentioned reference to 
files found in Noor Esoof’s folder on the MRC group folder network drive 
(“smb://mrc-smb.lifesci.dundee.ac.uk/mrc-group-folder/Noor Esoof”). 
 
Thesis Figure 4.1 and Thesis Table 4.1 
 
It has now been established that the raw data used for Thesis Figure 4.1 and Thesis 
Table 4.1 are different from what is reported in the PhD thesis.  Conclusions drawn 
from Thesis Figure 4.1 and Thesis Table 4.1 are thus misleading. Thesis Figure 4.1 
describes the use of two different anti-TTBK2 antibodies in the same experiment to 
conduct separate immunoprecipitations that lead to the results summarized in Thesis 
Table 4.1. The sources identifying the raw data used for this analysis, which also 
matches with the gel image used as Thesis Figure 4.1, are (a) a word document (file 
name “NEsoof 110624 MFP b.docx”), used for submission of the samples to the 
MRC mass spectrometry (MS) facility and (b) the actual MS measurements saved on 
a central server.  The word document states: “Aim of Project is to identify proteins 
that co-immunoprecipitate with [sic] endogenous TTBK2 and TTBK1”. The gel 
image in the submission form (the same image used in the thesis as Thesis Figure 4.1) 
is labelled with ‘TTBK1’ and ‘TTBK2’ above the respective gel lanes. These 
observations are consistent with the idea that the experiment in Thesis Table 4.1 used 
antibodies raised against TTBK1 and TTBK2, rather than 2 different antibodies 
against TTBK2.  
 
As shown in Table 1, the samples from the lane labelled ‘TTBK1’ contained 
consistently more TTBK1-related peptides than TTBK2-related peptides. As the well 
samples from the lane labelled ‘TTBK2’ contained more TTBK2-related peptides 
than TTBK1-related peptides, this is also suggests that the experiment used separate 
antibodies raised against TTBK1 and TTBK2, which means that Thesis Figure 4.1 has 
been mislabelled.  
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 TTBK1 lane TTBK2 lane 
TTBK1 peptide count 
[#sample - total (unique)] 
#35 – 143 (65) 
#36 – 49 (17) 
#37 – 0 
#38 – 0 
#39 – 0 
#40 – 0 
#41 – 0 
#42 – 0 
#43 – 2 (1) 
#44 – 6 (4) 
#45 – 6 (2) 
#46 – 0 
#47 – 0 
#48 – 0 
#49 – 0 
#50 – 0 
TTBK2 peptide count 
[#sample - total (unique)] 
#35 – 16 (9) 
#36 – 0 
#37 – 0 
#38 – 0 
#39 – 0 
#40 – 0 
#41 – 9 (1) 
#42 – 0 
#43 – 12 (8) 
#44 – 48 (20) 
#45 – 24 (10) 
#46 – 0 
#47 – 5 (2) 
#48 – 5 (1) 
#49 – 0 
#50 – 0 
Table 1: Raw data from MS submission form "NEsoof 110624 MFP b.docx". The data is formatted as 
“sample number – total peptides (unique peptides)”. 
 
 
Furthermore, only the data from the column “TTBK2 Ab1” are found in the file 
“NEsoof 110624 MFP b.docx”. The other column of Thesis Table 4.1 labelled 
“TTBK2 Ab2” corresponds to data found in experiment “NEsoof 110728 MFP 
b.docx”. The timestamp used in the file names shows that these two experiments were 
conducted over a month apart (24th of June 2011 versus 28th of July 2011). The thesis 
links all data in Thesis Table 4.1 to Thesis Figure 4.1, therefore use of the data in 
“NEsoof 110728 MFP b.docx” without addressing the different sources is 
inappropriate. A correct presentation of data would be to show only the lane labelled 
“TTBK2 Ab1” of Thesis Figure 4.1 with a gel image representative of experiment 
“NEsoof 110728 MFP b.docx” next to it, while also addressing the fact that these are 
independent experiments.  
 
On page 117, the PhD thesis describes how non-specific interacting proteins were 
filtered out by use of the IgG control samples. Thus, the peptides belonging to key 
protein interaction partners that were further investigated, such as SV2A and 
Synaptotagmin-1, should not appear in the IgG samples of these experiments. As 
 IV 
shown in Table 2, the IgG lane samples of experiment “NEsoof 110624 MFP b.docx” 
contain a substantial number of both SV2A and Synaptotagmin-1 peptides. Thus, 
without additional experimental evidence and explicit justification, neither one of 
these proteins should have been selected for further experiments as being strong 
candidates for specific TTBK2 interaction partners, which has implications for all 
data presented in the PhD thesis thereafter.  
 
NEsoof 110624 MFP b SV2A 
(in IgG lane) 
Synaptotagmin-1 
(in IgG lane) 
peptide count 
[#sample - total (unique)] 
#27 – 0 
#28 – 37 (30) 
#29 – 22 (15) 
#30 – 0 
#31 – 0 
#32 – 0 
#33 – 0 
#34 – 0 
#27 – 0 
#28 – 0 
#29 – 58 (32) 
#30 – 0 
#31 – 8 (3) 
#32 – 0 
#33 – 0 
#34 – 0 
Table 2: Raw data from MS submission form "NEsoof 110624 MFP b.docx". Data is taken from the IgG lane 
samples and is formatted as “sample number – total peptides (unique peptides)”. 
 
Similar conclusions can be drawn for the IgG lane samples of experiment “NEsoof 
110728 MFP b.docx”, as shown in Table 3. In this case no peptides for 
Synaptotagmin-1 were detected in the IgG control, but also here multiple SV2A 
peptides have been measured. 
 
NEsoof 110728 MFP b SV2A 
(in IgG lane) 
Synaptotagmin-1 
(in IgG lane) 
peptide count 
[#sample - total (unique)] 
#33 – 0 
#34 – 0 
#35 – 24(17) 
#36 – 0 
#37 – 0 
#38 – 0 
#39 – 0 
#33 – 0 
#34 – 0 
#35 – 0 
#36 – 0 
#37 – 0 
#38 – 0 
#39 – 0 
Table 3: Raw data from MS submission form "NEsoof 110728 MFP b.docx". Data is taken from the IgG lane 
samples and is formatted as “sample number – total peptides (unique peptides)”. 
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Thesis Table 4.8!
 
The raw data used for Thesis Table 4.8 is derived from two separate experiments. 
Columns titled “NP1”, “pS42”, “pS45”, “pS47”, “pS42+pS45”, “pS42+pS47”, 
“pS45+pS47” are derived from data linked in file “NEsoof 120823 
MFP_peptide_pulldown.docx”. The data in the column titled “pS42+pS45+pS47” are 
also linked to the same word document, but the link has been altered to point to data 
from a different experiment. The timestamp in the filename dates the file to the 23rd of 
August, 2012. The last modification of the file recorded occurred on 9th of April 2014. 
The altered link points to the data in file “NEsoof 120801 MFP.docx”, sample 02, 
marked as “S45 peptide”. As the column of the data this link replaced is titled 
“pS42+pS45+pS47”, this is unlikely to be an independent replicate put into this table, 
but instead a different experiment performed with differing conditions on a different 
date (23rd of August 2012 versus 1st of August 2012). 
 
The potential interaction partner listed at the top, “Spectrin beta chain, brain 2” is 
mixed up with a different Spectrin protein isoform. The raw mass spec data show the 
entry corresponding to the listed MASCOT scores and peptide counts as follows: 
“sp|Q62261|SPTB2_MOUSE (…) Spectrin beta chain, brain 1 OS=Mus musculus 
GN=Sptbn1 (…)” 
 
This shows that the full name of the correct protein is actually “Spectrin beta chain, 
brain 1”, and the gene identifier is “Sptbn1”, not “Sptbn2” as stated in Thesis Table 
4.8. 
 
 
Thesis Page 164 
 
The PhD thesis page 164 states: “SPTBN2 was not present in pull-downs with NP1 or 
singly-phosphorylated peptides”. As shown in Thesis Table 4.8 there are 10 peptides 
for SPTBN2 detected in sample NP. Therefore the quoted statement is incorrect. 
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Thesis Table 4.10 
 
The data in Thesis Table 4.10 is based on samples in the submission form “NEsoof 
120823 MFP_peptide_pulldown.docx” and the reported MASCOT scores for the 
listed proteins are correct in the different samples. However, the legend of Thesis 
Table 4.10 states: "Comparisons are shown only for proteins identified with a 
MASCOT score of 400 or more." This suggests that only the most abundant proteins 
in the experiment, above a certain threshold, are reported. This description is incorrect 
as, for example, the line for SYT1 in the column for sample “pS80+pS81+pT84” 
shows a MASCOT score of 157 and should therefore not have been included in 
Thesis Table 4.10 according to the selection criteria stated in the figure legend.  This 
is also the case for protein NEFM with MASCOT scores below 400.  
 
In addition, the raw data corresponding to the samples in submission form “NEsoof 
120823 MFP_peptide_pulldown.docx” contain many more protein hits with 
MASCOT scores greater than 400 that are not listed in Thesis Table 4.10. Therefore, 
this table not only lists proteins that do not fit the stated selection criteria, but also 
omits proteins that should have been reported, according to the selection criteria 
stated in the figure legend.   
 
Thesis Figure 4.16 
 
The Spectrin protein listed in Thesis Table 4.8, SPTBN1, was misidentified as 
SPTNB2. This also means that the wrong antibody was used for its detection in 
Thesis Figure 4.16, listed as “SPTBN2, ab58234” on PhD thesis page 65 in the 
“Materials and Methods” chapter. The detection of STPBN2 protein in whole cell 
lysate (labelled “input” in Thesis Figure 4.16) has, so far, not been reproduced by 
other members of the Alessi lab using the materials described in the PhD thesis. The 
major band detected by the SPTBN2 antibody is detected just below the 100 kDa 
marker, while the SPTBN2 band shown in Thesis Figure 4.16 and Thesis Figure 4.17 
is detected at around 250 kDa. All SPTBN2 blots may therefore be incorrect. 
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IV. List of Abbreviations 
 
Ach   Acetylcholine 
ADCA   Autosomal dominant cerebellar ataxia 
AFG3L2   ATPase family gene 3-like 2 
AGC     Kinase group containing PKA, PKC and PKG. 
AMP   Adenosine Monophosphate 
AP2    adaptor-related protein complex 2 
APS    Ammonium persulfate 
ATP   Adenosine Triphosphate 
ATN1    Atrophin 1 
ATXN   Ataxin 
BSA   Bovine Serum Albumin 
CACNA1A   Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
CamK2a   Ca2+/calmodulin-dependent protein kinase II 
cAMP   cyclic adenosine-3', 5'-monophosphate 
CBB    Coomassie brilliant blue 
CD   Circular dichroism 
CDK   Cyclin-dependent kinase 
CH    Calponin homology 
CK1    Casein kinase 1 
CLK   CDC2-Like kinase 
cpm   Counts per minute 
C. elegans  Caenorhabditis elegans 
cpm   Counts per minute 
CSP    Cysteine string protein 
Da   Dalton 
DMEM  Dulbecco's Modified Eagle's Medium 
DMP   Dimethyl pimelimidate 
DNA   Deoxyribonucleic acid 
DRPLA   Dentatorubral-pallidoluysian atrophy 
DSTT   Division of signal transduction therapy 
DTT   Dithiothreitol 
E. coli   Escherichia coli 
 XI 
ECL   Enhanced chemiluminescence 
EDTA   Ethylenediamine tetra acetic acid 
EF    Calcium-binding motifs composed of two helixes (E and F) joined by a loop. 
EGTA    Ethyleneglycol bis (2-aminoethylether)-N, N-tetra acetic acid 
ER    Endoplasmic reticulum 
Erk   Extracellular signal-regulated kinase 
FBS   Foetal bovine serum 
FGF    Fibroblast growth factor 
FP    Fluorescence polarisation 
GABA   γ-aminobutyric acid 
GFP   Green fluorescent protein 
GSK   Glycogen synthase kinase 
GST   Glutathione S-transferase 
HDL-4   Huntington’s disease-like 4 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HEK293  Human embryonic kidney 293 
HPLC   High performance liquid chromatography 
HSP70   70 kDa Heat shock protein 
HSR    Heat shock response 
IgG   Immunoglobulin G 
IHPS    Inositol high-polyphosphate series 
IP6    Inositol hexaphosphate 
ITC    Isothermal titration calorimetry 
ITPR1   Inositol 1,4,5-trisphosphate receptor, type 1 
KCNC3   Voltage-gated potassium channel subunit Kv3.3 
KD    Kinase-dead 
KLH    Keyhole limpet hemocyanin 
LB   Luria broth 
MALDI  Matrix-assisted laser desorption ionisation 
MAP    Microtubule-associated protein 
MAPK   Mitogen-activated protein kinase 
MEF   Mouse embryonic fibroblast 
MEM    Minimum essential medium 
mGluR1   Metabotropic glutamate receptor type 1 
 XII 
mRNA   Messenger ribonucleic acid 
MS/MS  Tandem mass spectrometry 
NMD   Nonsense-mediated decay 
NMR    Nuclear magnetic resonance 
NOE    Nuclear Overhauser effect 
NSF   N-ethylmaleimide sensitive factor 
N-terminal  Amino-terminal 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PDK1   3-phosphoinositide-dependent kinase 1 
PH   Pleckstrin homology 
PI3K   Phosphoinositide 3-kinase 
PKA   Protein kinase A (cAMP-dependent protein kinase) 
PKB   Protein kinase B (also known as Akt) 
PKC   Protein kinase C 
PLEKHG4   Pleckstrin homology domain-containing, family G member4 
PMSF   Phenylmethanesulphonylfluoride 
PP2    Protein phosphatase 2 
PP2R2B   Protein phosphatase 2, regulatory subunit B, beta 
PRKCG   Protein kinase C gamma type 
PSPL   Positional scanning peptide library 
ROS   Reactive oxygen species 
rpm   Revolutions per minute 
SCA    Spinocerebellar ataxia 
SCAMP   Secretory carrier-associated membrane protein 
SNARE  Soluble NSF attachment receptor 
SPR   Surface plasmon resonance 
SPTBN2  β2-spectrin 
SH3    Src homology 3 
SUMO   Small ubiquitin-like modifier 
SV2   Synaptic vesicle glycoprotein 2 
SVOP    SV2 related protein homolog 
TEMED   Tetramethylethylenediamine 
TFA   Trifluoroacetic acid 
 XIII 
TK   Thymidine kinase 
TBP    TATA-binding protein 
TTBK1  Tau tubulin kinase 1 
TTBK2  Tau tubulin kinase 2 
UPR    Unfolded protein response 
UPS    Ubiquitin-dependent proteasome system 
VAMP   Vesicle associated membrane proteins 
WT    Wild-type 
 
 XIV 
V. Amino acid code 
Amino acid or residue  Three letter symbol       One letter 
                                                                                                                    symbol 
Alanine    Ala    A 
Arginine     Arg     R 
Asparagine     Asn     N 
Aspartate     Asp     D 
Cysteine     Cys     C 
Glutamate     Glu     E 
Glutamine    Gln     Q 
Glycine     Gly     G 
Histidine    His    H 
Isoleucine    Ile    I 
Leucine     Leu     L 
Lysine     Lys     K 
Methionine     Met     M 
Phenylalanine    Phe    F 
Proline     Pro    P 
Serine     Ser    S 
Threonine    Thr    T 
Tryptophan    Trp    W 
Tyrosine    Tyr    Y 
Valine        Val                             V 
Any amino acid          Xaa    X 
!
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VI. Summary 
 
TTBK2 was first identified based on its physical association with microtubules and its 
ability to phosphorylate microtubule-associated proteins (tau, tubulin, MAP2) in vitro 
(Takahashi et al., 1995, Tomizawa et al., 2001). Since this discovery by Japanese 
scientists in 1995, considerable work has been invested in examining TTBK2’s 
relationship with aberrant tau phosphorylation and neurodegeneration in Alzheimer’s 
disease. However, these studies have never been substantiated in vivo.  
 
The identification of TTBK2 truncating mutations as the cause of spinocerebellar 
ataxia type 11 (SCA11), in 2007, emphasised that TTBK2 has a prominent 
physiological role in the nervous system. When I started my PhD, there was little 
known about TTBK2 and many fundamental questions about TTBK2 remained 
unanswered.  
 
In Chapter 3, I describe an initial analysis of TTBK2 substrate specificity by using an 
unbiased positional scanning peptide library and show that it has a conspicuous 
preference for a phosphotyrosine residue at the +2 position relative to the 
phosphorylation site. This information was then exploited to develop an optimised 
peptide substrate, named TTBKtide, to assess TTBK2 catalytic activity. TTBKtide 
was used to demonstrate that SCA11 truncating mutations lead to marked inhibition 
of TTBK2 kinase activity. 
 
The identification of TTBK2’s interacting proteins was of paramount importance to 
advance our understanding of both biological and disease processes. Identifying and 
characterising the key targets (substrates) of TTBK2 in the nervous system would 
provide vital new insights into the physiological role of TTBK2, which in turn, may 
uncover the molecular pathogenic mechanism underpinning the development of 
spinocerebellar ataxia type 11 (SCA11). To this end, I identified a number of TTBK2 
interactors by co-immunoprecipitation of endogenous TTBK2 from mouse brain 
homogenates (Chapter 4). This screen provided tantalising evidence that TTBK2 
operates in a distinct step of the synaptic vesicle cycle. An analysis of potential 
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protein substrates identified synaptic vesicle glycoprotein 2A (SV2A) as a substrate of 
TTBK2. Phosphopeptide mapping revealed that SV2A is phosphorylated at two 
clusters of three highly-conserved residues by TTBK2. These two phosphorylation 
clusters were then shown to mediate the phospho-dependent interactions of SV2A 
with AP2 clathrin adaptors, β2-spectrin and synaptotagmin 1. 
 
SV2A and synaptotagmin 1 are both synaptic vesicle membrane proteins. Their 
interaction is both physical and functional. In chapter 5, I describe the characterisation 
of the SV2A/synaptotagmin 1 interaction using biophysical and functional methods. I 
have used two different biophysical methods: Isothermal titration calorimetry (ITC) 
and fluorescence polarisation, for quantitative analyses of the SV2A/synaptotagmin 1 
phosphospecific interaction. Also, in collaboration with Prof. Michael Cousin’s 
laboratory (University of Edinburgh), the role of SV2A phosphorylation and the effect 
of disrupting the SV2A/synaptotagmin 1 interaction were examined via mutagenesis 
and optical imaging of pHluorin-tagged proteins in cultured neurons from wild-type 
mice. 
!
!
!
!
!
!
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1 General Introduction 
1.1 Signal transduction in the brain 
 
The human brain is an organ of staggering complexity. This jelly-like mass of tissue, 
weighing in at around 1.4 kilograms, contains approximately 86 billion nerve cells, or 
neurons (Herculano-Houzel, 2009) and an equal or slightly greater number of 
neuroglia (or glial cells) which serve to support and protect the neurons. Each neuron 
consists of a cell body, dendrites, and an axon (Figure 1.1). The cell body contains the 
nucleus and cytoplasm. The axon extends from the cell body and often gives rise to 
many smaller branches before ending at nerve terminals. Dendrites extend from the 
neuron cell body and receive messages from other neurons.  
 
All brain functions involve changes in the efficiency of communication between 
nerve cells via synapses, which are specialised intercellular junctions between 
neurons or between neurons and other excitable cells where signals are propagated 
from one cell to another with high spatial precision and speed. The dendrites are 
covered with synapses formed by the ends of axons from other neurons. 
 
Each of the billions of neurons in the human brain can have up to 10,000 synaptic 
connections. By establishing an ever-changing network of synapses, the brain is able 
to attain the level of functional complexity that underlies human behaviour. The 
formation and withdrawal of synaptic connections between neurons is a dynamic 
process that can be modified by experience. In addition, experience can change the 
efficacy of existing synapses. This constant change in the synaptic communication 
between neurons is called synaptic plasticity and is critical for higher brain functions 
such as learning and memory.  
 
Synaptic transmission is the currency of information exchange in the brain. Each of 
the 86 billion neurons can form thousands of synapses. Each synapse is independently 
regulated and this results in a vastly complex and intricate network. Nevertheless, 
from this apparent chaos emerges this pristine order of information processing by the 
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brain. Understanding the mechanisms that underlie brain activity and function 
remains one of the major challenges of modern science. 
 
 
Figure 1.1. Neurons are cells within the nervous system that transmit information to other nerve 
cells, muscle, or gland cells. Synapses are the contact points where one neuron communicates with 
another. This communication involves the release of neurotransmitters, which diffuse across the 
synapse, and bind to receptors on the surface of the target cell. [adapted from (Byrne, 2013)]. 
 
All the processes of how we react to stimuli, learn and retain information, and how we 
coordinate our movements rely on the complicated networks of neurons that 
communicate with each other and their targets. Knowledge of the molecular 
mechanisms underlying this fast and accurate intercellular signalling across synapses 
has expanded tremendously over the last century but much still remains to be 
discovered. 
 
1.2 Electrical versus chemical transmission 
 
By the early 1930s, it was well accepted that neurons are physically separated from 
one another by a narrow space. Discovering how neurons communicate across this 
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cleft was the major challenge facing neuroscience and would set the stage for the next 
great conceptual leap in the understanding of the nervous system.  
 
A vigorous debate went on from the 1930s through the 1960s as to whether 
communication across the synapses, was electrical or chemical in nature.  The 
electrical school of thought, championed by electrophysiologists, held that the nerve 
impulse or action potential was propagated along the axon to the nerve ending, 
changed the electrical field across the plasma membrane of the postsynaptic cell, and 
thereby produced a physiological response. The chemical school of thought, 
advocated by pharmacologists, believed that when the action potential came down the 
axon to the nerve terminal, it caused the fusion of neurotransmitter-containing 
vesicles with the presynaptic plasma membrane, releasing the neurotransmitter, which 
then diffused across the synaptic cleft and, through activation of a (hypothetical) 
receptor, produced a physiological response.  
 
The chemical school won this debate: over 99% of all synapses in the brain use 
chemical transmission (Figure 1.1). This hotly debated argument between 
physiologists and pharmacologists encompasses one of the key periods in the history 
of neuroscience and is now facetiously referred to as “the war of the soups and the 
sparks” (Valenstein, 2006). 
1.3 Communication between neurons occurs across the synapse 
 
Neuronal information processing requires exquisitely specific and rapid signalling 
mechanisms that must be flexible and easily modified. Neurons communicate 
primarily via the process of chemical synaptic transmission at a specialised site, the 
synapse. Synapses are specialised intercellular junctions between neurons and other 
excitable cells where signals are propagated from one cell to another with high spatial 
precision and speed.  
 
Synaptic signalling is mediated by a variety of chemical neurotransmitters that carry a 
signal from the presynaptic to the postsynaptic neuron. Independent of the 
neurotransmitter type, the same fundamental mechanisms are used at all synapses: 
Neurotransmitters are stored in synaptic vesicles in presynaptic nerve terminals and 
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are released when excitation of a presynaptic terminal triggers vesicle exocytosis. 
Released neurotransmitters then stimulate postsynaptic receptors to complete synaptic 
transmission (Figure 1.1). 
 
The basic feature of a synapse is a close apposition of specialised regions of the 
plasma membranes of two participating cells to form the synaptic interface. On the 
presynaptic side a cluster of neurotransmitter-filled synaptic vesicles is associated 
with the presynaptic plasma membrane (Figure 1.2). On the postsynaptic membrane, a 
thickening of the membrane marks an accumulation of neurotransmitter receptors. 
 
 
Figure 1.2. Visualisation of a synapse. Illustration of a synapse, showing the synaptic vesicles (green) 
packaged with neurotransmitters collected at the active zone ready to fuse and release neurotransmitter 
into the synaptic cleft in response to stimulation by an action potential [Adapted from the Science 
illustration visualisation challenge, (Johnson, 2005)]. 
 
Bernard Katz and co-workers developed the first cellular picture of the mechanism of 
transmitter release in the 1950s, Electrophysiological recordings of the frog 
neuromuscular junctions demonstrated that neurotransmitters are released in discrete 
quanta (Fatt and Katz, 1952). With the advent of electron microscopy, abundant 
membrane-bound organelles were observed in the presynaptic nerve terminal, leading 
to the discovery of synaptic vesicles. These observations resulted in the vesicle 
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hypothesis, which states that a vesicle contains a single quantum of transmitter (Katz, 
1969). This hypothesis was validated when synaptic vesicles were purified and shown 
to contain neurotransmitters (Whittaker, 1968). More sophisticated morphological 
techniques, including the examination of rapidly stimulated nerve terminals, resulted 
in a clearer picture of the flow of membranes in the presynaptic nerve terminal 
(Heuser and Reese, 1973).  
1.4 Synaptic vesicles 
 
Synaptic vesicles are uniformly small (20-nm radius), abundant organelles whose 
only known function is to take up and release neurotransmitters. They are relatively 
simple because only a limited number of proteins fit into a sphere of 40-nm diameter. 
Purified vesicles have a protein:phospholipid ratio of 1:3 with an unremarkable lipid 
composition (40% phosphatidylcholine, 32% phosphatidylethanolamine, 12% 
phosphatidylserine, 5% phosphatidylinositol, 10% cholesterol) (Benfenati et al., 
1989). Calculations suggest that each synaptic vesicle is composed of approximately 
10, 000 molecules of phospholipids and of proteins with a combined approximate 
molecular weight of 5-10 x 103 kDa (Jahn and Sudhof, 1993). Since an average 
protein has a molecular weight of around 50 kDa, synaptic vesicles contain 
approximately 200 protein molecules. Each of the 200 synaptic vesicle proteins must 
have a specific role and all parts must be carefully orchestrated and co-regulated to 
produce a productive outcome. 
 
 
1.5 Neurotransmitters 
1.5.1 What is a neurotransmitter? 
 
Neurotransmitters are chemical signals released from presynaptic nerve terminals into 
the synaptic cleft. The subsequent binding of neurotransmitters to specific receptors 
on postsynaptic neurons (or other classes of target cells) transiently changes the 
electrical properties of the target cells, leading to an enormous variety of postsynaptic 
effects. 
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Over the years, a number of formal criteria have emerged that definitively identify a 
substance as a neurotransmitter. Nonetheless, identifying the neurotransmitters active 
at any particular synapse remains a difficult undertaking, and for many synapses 
(particularly in the brain), the nature of the neurotransmitter is not well established 
(Snyder and Innis, 1979). Substances that have not met all the criteria outlined in 
below are referred to as “putative” neurotransmitters. 
 
1.5.2 Criteria that define a neurotransmitter 
 
In an influential review published in 1958, William Paton set out five criteria that 
must be satisfied before a substance can be considered a neurotransmitter (Paton, 
1958): (1) the enzymes involved in the synthesis of the substance must be present 
within the presynaptic neurons; (2) the substance must be released from the axon 
terminals when the presynaptic fibers are stimulated; (3)  the action of the substance 
when applied to the postsynaptic cells must accurately mimic that seen during normal 
synaptic transmission; (4) a mechanism must be present at the site of synapses to 
terminate the action of the putative transmitter; and (5) the effect of drugs (whether 
agonists and antagonists) on the postsynaptic cells must be the same when the 
putative transmitter substance is applied to the synapse. Since then, a sixth criterion 
has been added to this list by neuroscientists, namely, that the postsynaptic cells must 
bear the appropriate receptors for the transmitter. 
 
The distinctive characteristics of neurotransmitters, compared to other signalling 
molecules, are made clearer by comparison with the actions of the hormones secreted 
by the endocrine system. Hormones typically influence target cells far removed from 
the hormone-secreting cell. This “action at a distance” is achieved by the release of 
hormones into the bloodstream. In contrast, the distance over which neurotransmitters 
act is miniscule. At many synapses, transmitters bind only to receptors on the 
postsynaptic cell that directly underlies the presynaptic terminal (Figure 1.3A); in 
such cases, the transmitter acts over distances less than a micrometre. Even when 
neurotransmitters diffuse locally to alter the electrical properties of multiple 
postsynaptic (and sometimes presynaptic) cells in the vicinity (Figure 1.3B), they act 
only over distances of tens to hundreds of micrometres. While the elongated axonal 
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processes of neurons allow neurotransmitters to be released as much as a metre away 
from the neuronal cell body, these transmitters still act only near the presynaptic site 
of release (Figure 1.3C). 
 
 
Figure 1.3. Localisation of neurotransmitter action. Neurotransmitters in general act either locally 
(A), by altering the electrical excitability of a small region of a single postsynaptic cell, or more 
diffusely (B), by altering the electrical excitability of a few postsynaptic cells. (C) Neurons can exert 
their actions over greater distances by having long axons that locally release neurotransmitters onto 
distant targets. [Adapted from (Purves, 2001)] 
 
1.5.3 Two major categories of neurotransmitters 
 
Acetylcholine (ACh), the first neurotransmitter discovered, was originally described 
as "vagus stuff" in 1921 by Otto Loewi because of its ability to mimic the electrical 
stimulation of the vagus nerve (Sakmann, 1992). It is now known to be a 
neurotransmitter at all autonomic ganglia, at many autonomically innervated organs, 
at the neuromuscular junction, and at many synapses in the central nervous system 
(CNS). By the 1950s, the list of neurotransmitters (defined by the criteria described 
previously) had expanded to include four amines — adrenaline, noradrenaline, 
dopamine, and serotonin — in addition to acetylcholine (ACh). Over the following 
decade, three amino acids — glutamate, γ-aminobutyric acid (GABA), and glycine —
were also shown to be neurotransmitters. Subsequently, other small molecules were 
added to the list, and considerable evidence now suggests that histamine, aspartate, 
and ATP should be included. The most recent class of molecules discovered to be 
transmitters are a large number of polypeptides (neuropeptides). Since the 1970s, 
more than 100 such molecules have been shown to meet at least some of the criteria 
outlined. 
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It is useful to separate this variety of agents into two broad categories based simply on 
their size. Neuropeptides, which include somatostatin and cholecystokinin, are 
relatively large transmitter molecules composed of 3 to 36 amino acids. Individual 
amino acids, such as glutamate and γ-aminobutyric acid (GABA), as well as the 
transmitters acetylcholine, serotonin, and histamine, are much smaller than 
neuropeptides and have therefore come to be called small-molecule neurotransmitters. 
Within the category of small-molecule neurotransmitters, the biogenic amines 
(dopamine, noradrenaline, adrenaline, serotonin, and histamine) are often discussed 
separately because of their similar chemical properties and postsynaptic actions. 
 
By far the most prevalent transmitter is glutamate, which is excitatory at well over 
90% of the synapses in the human brain (Izquierdo et al., 1993). The next most 
prevalent is GABA, which is inhibitory at more than 90% of the synapses that do not 
use glutamate. Even though other transmitters are used in far fewer synapses, they 
may be very important functionally - the great majority of psychoactive drugs exert 
their effects by altering the actions of some neurotransmitter systems, often acting 
through transmitters other than glutamate or GABA. 
 
 
1.5.4 Excitatory and inhibitory neurotransmitters 
 
Some neurotransmitters are commonly described as "excitatory" or "inhibitory". The 
only direct effect of a neurotransmitter is to activate one or more types of receptors. 
The effect on the postsynaptic cell depends, therefore, entirely on the properties of 
those receptors. It happens that for some neurotransmitters (for example, glutamate), 
the most important receptors all have excitatory effects: that is, they increase the 
probability that the target cell will fire an action potential. For other neurotransmitters, 
such as GABA, the most important receptors all have inhibitory effects (although 
there is evidence that GABA is excitatory during early brain development). There are, 
however, other neurotransmitters, such as acetylcholine, for which both excitatory and 
inhibitory receptors exist; and there are some types of receptors that activate complex 
metabolic pathways in the postsynaptic cell to produce effects that cannot 
 9 
appropriately be called either excitatory or inhibitory. Thus, it is an oversimplification 
to call a neurotransmitter excitatory or inhibitory - nevertheless it is convenient to call 
glutamate excitatory and GABA inhibitory so this usage is seen frequently. 
 
1.6 Molecular mechanisms of neuronal signal transduction 
 
On the basis of those initial studies, elucidating the biochemical mechanisms by 
which neurotransmitters, through activation of their receptors, produce their 
physiological effects within their postsynaptic, target nerve cells, would be an 
essential step toward understanding nervous system function. Indeed, the molecular 
mechanisms underlying signal transduction in the nervous system have been the 
subject of intense scrutiny over the past five decades.  
 
Paul Greengard pioneered research in neuronal signal transduction in the 1960s. He 
was inspired by earlier studies carried out by Earl Sutherland and Edwin Krebs, who 
were interested in understanding how the hormones glucagon and adrenaline break 
down glycogen to glucose in liver and muscle cells. Sutherland and his colleagues 
found that these hormones stimulated the formation of cyclic adenosine 
monophosphate (cAMP) from adenosine triphosphate (ATP) by virtue of activating a 
class of enzymes termed hormone-sensitive adenylyl cyclases. Sutherland then 
showed that cAMP could mimic the hormones, causing the breakdown of glycogen to 
glucose (Sutherland, 1972). Krebs and his colleagues subsequently showed that 
cAMP caused the breakdown of glycogen to glucose by activating an enzyme that 
they called cAMP-dependent protein kinase (PKA). Krebs further showed that one 
substrate for PKA, when phosphorylated, was itself an enzyme that caused the 
breakdown of glycogen to glucose. The action of protein kinases is reversed by means 
of enzymes called protein phosphatases. 
 
Greengard’s initial hypothesis was that the same signalling machinery used by the 
endocrine system to break down glycogen to glucose might be used for 
communication between nerve cells. His team searched the brain for signalling 
enzymes analogous to those in liver and muscle and they found a family of adenylyl 
cyclases, analogous to the hormone-sensitive adenylyl cyclases described by 
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Sutherland, which converted ATP to cAMP in the presence of neurotransmitters. The 
first of these was a dopamine-sensitive adenylyl cyclase: in the presence of dopamine, 
this membrane-bound enzyme stimulated formation of cAMP. Moreover, the data 
indicated that this enzyme might play a role in neuronal signal transduction (Kebabian 
and Greengard, 1971).  
 
At about the same time, Eishichi Miyamoto and J. F. Kuo (also from Paul 
Greengard’s laboratory) demonstrated PKA activity in the brain (Miyamoto et al., 
1969). The concentration of this enzyme was enormously higher in brain than in liver. 
Even more intriguing was the fact that the enzyme was concentrated in the synaptic 
region of nerve cells. These data were consistent with a possible role for PKA in 
synaptic transmission. Soon thereafter, a second distinct class of regulated protein 
kinase was discovered. It was named cyclic guanosine monophosphate (cGMP)–
dependent protein kinase (PKG) and which was activated selectively by cGMP rather 
than cAMP (Kuo and Greengard, 1970). PKG was present both in brain and in non-
neural tissues. Subsequently, Howard Schulman, in collaboration with Paul 
Greengard, discovered a third group of regulated protein kinases, which were 
stimulated by calcium in the presence of an unidentified endogenous heat-stable 
protein, later shown to be the calcium effector protein calmodulin (Schulman and 
Greengard, 1978). 
 
The discovery in the nervous system of several neurotransmitter-sensitive enzymes 
that made cAMP and of several second messenger–dependent protein kinases 
reinforced the notion that second messengers and protein kinases are involved in 
signalling in the brain. This idea was supported by the discovery of a large number of 
brain-specific substrate proteins for these protein kinases. More than 100 substrate 
proteins for protein kinases that were highly enriched in or exclusively localised to the 
brain, some of which were present in very high concentrations were identified 
(Greengard et al., 1999). Moreover, injections of various second messengers, protein 
kinases, and protein phosphatases, as well as activators, inhibitors and substrates of 
these enzymes, were able to either mimic or antagonise the ability of 
neurotransmitters to produce physiological responses in nerve cells, such as changes 
in ligand-gated ion channels, voltage-gated ion channels, ion pumps, and transcription 
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factors. Combined, these data have provided overwhelming evidence of a role for 
those signal transduction pathways in synaptic transmission (Greengard et al., 1999). 
 
In addition, studies in which purified protein kinases or kinase inhibitors have been 
microinjected into defined cells while a specific response is monitored have 
demonstrated that protein phosphorylation is both necessary and sufficient to mediate 
responses of excitable cells to extracellular signals (Llinas et al., 1985, Llinas et al., 
1991, Greengard et al., 1993, Castellucci et al., 1980, Castellucci et al., 1982). Those 
independent studies conclusively demonstrated that the efficacy of neurotransmitter 
release from the presynaptic terminal, in response to the nerve impulse, is regulated 
by protein phosphorylation and dephosphorylation.  
 
Paul Greengard was awarded (jointly with Arvid Carlsson and Eric R. Kandel) the 
Nobel Prize for Physiology or Medicine for his discoveries concerning signal 
transduction in the nervous system in 2000. 
 
 
1.7 Protein phosphorylation 
 
The rapid and reversible phosphorylation of proteins catalysed by protein kinases and 
protein phosphatases is a well-recognised mechanism of regulation in cells. This 
bidirectional process is a highly flexible method of influencing cellular activity in 
response to a variety of incoming stimuli. The first physiological role for protein 
phosphorylation was identified about 50 years ago while investigating the regulation 
of glycogen metabolism (Krebs and Fischer, 1955, Sutherland, 1972). In fact, many 
aspects of gene regulation; cell cycle control, transport, and secretion; actin 
remodelling; and cell adhesion are controlled by this mechanism (Krebs, 1985, 
Hunter, 1995, Pawson and Scott, 1997, Cohen, 2000, Goodman and Smolik, 2000, 
Pawson and Nash, 2000). The utility of protein phosphorylation as the predominant 
form of covalent modification of proteins in vivo is exemplified by the finding that 
∼30% of intracellular proteins are phosphoproteins (Hunter, 1987). Not surprisingly, 
the breakdown in signal transduction may be the cause or consequence of many 
diseases, including cancer, diabetes, arthritis, and Alzheimer's (Cohen, 1999). 
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1.8 Protein phosphorylation systems 
 
All protein phosphorylation systems consist minimally of three components. These 
include the phosphoproteins (substrates) themselves, which change their biological 
properties during phosphorylation/dephosphorylation. In addition, two classes of 
enzymes are needed for phosphorylation/dephosphorylation reactions. One set of 
these enzymes includes the protein kinases, phosphotransferases that catalyse transfer 
of phosphate from ATP to proteins on specific serine, threonine or tyrosine residues. 
The other set of enzymes includes the phosphoprotein phosphatases, which 
dephosphorylate the phosphoproteins and thereby return the particular protein 
phosphorylation system to its basal state (Figure 1.4). 
 
Figure 1.4. Effects of protein phosphorylation. Fundamental outcomes of phosphorylation of 
proteins by kinases and dephosphorylation by phosphatases are the regulation of the activity and the 
modulation of protein-protein interactions.  
 
Most signalling pathways are composed of common elements. The initial signal is 
transduced through a receptor at the plasma membrane (such as a G-protein coupled 
receptor, or a receptor tyrosine kinase or phosphatase), which results in activation of 
the receptor or the mobilisation of receptor-associated proteins to generate some form 
of intracellular message (Figure 1.5). This signal is then directed throughout the cell 
either by the diffusion of a small soluble second messenger or the translocation of an 
activated enzyme.  
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At a molecular level, phosphorylation mediates the regulation of enzymatic activities 
by causing allosteric conformational changes, or by directly enhancing or blocking 
access to enzyme catalytic sites (Johnson and Barford, 1990, Barford, 1991, Johnson 
and O'Reilly, 1996). More recently it has been realised that an essential feature of 
signalling by protein phosphorylation is the modulation of protein–protein 
interactions. These are mediated by a growing number of protein interaction modules 
domains that may associate with their binding partners in a phosphorylation-
dependent manner. Examples of these domains include the Src homology 2 (SH2) 
domain, which is a sequence-specific phosphotyrosine-binding module present in 
many signalling molecules and the forkhead-associated (FHA) domain, which is a 
small protein that recognises phosphothreonine epitopes on proteins (Cantley et al., 
1991, Pawson and Gish, 1992, Pawson, 1995). These protein–protein interactions 
generate molecular networks that drive intracellular signalling events. 
Phosphorylation is a crucial part of the underlying biochemical mechanisms through 
which specificity is generated during signal transduction, and it provides the means by 
which signalling molecules may act in combination to generate complex biological 
responses (Pawson and Nash, 2000). 
 
 
Figure 1.5. An outline of a signal transduction cascade. In a typical signal transduction cascade, 
extracellular signal molecules (red) bind to receptors (yellow) and initiate intracellular cascades that 
relay and amplify the signal at each step of the cascade via activation of enzymes (green), which 
regulate other enzymes and non-enzymatic substrates (blue). The net output of such signal transduction 
“pathways” induces cellular changes such as changes in gene expression, cell division, cell death or 
differentiation, or the modulation of protein-protein interactions. 
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1.6 Protein kinases 
 
Ever since the discovery nearly 50 years ago that reversible phosphorylation regulates 
the activity of glycogen phosphorylase, there has been intense interest in the role of 
protein phosphorylation in regulating protein function. With the advent of DNA 
cloning and sequencing in the mid-1970s, it rapidly became clear that a large family 
of eukaryotic protein kinases exists, and the identification of novel protein kinases led 
to the speculation that a vertebrate genome might encode as many as 1001 protein 
kinases (Hunter, 1987).  
 
However, the near-completion of working draft of the human genome sequence in 
2001 paved the way for the systematic identification of almost all human protein 
kinases. This venture, dubbed as the ‘kinome project’ (Manning et al., 2002), 
involved the use of automated computational predictions to screen genomic, 
complementary DNA (cDNA) and EST (expressed sequence tag) sequences from 
genomic sequence databases for the characteristic motifs of protein kinases.  Using 
this approach, the authors catalogued the protein kinase complement of the human 
genome and a total of 518 kinases were identified. The total number of kinases was 
about half that predicted earlier, but it is still a strikingly large number, constituting 
about 1.7% of all human genes. 
 
To compare related kinases in human and model organisms and to gain insights into 
kinase function and evolution, all the kinases were classified into a hierarchy of 
groups, families, and subfamilies. Kinases were classified primarily by sequence 
comparison of their catalytic domains, aided by knowledge of sequence similarity and 
domain structure outside of the catalytic domains.  
 
With the exception of a few atypical kinases, the kinase domains of most members of 
this superfamily share very similar catalytic motifs that are responsible for the 
phosphoryl transfer. Thus, the kinome can be classified into eight families, based on 
their sequence similarity: AGC (PKA, PKG and PKC family), CAMK 
(Ca2+/calmodulin- dependent family), CK1 (Casein kinase 1 family), CMGC (CDK, 
MAPK, GSK3 and CLK family), STE (homologues of the yeast Sterile kinases 
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family), TK (Tyrosine kinases family), TKL (Tyrosine kinase-like kinases family) and 
atypical kinases family (Figure 1.6 on the next page). 
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Figure 1.6. The human kinome. 518 kinases are currently found in the human genome, which 
constitute the human kinome. Kinases were classified into eight families based on the similarity of the 
kinase domains. TTBK1 and TTBK2 (underlined in red) are part of the CK1 family of kinases. 
Adapted from (Manning et al., 2002).
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1.9  First description of TTBK2 
 
In the course of the purification of proteins associated with microtubules from bovine 
brain, Takahashi et al. (1995) identified a novel protein kinase. Further biochemical 
characterisation of this newly-discovered kinase showed that it was a serine/threonine 
kinase with molecular mass of 32 kDa and that it phosphorylated proteins tau, MAP2 
(microtubule-associated protein 2), tubulin and α-casein in vitro. Hence, it was 
initially named ‘Tau Tubulin Kinase’ (TTK) (Takahashi et al., 1995).  
 
The discoverers of TTK had an enduring interest in the role of tau 
hyperphosphorylation and its complex role in Alzheimer’s disease (AD) and invested 
considerable work in identifying the specific phosphorylation sites and their 
relationship to proteinaceous tau aggregates characteristic of AD brains. However, 
they obtained only in vitro evidence that TTK phosphorylates tau at Ser208 and 
Ser210 (Tomizawa et al., 2001), which are priming sites for the phosphorylation of 
tau by GSK-3β (Glycogen synthase kinase 3 beta), which is known to influence tau 
pathology (Noble et al., 2005). 
 
As a consequence of the ‘kinome project’ in 2002 (Manning et al., 2002), TTK was 
renamed as TTBK2 (tau tubulin kinase 2), while another protein kinase, whose kinase 
domain shares significant sequence homology with TTBK2’s kinase domain was 
identified and named TTBK1 (tau tubulin kinase 1). TTBK1 and TTBK2 share 84% 
sequence homology within the catalytic kinase domain, but display modest homology 
in the non-catalytic region (Figure 1.7). 
 
Both TTBK isoforms (TTBK1 and TTBK2) belong to the CK1 (casein kinase 1) 
group of eukaryotic protein kinases composed of CK1 isoforms (CK1α, CK1α2, 
CK1δ, CK1ϵ, CK1γ1, CK1γ2 and CK1γ3), VRK (vaccinia-related kinase) isoforms 
(VRK1, VRK2 and VRK3) (Manning et al., 2002). CK1 differs from most other 
protein kinases by the presence of the S-I-N motif instead of A-P-E in kinase domain 
region VIII (Hanks and Hunter, 1995). TTBK1 and TTBK2 possess a P-P-E motif at 
this site. TTBK2 possesses 38% identity with CK1δ within the kinase domain, but 
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there is no obvious homology beyond the catalytic moiety of TTBK to CK1 or VRK 
isoforms.  
 
1.9.1 Expression of TTBK isoforms in different tissues 
 
The TTBK1 gene is located on human chromosome 6p21.1 and is composed of 14 
exons and 15 introns with a cDNA length of 6932 bp (Ensembl transcript 
ENST00000259750). The TTBK1 protein is 1321 amino acids in length, has a serine-
threonine kinase domain (residues 34-297), and a unique polyglutamate domain in the 
middle region of the sequence (Figure 1.7). Human TTBK1 homologs were found in 
mice, Caenorhabditis elegans and Drosophila melanogaster (Sato et al., 2006). 
 
The gene encoding TTBK2 is located on human chromosome 15q15.2 and is 
composed of 14 exons and 15 introns with a cDNA length of 10905 bp (Ensembl 
transcript ENST00000267890).  The longest open reading frame is 3,732 nucleotides 
long, encoding a protein of 1244 amino acids. The gene is alternatively spliced 
yielding six shorter transcripts, with ubiquitous expression in human adult and foetal 
tissues (Houlden et al., 2007). The N-terminus of TTBK2 encodes a serine-threonine 
kinase domain (residues 21-284). However, the C-terminal region possesses no 
obvious functional domains or motifs and therefore its function has not been 
delineated. Notably, TTBK1’s polyglutamate region is not conserved in TTBK2 
(Figure 1.7). 
 
TTBK1 is specifically expressed in the brain. Northern blotting of a human tissue 
panel showed TTBK1 mRNA in adult brain cortex and cerebellum, as well as in 
foetal brain. Weak expression of TTBK1 was detected in the spinal cord and testis. 
No apparent TTBK1 expression was seen in a range of other tissues, including heart, 
liver, kidney and lung. In situ hybridisation (ISH) of mouse brain has shown TTBK1 
gene expression in perinuclear and cytoplasmic regions of large cortical pyramidal 
cells in the temporal cortex cortical layers, layers of the hippocampus and granular 
layer of cerebellum. Neuronal expression of TTBK1 in both mouse and human brain 
has been confirmed by immunohistochemistry (IHC) (Sato et al., 2006). 
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In contrast to TTBK1, TTBK2 expression can be detected in other tissues, including 
heart, muscle, liver, thymus, spleen, lung, kidney, testis and ovary (Takahashi et al., 
1995, Tomizawa et al., 2001). In the mouse and rat brain, TTBK2 mRNA expression 
was found at high levels in the cerebellum and hippocampus as shown by in situ 
hybridisation (Sato et al., 2006). Another study revealed that TTBK2 mRNA was also 
detected in all brain regions in human, rat and mouse (Houlden et al., 2007) by in situ 
hybridisation. The highest level of expression of TTBK2 mRNA was observed in the 
cerebellum Purkinje cells, granular cell layer, hippocampus, midbrain and substantia 
nigra (Houlden et al., 2007). Lower expression was seen in the cortex of human, rat 
and mouse brains.  
 
 
Figure 1.7. Pairwise sequence alignment of human TTBK1 and TTBK2. TTBK1 and TTBK2 share 
84% sequence homology (shaded in turquoise blue) in their kinase domain sequences. SCA11-causing 
mutations truncate the TTBK2 protein at amino acids 448, 449 and 450 (highlighted in red). The 
polyglutamic acid stretch (highlighted in green) of TTBK1 is not shared by TTBK2 and both kinases 
share modest homology outside their kinase domains. 
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1.10      Putative function of TTBKs in tau regulation 
 
The putative function of TTBK1, with respect to AD pathogenic mechanisms, has 
been studied by Sato et&al. (2008). TTBK1 has been shown, by partial phosphopeptide 
mapping, to phosphorylate tau in vitro (Sato et al., 2006). Similarly, TTBK2 has also 
been shown to phosphorylate tau in vitro at Ser208 and Ser210 (Tomizawa et al., 
2001).  
 
The examination of a transgenic TTBK1 mouse model, in which the protein is highly 
expressed in the subiculum and cortical pyramidal layers, has been reported (Sato et 
al., 2006). Those mice show increased phosphorylation of both tau at Ser262/356 
residues and of the neurofilament protein. The mice also showed significant age-
dependent memory impairment as determined by a spatial learning radial arm water 
maze test. The fact that TTBK1 has not been shown to directly phosphorylate tau at 
Ser262/356 in vitro indicated that TTBK1 might enhance phosphorylation at this site 
either by activation of other kinases or through priming of tau by direct 
phosphorylation at other sites (Sato et al., 2008). 
 
Subsequently, Xu et&al. (2010) used the same TTBK1 mice to generate bigenic mice 
that overexpress full-length TTBK1 and the disease-causing P301L tau mutant (Xu et 
al., 2010). These mice show accumulation of tau aggregates in cortical and 
hippocampal neurons at 12-13 months of age as well as enhanced tau 
phosphorylation. The bigenic mice also showed significant locomotor dysfunction as 
well as enhanced loss of motor neurons. 
 
The potential importance of TTBK1 in AD is supported by human genetic data from 
two independent genome-wide association studies. Vázquez-Higuera et&al. (2011) 
analysed nine TTBK1 gene single nucleotide polymorphisms (SNPs) in a group of 
Spanish AD patients and controls (Vazquez-Higuera et al., 2011). Based on the data 
generated, it was speculated that reduced TTBK1 expression in minor allele 
homozygotes (rs2651206 in intron 1, rs10807287 in intron 5 and rs7764257 in intron 
9) could lead to lower tau phosphorylation and neurofibrillary tangle formation. 
Subsequently, Yu et&al. (2011) confirmed that minor alleles of the rs2651206 
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polymorphism were significantly associated with a reduced risk of late onset AD in a 
Han Chinese population (Yu et al., 2011). 
 
Interestingly, both TTBK1 and TTBK2 can phosphorylate tau in vitro at sites that are 
found in paired helical filaments (PHFs) that constitute the characteristic Alzheimer's 
disease (Sato et al., 2006, Tomizawa et al., 2001). One would therefore expect that an 
upregulation or overactivation of each one of these kinases would lead to increased 
tau phosphorylation and predispose to neurodegeneration. Indeed, genetic variations 
in TTBK1, which are thought to result in decreased TTBK1 activity, can decrease the 
risk of AD (Vazquez-Higuera et al., 2011, Yu et al., 2011).  
 
1.11    Identification of TTBK2 as the causative gene for SCA11 
 
Apart from the tentative in vitro evidence of tau phosphorylation by TTBK2, its 
physiological role has not been explored since its discovery. However, in 2007, the 
discovery of a pathogenic mutation in the TTBK2 gene, causing a neurological 
condition, underscored the fundamental physiological importance of TTBK2. 
 
Worth et al. (1999) identified a British family with a relatively pure form of 
autosomal dominant cerebellar ataxia, a genetic syndrome with progressive 
degeneration of the cerebellum (Figure 1.8), causing uncoordinated movements in 
gait, eye movement, speech, and other motor coordination skills. The affected family 
from Devon, on the southwest coast of England, stretched over 8 generations and 
affected individuals had progressive cerebellar ataxia, abnormal eye signs and 
pyramidal features, as well as cerebellar atrophy visible upon magnetic resonance 
imaging (Figure 1.8). 
 
1.11.1 The cerebellum and cerebellar atrophy 
 
The cerebellum (“little brain” in Latin) is a structure that is located at the back of the 
brain, underlying the occipital and temporal lobes of the cerebral cortex (Figure 1.8). 
Although the cerebellum accounts for approximately 10% of the brain’s volume, it 
contains more than 50% of the total number of neurons in the brain. On average the 
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human cerebellum weighs 154g and packs 69 billion neurons, while the human 
cerebral cortex weighs, on average 1233 grams and contains 16 billion neurons 
(Herculano-Houzel, 2009). 
 
Historically, the cerebellum has been considered a motor structure, because cerebellar 
damage leads to impairments in motor control and posture and because the majority 
of the cerebellum’s outputs are to parts of the motor system. Motor commands are not 
initiated in the cerebellum; rather, the cerebellum modifies the motor commands of 
the descending pathways to make movements more adaptive and accurate (Passot et 
al., 2012). Two types of neurons play dominant roles in the cerebellar circuit: 
Purkinje cells and granule cells. Purkinje cells are among the most distinctive neurons 
in the brain, and also among the earliest types to be recognised — they were first 
described by the Czech anatomist Jan Evangelista Purkyně in 1837 (Zarsky, 2012). 
Purkinje cells use GABA as their neurotransmitter (Sastry et al., 1997), and therefore 
exert inhibitory effects on their targets. Cerebellar granule cells, in contrast to 
Purkinje cells, are among the smallest neurons in the brain. They are also the most 
numerous neurons in the brain: In humans, estimates of their total number average 
around 50 billion (D'Angelo, 2013), which means that about 3/4 of the brain's neurons 
are cerebellar granule cells. 
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Figure 1.8. Upper panel: Drawing of the human brain. The cerebellum is a structure that is located 
at the back of the brain, underlying the occipital and temporal lobes of the cerebral cortex. Lower 
panel: Magnetic resonance imaging (MRI) scans of two brains. The brain on the left shows atrophy 
of the cerebellum, a pathological hallmark of ataxia patients, compared to the brain on the right shows 
a normal cerebellum. [adapted from http://pedclerk.bsd.uchicago.edu/page/ataxia] 
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1.11.2 Genome-wide linkage and identification of causative mutation 
 
Using a genome-wide linkage strategy to screen the members of the affected family, 
Worth et al. (1999) found linkage to marker D15S1039. Construction of haplotypes 
defined a 7.6 centimorgan (cM) interval between the flanking markers D15S146 and 
D15S1016, thereby assigning the disease locus, designated SCA11 (spinocerebellar 
ataxia type 11), to chromosome 15q14-q21.3.  
 
Houlden et al. (2007) narrowed the SCA11 locus further to a 5.6 cM region 
containing 134 protein-coding genes. After screening 54 genes in the linked region 
identified on chromosome 15q15-q21, none of which had a pathogenic mutation, the 
gene encoding tau tubulin kinase 2 (TTBK2) was sequenced and a 1-base insertion of 
an adenosine in exon 13 at nucleotide 1329, codon 444 was exposed (Figure 1.9). 
This insertion created a premature stop codon (TGA) in the mRNA at codon 450, 
truncating the normal protein from 1244 to 450 amino acids.  
 
The authors proceeded to screen another cohort of 40 families with autosomal 
dominant pure SCA, for which no genetic mutations were identified, for TTBK2 
mutations. A frameshift deletion of 2 bases (GA) in exon 13 of TTBK2 at nucleotides 
1284-1285, codons 428 and 429 (Figure 1.9) was found in one of the families 
screened. This created a premature stop site (TGA) in the mRNA at codon 449. The 
family was of Pakistani ancestry, with five affected individuals present over three 
generations (family 2). Both mutations segregated in the affected family members, 
and neither was detected in over 400 elderly European-descended British or in 50 
elderly Pakistani controls individuals.  
 
The discovery of TTBK2 mutations prompted other research groups assess the 
prevalence and phenotypic spectrum of SCA11. Bauer et al. (2010) screened a cohort 
of 148 index patients of predominantly German and French descent with autosomal 
dominant spinocerebellar ataxia, who were negative for repeat expansions and 
mutations in known SCA genes, for mutations in TTBK2. All 148 patients were 
negative for all the conventional known SCA mutations. In two of 148 patients - one 
German and one French - the authors identified two SCA11-causing mutations. 
 25 
Remarkably, both carried an identical two-base pair deletion (c.1306_1307delGA) in 
exon 12 leading to a premature stop codon, truncating the normal protein from 1244 
to 448 amino acids. 
 
Two other cohorts of SCA patients were screened for TTBK2 mutations. To 
investigate the frequency of SCA11 in Chinese SCA patients, Xu et al. (2010) 
examined the TTBK2 gene in 68 unrelated probands diagnosed with dominantly 
inherited ataxia using the denaturing high-performance liquid chromatography 
(dHPLC) method. All analysed samples displayed the normal elution profile, which 
signified that no disease-related mutation was identified, thus providing evidence that 
SCA11 is a rare form of ataxia in China.  
 
Edener and colleagues (2009) screened 49 unrelated familial cases with ataxia for 
TTBK2 mutations. Sequencing all coding exons revealed, amongst others, two novel 
missense exchanges at evolutionarily conserved amino acid positions. A disease 
causing effect was excluded with high probability for both variations as they were 
also detected in control samples (Edener et al., 2009). 
 
 
Figure 1.9. Domain architecture of the TTBK2 protein. The longest transcript produces a 1244-
residue protein with a kinase domain (amino acids 21-284) at its N-terminus. The rest of the protein 
possesses no defined functional domains or motifs. The SCA11-causing truncating mutations identified 
leave the kinase domain intact but eliminate most of the non-catalytic portion of the protein. 
 
In summary, four SCA11-causing TTBK2 mutations have been identified so far. 
Strikingly, all four are frameshift mutations that truncate the wild-type TTBK2 
protein from 1244 to 450, 449 and 448 (two mutations) amino acids respectively 
(Figure 1.9). The mutations mapped to the conserved serine-rich region of the protein, 
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and all four mutations do not affect the kinase domain but, however, eliminate most 
of the non-catalytic portion of the protein. 
 
1.12      Spinocerebellar ataxia 
 
Ataxia, a term derived from a Greek word meaning ‘loss of order’, is used clinically 
to describe lack of voluntary coordination of muscle movements, with poor 
coordination between limbs. It is a neurological dysfunction of motor coordination 
that can affect gaze, speech, gait and balance. Individuals suffering from ataxia are at 
first clumsy and unable to walk steadily, and have slurred speech. Patients can 
eventually lose the ability to swallow and breathe in a coordinated fashion, which can 
eventually be fatal (Orr, 2012). 
 
Ataxia is the consequence of a neurodegenerative process that affects a specific 
population of nerve cells, whose vulnerability determines the clinical manifestations 
of the disease. The origin of many forms of ataxia can be traced back to dysfunction 
of the parts of the nervous system that coordinate movement, especially the 
cerebellum, which plays a very important role in motor coordination and the fine 
adjustments of movement. Ataxia can result from the variable degeneration of 
neurons in the cerebellum, brain stem, spinocerebellar tracts, and their 
afferent/efferent connections. Cerebellar ataxia is the most common form of ataxia 
and is caused by dysfunction either within the cerebellum or in its afferent and 
efferent pathways. Spinocerebellar ataxia (SCA) is caused by anomalous function of 
the spinocerebellum, the part of the cerebellar cortex that receives somatosensory 
input from the spinal cord. 
 
Although there are sporadic forms of SCAs, the term is most often used to refer to the 
hereditary forms, and in particular the autosomal dominant forms. The autosomal 
dominant SCAs are typically late-onset, progressive, and often fatal 
neurodegenerative disorders. They are characterised by cerebellar ataxia and 
frequently other symptoms related to dysfunction of additional neural pathways. 
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1.12.1      Clinical Features of the Spinocerebellar Ataxias 
 
Autosomal dominant spinocerebellar ataxias (SCAs) comprise a highly heterogeneous 
group of dominantly-inherited ataxias, where the age of onset of the clinical 
symptoms is typically between 30 and 50 years of age, although early onset in 
childhood and onset in later decades after 60 years have been reported for specific 
SCA subtypes (Duenas et al., 2006). During the past 20 years, more than 30 SCA 
subtypes have been described (Table 1.1.). They are designated as SCA1 to SCA30, 
where the numbers indicate the chronological order of discovery of the genomic locus 
by genome-wide linkage of affected families. 
 
The prognosis is variable depending on the underlying cause of the spinocerebellar 
ataxia subtype. Epidemiological data indicate that SCAs might be more common than 
previously estimated with prevalences over 5–7 in 100,000 in some geographical 
areas reaching 18.5/100,000 in Japan when including dominant, recessive and 
sporadic SCAs and familial spastic paraplegia (Tsuji et al., 2008). This is similar to 
the prevalences reported for other uncommon motor neurodegenerative diseases, such 
as Huntington’s disease or motor neuron diseases. 
 
Although ataxia is the prominent symptom in SCAs, few mutations cause an almost 
pure cerebellar syndrome and isolated neurodegeneration in the cerebellar cortex. 
Most SCAs are multisystemic disorders presenting clinical variability and even those 
SCA subtypes regarded as ‘pure’ cerebellar forms reveal neurodegeneration not only 
in the cerebellum and spinocerebellar tracts, but also in many other areas of the 
central and peripheral systems. SCAs are characterised by progressive ataxia that is 
variably associated with other neurological symptoms. The clinical hallmarks result 
from a progressive degenerative process that mostly affects the cerebellum, brainstem 
and spinal cord (Figure 1.10).  
 
SCAs are associated with several genomic loci. The disease gene has been identified 
for several genetic variants of familial ataxias (SCA1–3, 6–8, 10, 11, 12, 14, 17, 
FGF14 (fibroblast growth factor 14)–SCA and dentatorubral-pallidoluysian atrophy 
(DRPLA)) (Table 1.1.). SCA1–3, 6, 7, 17 and DRPLA are associated with an 
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expanded CAG-repeat in the open reading frames of the corresponding genes, which 
are translated into long polyglutamine tracts. Longer expansions are associated with 
earlier onset and more severe disease in subsequent generations. The most common 
presentation of SCA is dominantly transmitted ataxia 'plus', which is characterised by 
variable associations between cerebellar dysfunction, supranuclear ophthalmoplegia, 
slow saccades, optic atrophy, pyramidal and extrapyramidal features, mild-to-
moderate dementia, amyotrophy and peripheral neuropathy. SCA's diagnostic 
pathological feature is usually olivopontocerebellar atrophy, which is the 
degeneration of neurons in specific areas of the brain – the cerebellum, pons, and 
inferior olives (Zoghbi and Orr, 2000) (Figure 1.10). 
 
 
Figure 1.10. The principal sites of neuronal loss and organ dysfunction in spinocerebellar ataxia 
type 1 (SCA1), SCA2, SCA3, SCA6, SCA7, SCA17 and dentatorubral-pallidoluysian atrophy 
(DRPLA) (see also Table 1.1.). Large dots indicate severe neuronal loss. Blue dots indicate 
involvement of extrapyramidal nuclei. Green dots indicate cranial nerve involvement. Retinal 
degeneration is associated with SCA7.  [Adapted from (Taroni and DiDonato, 2004)]. 
 
1.12.2  Genetic mutations causing neurodegeneration in the spinocerebellar 
ataxias 
 
To date, more than 30 SCA genes or loci have been identified (Matilla-Duenas, 2008) 
(Table 1.1). Recognised mechanisms leading to spinocerebellar neurodegeneration  
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include polyglutamine expansions (SCAs 1, 2, 3, 6, 7, 17 and DRPLA); non-coding 
expansions (SCA10 and SCA12); as well as conventional mutations in genes 
encoding a cytoskeletal protein (βIII spectrin (SPTBN2), SCA5), an ion channel 
(voltage gated potassium channel Kv3.3, SCA13), a protein kinase (protein kinase C 
gamma (PRKCG), SCA14), an intracellular calcium channel (inositol 1,4,5-
triphosphate receptor 1, SCA15), a fibroblast growth factor (FGF14, SCA27) and an 
ATPase family gene 3-like 2 (AFG3L2, SCA28). 
 
SCAs 1, 2, 3, 6, 7, 17 and DRPLA are all caused by the expansion of a translated 
CAG repeat sequence leading to an abnormally long polyglutamine (polyQ) tract in 
the encoded proteins named ataxins 1, 2 and 3, alpha 1A-voltage-dependent calcium 
channel, ataxin 7, TATA-box-binding protein and atrophin 1, respectively, hence 
included in the group regarded as polyglutaminopathies. They all show common 
features, the progressive neurodegeneration of neuronal subsets in distinct brain areas 
and the formation of polyQ-containing protein aggregates forming characteristic 
nuclear or cytoplasmic inclusions (Duenas et al., 2006). The age at onset and severity 
of disease symptoms inversely correlate with the length of the glutamine repeat.  
 
SCAs 8, 10 and 12, are caused by repeat expansions located outside of the coding 
region of the disease genes (Holmes et al., 1999, Wakamiya et al., 2006, Daughters et 
al., 2009). While SCAs 8 and 10 appear to be caused by toxic RNA gain-of-function 
mechanisms (although SCA8 might be also caused by polyglutamine expansions), 
SCA12 is caused by dysregulation of the activity of the crucial enzyme protein 
phosphatase 2 (PP2, formerly named PP2A) in cerebellar Purkinje cells. Different 
mechanisms are responsible for cerebellar ataxia and neurodegeneration in SCAs 5, 
13, 14, 15, 27 and 28 where alterations in amino acid composition in beta-III spectrin 
(SPTBN2) (Ikeda et al., 2006), potassium channel KCNC3 (Waters et al., 2006), 
protein kinase C gamma (PRKCG) (Chen et al., 2003, Yabe et al., 2003), the Inositol 
1,4,5-triphosphate receptor (ITPR1) (van de Leemput et al., 2007), fibroblast growth 
factor 14 (FGF14) (van Swieten et al., 2003), and the ATPase family gene 3-like 2 
protein (AFG3L2) (Maltecca et al., 2009), respectively, elicit disease symptoms in 
these SCA subtypes.  
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Table 1.1. Genetic heterogeneity and molecular pathogenesis in the spinocerebellar ataxias (adapted from (Matilla-Duenas et al., 2010)). 
SCA subtype Genomic 
location 
Gene Protein Function DNA mutation 
SCA1 6p22.3 ATXN1 Ataxin 1 Transcription regulation (CAG)n 
SCA2 12q24.12 ATXN2 Ataxin 2 RNA metabolism (CAG)n 
SCA3/MJD 14q32.12 ATXN3 Ataxin 3 De-ubiquitination, (CAG)n 
Transcription regulation 
SCA4 16q24-ter SCA4 U U U 
SCA5 11q13.2 SPTBN2 ß2-spectrin Neuronal membrane skeleton ID, MM 
SCA6 19p13.2 CACNA1A CACNA1A Ca2+ signalling/homeostasis (CAG)n 
SCA7 3p14.1 ATXN7 Ataxin 7 Transcription regulation (CAG)n 
SCA8 13q21 ATXN8OS/ 
ATXN8 
Ataxin 8 U (CUG/CAG)n 
SCA9 U U U U U 
SCA10 22q13.31 ATXN10 Ataxin 10 Neuritogenesis Intronic 
(ATTCT)n 
SCA11 15q15.2 TTBK2 Tau tubulin kinase 
2 
U FM 
SCA12 5q32 PPP2R2B PPP2R2B Regulation of PP2 activity 5′-UTR (CAG)n 
transcription regulation 
SCA13 19q13.33 KCNC3 KCNC3 K+ signalling MM 
SCA14 19q13.42 PRKCG PRKCG Phosphorylation ID, MM 
SCA15b 3p26.1 ITPR1 Inositol 1,4,5-
triphosphate 
receptor 1 
Inositol 1,4,5-triphosphate 
calcium signalling 
D,MM 
SCA16 8q23–q24.1 U U U U 
SCA17/HDL4 6q27 TBP TBP General transcription (TFIID 
complex) 
(CAG)n 
SCA18 7q22–q32a U U U U 
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SCA19 1p21–q21a U U U U 
SCA20 11q12.2–
11q12.3a 
U U U Chromosomal 
duplication 
SCA21 7p21.3–
p15.1a 
U U U U 
SCA22 1p21–q23a U U U U 
SCA23 20p13–
p12.2a 
U U U U 
SCA24 U U U U U 
SCA25 2p21–p15a U U U U 
SCA26 19p13.3a U U U U 
SCA27 13q33.1 FGF14 FGF14 Signal transduction, FM, MM, 
translocation Regulation NaV channels, 
Excitability of Purkinje cells 
SCA28 18p11.21 AFG3L2 ATPase family 
gene 3-like 2 
ATPase MM 
SCA29b 3p26 U U U U 
SCA30 4q34.3–
q35.1a 
U U U U 
DRPLA 12p13.31 ATN1 Atrophin 1 Transcription repression 
(nuclear receptor corepressor) 
(CAG)n 
16q-ADCA 16q22.1 PLEKHG4 Puratrophin 1 Intracellular signalling, 
cytoskeleton dynamics 
5′-UTR SNP 
Unknown U U U U U 
Table 1.1. (continued). Genetic heterogeneity and molecular pathogenesis in the spinocerebellar ataxias (adapted from (Matilla-Duenas et al., 2010)). 
Genes noted in genomic location according to Ensembl 
D: deletion, FM: frameshift mutation, ID: in-frame deletion, MM: missense mutation, SNP: single nucleotide polymorphism, UTR: untranslated region, U: unknown 
aGenes not noted according to HUGO Gene Nomenclature Committee 
bSCA29 maps to the same genomic location than SCA15  
HDL4: Huntington’s disease-like 4; MJD: Machado-Joseph disease
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In the rest of SCAs, the mutations and, therefore, the genes remain to be identified 
and characterised. Understanding the pathogenic mechanisms underlying 
neurodegeneration in spinocerebellar ataxias is leading to the identification of 
potential therapeutic targets that will ultimately facilitate drug discovery. 
 
1.12.3 Cellular and molecular pathways implicated in neurodegeneration in the 
spinocerebellar ataxias. 
More than 30 genes have been identified triggering the well-described clinical and 
pathological phenotype of SCAs. The underlying cellular and molecular events are, 
however, still poorly understood. Studies of the functions of the proteins implicated in 
SCAs and the corresponding altered cellular pathways point to major aetiological 
roles for defects in transcriptional regulation, protein aggregation and clearance, 
alterations of calcium homeostasis, and activation of pro-apoptotic routes among 
others, all leading to synaptic neurotransmission deficits (Figure 1.11), 
spinocerebellar dysfunction, and, ultimately, neuronal demise (Matilla-Duenas et al., 
2010).  
 
Table 1.2 summarises the known cellular and molecular pathways that are known to 
be perturbed in some SCA subtypes. More mechanistic and detailed insights are 
emerging on these molecular routes. The growing understanding of how dysregulation 
of these pathways trigger the onset of symptoms and mediate disease progression is 
leading to the identification of conserved molecular targets influencing the critical 
pathways in pathogenesis that will serve as effective therapeutic strategies in vivo, 
which may also prove beneficial in the treatment of SCAs. 
 
1.12.4       Common occurring pathways mediating polyglutamine neurotoxicity: 
                  protein aggregation, misfolding, stability and clearance 
 
Seven spinocerebellar ataxia subtypes including SCAs 1, 2, 3/Machado–Joseph 
disease, 6, 7, 17 and DRPLA, are all caused by the expansion of a CAG repeat 
sequence in specific genes leading to abnormally long polyglutamine (polyQ) tracts in  
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SCA subtype Identified cellular and molecular pathways Numbers 
on Fig. 1.11 
SCA1 Aggregation, apoptosis/caspases, autophagy, calcium and 
dopaminergic signalling, dysruption of vesicular transport, ER, gene 
transcription, HSR, mitochondrial dysfunction, PI3K/Akt, PP2, 
PRKC, SUMOylation, synaptic neurotransmission deficits (glutamate, 
GABA), UPR, UPS 
(1–12, 14, 
16) 
SCA2 Aggregation, apoptosis/caspases, autophagy, calcium and 
dopaminergic signalling, ER, gene transcription, HSR, mitochondrial 
dysfunction, synaptic neurotransmission deficits (glutamate, GABA), 
UPR, UPS 
(1–4, 7–12, 
17) 
SCA3 Aggregation, apoptosis/caspases, autophagy, dopaminergic signalling, 
ER, gene transcription, HSR, mitochondrial dysfunction, 
SUMOylation, synaptic neurotransmission deficits (glutamate, 
GABA), UPR, UPS 
(1–3, 7–12) 
SCA5 Neuronal membrane skeleton, synaptic neurotransmission deficits 
(glutamate, GABA) 
(6, 11, 15) 
SCA6 Aggregation, apoptosis/caspases, autophagy, dopaminergic signalling, 
ER, gene transcription, HSR, mitochondrial dysfunction, synaptic 
neurotransmission deficits (glutamate, GABA), UPR, UPS 
(1–4, 7–12) 
SCA7 Aggregation, apoptosis/caspases, autophagy, ER, gene transcription, 
mitochondrial dysfunction, SUMOylation, synaptic neurotransmission 
deficits (glutamate, GABA), UPR, UPS 
(1–3, 6–12) 
SCA8 Aggregation, apoptosis/caspases, gene transcription, mitochondrial 
dysfunction, synaptic neurotransmission deficits (glutamate, GABA), 
UPR, UPS 
(1, 2, 6–9, 
11, 12, 15) 
SCA10 Neuritogenesis. (16) 
SCA12 Apoptosis/caspases, dysruption of vesicular transport, gene 
transcription, PP2, tau phosphorylation 
(2, 5, 7, 14) 
SCA13 Potassium channel signalling (13) 
SCA14 Calcium, neuritogenesis, synaptic neurotransmission deficits 
(glutamate, GABA) 
(4, 11, 16) 
SCA15 Calcium homeostasis (2, 4, 16) 
SCA17/HDL4 Aggregation, apoptosis/caspases, autophagy, dopaminergic signalling, 
ER, gene transcription, HSR, mitochondrial dysfunction, synaptic 
neurotransmission deficits (glutamate, GABA), UPR, UPS 
(1–3, 7–12) 
SCA27 Dopaminergic signalling, signal transduction, sodium voltage channel (11, 17) 
SCA28 Mitochondrial dysfunction (2, 9) 
DRPLA Aggregation, apoptosis/caspases, autophagy, ER, gene transcription, 
HSR, mitochondrial dysfunction, synaptic neurotransmission deficits 
(glutamate, GABA), UPR, UPS 
(1–3, 7–12) 
19q-ADCA Actin dynamics, intracellular signalling, synaptic neurotransmission 
deficits 
(7, 11) 
Table 1.2. Cellular and molecular pathways implicated in the spinocerebellar ataxia. [adapted from 
(Matilla-Duenas et al., 2010)] 
ER: endoplasmic reticulum; GABA: γ-aminobutyric acid; HDL4: Huntington’s disease-like 4; HSR: 
heat shock response; UPR: unfolded protein response; UPS: Ubiquitin-dependent proteasome system. 
 
the encoded proteins (Zoghbi and Orr, 2000). A similar pathogenic pathway is likely 
to underlie these SCAs, since each of the expanded CAG repeats encodes 
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polyglutamine and the pathogenic minimum number of repeats that cause disease is 
roughly the same, at around 40 copies of the repeat in most of the different subtypes. 
Toxic gain-of-function mechanisms are likely to be responsible for the 
polyglutamine-containing protein is aggregation and deposition of misfolded proteins 
leading to neuronal dysfunction and eventually cell death. 
 
 
 
Figure 1.11. Molecular mechanism of neurodegeneration in the spinocerebellar ataxias. [adapted 
from (Matilla-Duenas et al., 2010)] 
1 aggregation, 2 apoptosis, 3 autophagy, 4 Ca2+ homeostasis/signalling alterations, 5 disruption of 
axonal transport and vesicle trafficking, 6 excitotoxicity, 7 interference with gene transcription, 8 
mitochondrial impairment, 9 oxidative stress, 10 alterations of proteasome degradation, 11 synaptic 
neurotransmission deficits, 12 unfolded protein response (UPR), 13 potassium channel dysfunction, 14 
tau phosphorylation, 15 neuronal membrane skeleton, 16 neuritogenesis, 17 voltage-gated Na+ 
channels. Ca2+ calcium ions, ER endoplasmic reticulum, GABA γ-aminobutyric acid, Glu glutamate, 
ITPR1 inositol 1,4,5-triphosphate receptor type 1, K+ potassium ions, mGluR1 metabotropic glutamate 
receptor type 1, Na+ sodium ions, Q glutamine. [Adapted from (Matilla-Duenas et al., 2010)] 
 
Proteins with expanded stretches of polyglutamine adopt an abnormal configuration 
resulting in the formation and deposition of polyglutamine aggregates in disease 
neurons forming characteristic nuclear or cytoplasmic inclusions, which are 
neuropathological hallmarks in these diseases (Ross and Poirier, 2004). These 
inclusions contain cellular components such as ubiquitin, the proteasome, HSP70 (70 
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kDa heat shock protein), and transcription factors among others (Cummings et al., 
1998, McCampbell et al., 2000, Schmidt et al., 2002). Whether the toxicity is a direct 
result of the aggregates or results from intermediary structures formed during the 
process of aggregation has been the object of controversy, but blocking aggregation is 
still one approach attempted to minimise toxicity.  
 
A possible mechanism for aggregate formation by the mutant protein would be by 
loss of native state stability by the expanded polyglutamine and, thus, leading to the 
formation and accumulation of a partially unfolded, aggregation-prone species, 
resulting in fibrillisation. This phenomenon probably accounts for the earlier age of 
onset and higher severity of disease symptoms observed when mutant ataxins contain 
longer numbers of glutamines. 
 
1.12.5 Dysregulation of transcription and gene expression 
 
Several lines of evidence implicate those ataxins containing long stretches of 
polyglutamines in the regulation of gene transcription. Nuclear expression of 
polyglutamine-expanded proteins is an essential step in polyglutamine pathogenesis, 
and the resulting transcriptional dysregulation caused by ataxins containing expanded 
polyglutamines results in neuronal dysfunction and death in a few SCAs (Helmlinger 
et al., 2006). Interference with gene expression occurs by the effects of the mutation 
exerted on the interaction of ataxins with transcriptional regulatory proteins and DNA 
or on chromatin remodelling. 
 
For instance, in SCA1, ataxin 1 interacts with several transcription factors regulating 
transcription including the transcriptional co-repressors/activators (Matilla et al., 
1997). The mutant forms of ataxin-1 exert alterations in the expression levels of genes 
regulated by those transcriptional regulators leading to alterations of Wnt-receptor 
signalling, retinoid acid/thyroid hormone signalling, and nucleic acid binding 
(Matilla-Duenas et al., 2008). Similarly, ataxins 2, 3 and 7, and the SCA17 and 
DRPLA gene products, the basal transcription factor TATA-binding protein (TBP) 
and atrophin 1, respectively, are directly involved in transcription as components of 
transcriptional regulatory complexes (Shimohata et al., 2000, Li et al., 2002, Zhang et 
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al., 2002, Helmlinger et al., 2004), and the genes and pathways regulated by these 
factors are just being identified. Interference with transcriptional regulations of 
specific subset of genes by polyglutamine expansions lead to neuronal dysfunction 
such as axonal and neurite integrity (Friedman et al., 2007) and accounts for the cell-
type specificity degeneration observed in spinocerebellar ataxias, through the 
sequestration of factors by the long glutamine stretches within the mutant proteins, 
whose expression are confined to cells that degenerate in these conditions (Matilla et 
al., 1997). 
 
1.12.6 Alterations in calcium homeostasis 
 
Several lines of evidence point to derangements of neuronal calcium signalling in 
neurodegeneration of spinocerebellar ataxias. Cerebellar Purkinje cells seem to be 
particularly sensitive to fluxes in intracellular calcium levels, which could result from 
different sources, such as the reduction of chaperone activity and endoplasmic 
reticulum (ER) stress. Several neuronal genes, abundantly expressed in Purkinje cells 
that are involved in calcium signalling or homeostasis, are down-regulated in the 
cerebellum of SCA1 mutant mice before the occurrence of detectable motor 
impairment or pathology (Worth et al., 2000, Serra et al., 2004). This suggests a 
major role of disruption of calcium homeostasis in cerebellar Purkinje cells that could 
be importantly involved in the pathogenic process and/or the survival of these cells in 
SCA1. 
 
In SCA2, mutant ataxin 2, but not wild-type, specifically associates with the cytosolic 
C-terminal region of type 1 ITPR1 (Inositol 1,4,5-triphosphate receptor type 1), an 
intracellular calcium release channel (Liu et al., 2009). Association of Atxn2[58 
glutamines] with the receptor increases the sensitivity of ITPR1 to activation by 
inositol-tri-phosphate in planar lipid bilayer reconstitution experiments. This evidence 
indicates that disturbed neuronal Ca2+-signalling may play an important role in SCA2 
neuropathology. 
 
Furthermore, SCA6 is caused by polyglutamine expansion in the CACNA1A gene, 
which encodes an alpha (2.1) subunit, formerly named [alpha]1A, the major pore-
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forming subunit of the CaV2.1 voltage-dependent P/Q-type calcium channel 
(Zhuchenko et al., 1997, Pietrobon, 2013).  
 
Also, SCA14 is caused by mutations in protein kinase C gamma (PKC gamma). 
Interestingly, 18 of 22 mutations are concentrated in the C1 domain, which binds 
diacylglycerol and is necessary for translocation and regulation of PKC gamma kinase 
activity. Wild-type PKC gamma, but not C1 domain mutants, inhibits Ca2+ influx in 
response to muscarinic receptor stimulation (Adachi et al., 2008). The resulting 
sustained Ca2+ entry imbalances Ca2+ homeostasis and Ca2+-mediated signalling in 
Purkinje cells and contributes to the neurodegeneration characteristic of SCA14. 
 
SCA15 is caused by deletions and missense mutations in the ITPR1. The ITPR1 
couples to intracellular Ca2+ channels to facilitate Ca2+ release from the endoplasmic 
reticulum after activation by the intracellular second messenger inositol 1,4,5-
triphospate. SCA15 results then from impaired inositol 1,4,5-triphospate-mediated 
intracellular second-messenger signalling and disturbed calcium release altering 
intracellular calcium homeostasis. 
 
1.12.7 Mitochondrial stress and apoptosis 
 
There is mounting evidence to suggest that neuronal death in spinocerebellar ataxias 
results from the direct activation of apoptotic pathways (Lipinski and Yuan, 2004). In 
addition to the role of mitochondria in intracellular calcium homeostasis as discussed 
earlier, polyglutamine-expanded cellular death of cerebellar neurons by 
polyglutamine-expanded containing proteins, is preceded by recruitment of caspases 
into polyQ aggregates (Sanchez et al., 1999).  
 
Further indication of mitochondrial dysfunction resulting or contributing to ataxia is 
exemplified by AFG3L2 (ATPase family gene 3-like 2), a ubiquitous nuclear-encoded 
mitochondrial protease that forms hetero-oligomeric paraplegin-AFG3L2 and homo-
oligomeric AFG3L2 complexes in the inner mitochondrial membrane. These 
complexes ensure protein quality control in the inner membrane, jointly with a 
chaperone-like activity on the respiratory chain complexes. Mutations in AFG3L2 
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have been identified in SCA28 (Taroni and DiDonato, 2004). In this SCA subtype, 
respiratory chain dysfunction and increased reactive oxygen species production 
caused by AFG3L2 haploinsufficiency seem to lead to degeneration of Purkinje cells 
and cerebellar dysfunction (Maltecca et al., 2009). This data implicates impaired 
mitochondrial proteolysis as a novel pathway in cerebellar neurodegeneration. 
 
 
1.12.8 Alterations in synaptic neurotransmission 
 
Alterations in glutamate synaptic neurotransmission represent another mechanism 
mediating neurodegeneration in SCAs. In SCA1 transgenic mice, motor dysfunction 
precedes neuronal death, demonstrating that mutant ataxin-1 produces disruption of 
motor functions in SCA1 not by killing cells, but by affecting some Purkinje cellular 
functions including alterations in synaptic plasticity (Clark et al., 1997). Elevated 
intracellular calcium levels mediated by calcium-permeable glutamate receptors have 
been proposed as a possible mechanism (Serra et al., 2004). The importance of 
maintaining proper glutamate transmission in the Purkinje cell/parallel fibre synapse 
for proper motor function is supported from studies with ataxia mouse mutants. For 
instance, mice lacking mGluR1 (metabotropic glutamate receptor type 1) display 
significant motor deficits and, importantly, introduction of mGlur1 expression into 
Purkinje cells of mGluR1−/− mice restores normal motor function (Ichise et al., 2000). 
 
RNA-mediated neurotoxicity has been implicated in SCA8 pathogenesis (Daughters 
et al., 2009). Recent studies have revealed that the SCA8 expansion is expressed in 
both directions (CUG and CAG) and that a novel gene expressed in the CAG 
direction encodes a pure polyglutamine expansion protein (ataxin 8; ATXN8) (Ikeda 
et al., 2008). Moreover, the expression of non-coding (CUG)(n) expansion transcripts 
(ataxin 8 opposite strand, ATXN8OS) and the discovery of intranuclear 
polyglutamine inclusions suggests that SCA8 pathogenesis may involve toxic gain-of-
function mechanisms at both the protein and RNA levels. The SCA8 mice have 
revealed a loss of cerebellar GABAergic inhibition and, similar to human patients, 
intranuclear inclusions containing expanded polyQ in Purkinje cells and other 
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neurons. This data could provide a convincing explanation for the lack of penetrance 
observed in SCA8 patients (Worth et al., 2000, Corral et al., 2005). 
 
Two SCA mutations impinge on glutamate signalling just upstream of calcium 
release. SCA5 is caused by mutations in β-III spectrin (SPTBN2), which stabilises the 
EAAT4 (excitatory amino acid transporter 4) glutamate transporter at the cell surface 
(Ikeda et al., 2006). Deleterious mutation in SPTBN2 would then lead to a decrease in 
reuptake of glutamate from the synapse and a strengthening of glutamatergic 
signalling. SCA20 is caused by a chromosomal duplication of 260 kb on chromosome 
11q12 (Knight et al., 2008). A prominent candidate gene in this genomic region is 
DAGLA (diacylglycerol lipase alpha), which is highly expressed in Purkinje cell 
dendritic spines and serves to weaken glutamatergic signalling (Knight et al., 2008). 
Further experiments are necessary to determine whether duplication of DAGLA itself 
is primarily responsible for symptoms or if other genes in the critical region are more 
important. 
 
1.12.9  Additional pathways to ataxia 
 
While many of the genes mutated in the SCAs play a clear role in gene expression, 
calcium homeostasis, mitochondrial stress and apoptosis and synaptic 
neurotransmission; the existence of additional pathways to ataxia underline the 
complexity of this phenotype. Some of the emerging pathways that play an important 
role in SCA cerebellar dysfunction were highlighted in Table 1.2 and Figure 1.11. 
Whether these pathways function independently of each other or are all 
interconnected remains to be determined, though the fact that 18 of 23 proteins that 
cause hereditary ataxia in humans connect to each other either directly or indirectly 
via protein-protein interactions suggests a high degree of convergence (Lim et al., 
2006). 
 
Notably, three SCA genes are involved in phosphorylation-dependent intracellular 
signalling. Firstly, a CAG repeat expansion in the 5′UTR of PPP2R2B (Protein 
Phosphatase 2, Regulatory Subunit B) causes SCA12. PP2R2B encodes BB1 and 
BB2, regulatory subunits of protein phosphatase A (PP2A) involved in determining 
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subcellular localisation and substrate specificity of the enzyme. The pathogenic 
consequences of the SCA12 mutation remain unknown, though PP2R2B may play a 
role in recruiting PP2A to the outer mitochondrial membrane, where it helps to 
regulate mitochondrial morphology and promote apoptosis (Dagda et al., 2008). 
 
Secondly, multiple mutations in the brain-specific serine/threonine kinase PKCγ can 
cause SCA14 (Dalski et al., 2006). Both cell culture experiments and an SCA14 
transgenic mouse model demonstrate that these mutations in PKCγ alter the 
downstream signalling ability of PKCγ (Verbeek et al., 2008). 
 
Thirdly, SCA11 is caused by truncating mutations in TTBK2 (tau tubulin kinase 2) 
(Houlden, 1993). TTBK2 is also a serine/threonine kinase, the investigation of which 
is the focus of this thesis.  
 
1.13      Pathogenesis of SCA11 
 
How do TTBK2 truncating mutations lead to neuronal dysfunction and ultimately 
neuronal demise of Purkinje cells of the cerebellum? 
 
Semiquantitative PCR with reverse transcription (RT-PCR) on RNA extracted from 
lymphoblasts of affected individuals in families 1 and 2, showed that each mutation 
was associated with an approximate 50% reduction in total TTBK2 mRNA relative to 
lymphoblast mRNA from unaffected individuals (Houlden et al., 2007). Treating 
lymphoblasts from affected individuals of both families with cycloheximide, a potent 
inhibitor of protein synthesis that also blocks the nonsense-mediated decay (NMD) 
pathway, resulted in increased total TTBK2 mRNA and a selective increase in the 
abundance of the mutant mRNA, which became roughly equal to that of the normal 
transcript.  Some mutant transcript was detected on fragment analysis, which suggests 
that a proportion of the mutant mRNA escapes NMD. Thus, all four TTBK2 
mutations, which insert premature stop codons in the mRNA, lead to the production 
of a truncated protein and/or nonsense-mediated decay (NMD) of the mutant 
transcript.  
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Nonsense-mediated mRNA decay (NMD) is one of the major cellular surveillance 
mechanisms for mRNA quality control (Isken and Maquat, 2007). The NMD pathway 
detects and degrades mRNA bearing a premature termination codon, thus preventing 
the accumulation of potentially toxic protein or eliminating the detrimental effects of 
truncated protein expressed from the mRNA containing the premature stop codon 
(Frischmeyer and Dietz, 1999). In mammalian cells, RNA with a premature stop 
codon located more than 50 nucleotides upstream of the exon-exon junction is usually 
recognised (Nagy and Maquat, 1998) and degraded by the NMD pathway during the 
initial round of translation (Ishigaki et al., 2001). The NMD pathway has been shown 
to be involved in the pathological development of a number of inherited disorders 
(Frischmeyer and Dietz, 1999). 
 
Rather than generating a truncated TTBK2 protein, analyses of fibroblasts from the 
affected members of SCA11-family 1 revealed substantial loss of the mutant mRNA 
through the NMD pathway (Houlden et al., 2007). As a consequence, most of the 
expression of TTBK2 protein was from the normal allele as an approximate 50% 
reduction in total TTBK2 mRNA relative to lymphoblast mRNA from unaffected 
individuals was observed. This may result in haploinsufficiency of TTBK2, which can 
produce a concomitant reduction in the phosphorylation of its targets, which leads to 
the pathogenesis of SCA11. 
 
However, low levels of the truncated TTBK2 mRNA encoded by the mutant allele 
could be detected in the fibroblasts of affected individuals, indicating that a small 
proportion of the mutant mRNA escapes NMD. The truncating mutations could result 
in a mutant TTBK2 that lacks the non-catalytic C-terminal portion and act in a 
dominant-negative manner to inhibit the function of the wild-type TTBK2 expressed 
from the normal allele.  
 
Therefore, two plausible pathogenetic mechanisms of SCA11 should be 
contemplated: haploinsufficiency (loss of half of the kinase activity) or dominant 
negative effects of mutant TTBK2 protein. Identifying and characterising the key 
targets (substrates) of TTBK2 in neurons would provide vital new insights into the 
physiological role of TTBK2, which may, in turn, uncover the molecular pathogenic 
mechanism underpinning the development of spinocerebellar ataxia type 11 (SCA11). 
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1.14     Recently-discovered role of TTBK2 in ciliogenesis 
 
Recently, a specific role of TTBK2 was defined in mouse development: it acts at the 
mature basal body to promote the initiation of ciliogenesis (Goetz et al., 2012). In the 
course of a genetic screen for mutations that affect neural patterning in the mouse 
embryo, TTBK2 was identified as an essential gene for Sonic Hedgehog (Shh) 
signalling because it was required for formation of primary cilia.  
 
The primary cilium has critical roles in human development and disease, but the 
mechanisms that regulate ciliogenesis are not understood. Crucially, SCA11 disease-
associated mutants of TTBK2 can inhibit ciliogenesis in wild-type (WT) cells, 
suggesting that the mutations cause disease by interfering with the product of the WT 
allele. The authors hypothesised that ciliogenesis may be perturbed in individuals 
with SCA11 (Goetz et al., 2012). However, it cannot be distinguished whether the 
pathology of SCA11 is due to interference with ciliogenesis or to other targets of 
TTBK2 in the nervous system. Nevertheless, These findings raise the possibility that 
cilia may play a role in preventing neural degeneration. 
 
1.15      Aims and scope of the thesis 
 
TTBK2 was first identified based on its physical association with microtubules and its 
ability to phosphorylate microtubule-associated proteins (tau, tubulin, MAP2) in vitro 
(Takahashi et al., 1995, Tomizawa et al., 2001). This discovery was made by Japanese 
scientists in 1995, and since then considerable work has been invested in examining 
TTBK2’s relationship with aberrant tau phosphorylation and neurodegeneration in 
Alzheimer’s disease. However, these studies have never been substantiated in vivo.  
 
The identification of TTBK2 truncating mutations as the cause of spinocerebellar 
ataxia type 11 (SCA11), in 2007, highlighted the physiological importance of TTBK2 
in the nervous system. When I began my PhD, there was little known about TTBK2 
and many fundamental questions about TTBK2 remained unanswered: how do the 
disease mutations impact on TTBK2 activity, what was its physiological substrate, 
what signal transduction network it participates in and what is its physiological 
function? 
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To fully appreciate the role of any given protein kinase plays in cellular signalling, 
one needs to identify interacting partners as well as downstream substrate(s). To 
achieve this objective, the basic biochemistry of the protein kinase needs to be 
investigated first. 
 
TTBK2’s substrate specificity and selectivity had not been investigated and the 
question of how SCA11-causing truncating mutations affect protein expression and 
kinase activity was not addressed. Therefore, I sought to characterise the substrate 
specificity of TTBK2 (Chapter 3) by using an unbiased positional scanning peptide 
library. This screen revealed that it has a conspicuous preference for a 
phosphotyrosine residue at the +2 position relative to the phosphorylation site. This 
information was then exploited to develop an optimised peptide substrate, named 
TTBKtide, to assess TTBK2 catalytic activity. TTBKtide was used to demonstrate 
that SCA11 truncating mutations lead to marked inhibition of TTBK2 kinase activity. 
 
Regarding the physiological function of TTBK2, the identification and 
characterisation of the interacting partners and key targets (substrates) of TTBK2 in 
the nervous system would provide vital new insights into the physiological role of 
TTBK2. This, in turn, may uncover the molecular pathogenic mechanism 
underpinning the development of spinocerebellar ataxia type 11 (SCA11). To this 
end, I aimed to identify TTBK2 interactors and substrate(s) by co-
immunoprecipitation of endogenous TTBK2 from mouse brain homogenates (Chapter 
4). This screen provided tantalising evidence that TTBK2 operates in a distinct step of 
the synaptic vesicle cycle. An analysis of potential protein substrates identified 
synaptic vesicle glycoprotein 2A (SV2A) as a potential substrate of TTBK2. Further 
work involved the mapping of the TTBK2 phosphorylation sites on SV2A and the 
exploration of the functional significance of the phosphorylation sites. 
 
This corpus of work provides the first fundamental clues to the physiological function 
of the TTBK2 protein kinase in neurons. The tantalising evidence points towards a 
role for TTBK2 in synaptic vesicle trafficking. It also uncovers a hitherto unknown 
signalling pathway. This opens up several avenues of investigation into the molecular 
mechanisms that underlie synaptic vesicle trafficking deficits caused by TTBK2 
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mutations. Further work will thus allow us to arrive at a more complete picture of the 
impact of TTBK2 truncating mutations on synaptic vesicle trafficking and hence its 
contribution to the pathogenesis of SCA11. 
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2 MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Commercial reagents 
Common reagents and buffers were from BDH (Lutterworth, UK) or Sigma-Aldrich 
(Poole, UK) unless otherwise stated. Cellophane films and All Blue Precision Plus 
pre-stained protein markers were from BioRad (Herts, UK). Dialysed foetal calf 
serum (FCS) was from Biowest (Nuaillé, France). CHAPS detergent was from 
Calbiochem (Merck Biosciences Ltd, Nottingham, UK). Cell culture dishes, cryovials 
and Spin-X columns were from Corning Incorporated (New York, USA). Cell 
scrapers were from Costar (Cambridge, USA). 40% (w/v) 29:1 Acrylamide: Bis-
Acrylamide solution was from Flowgen Bioscience. Protein G-sepharose, 
Glutathione-sepharose, Enhanced chemiluminescence (ECL) kit, Hyperfilm MP and 
[γ32P]-labelled ATP were purchased from GE Healthcare (Piscataway, USA). 
Dulbecco’s modified eagle medium (DMEM), L-15 Leibovitz medium, Opti-MEM 
reduced serum media, Foetal bovine serum (FBS), tissue culture grade Dulbecco’s 
phosphate buffered serum (PBS), Trypsin/EDTA solution, L-glutamine, non-essential 
amino acids, vitamins, sodium pyruvate and antibiotic/antimycotic were from GIBCO 
(Paisley, UK). Pre-cast NuPAGE Novex SDS polyacrylamide 4-12% Bis-Tris gels, 
NuPAGE MES and MOPS running buffer (20X), 10X NuPAGE sample reducing 
agent, 4X NuPAGE LDS sample buffer, Colloidal blue staining kit, ProLong Gold, 
SYBR DNA gel stain were from Invitrogen (Paisley, UK). Instant Blue staining 
solution was purchased from Expedion (Cambridgeshire). Photographic developer 
(LX24) and liquid fixer (FX40) were from Kodak (Liverpool, UK). X-ray films were 
from Konica Corporation (Japan). Agarose was from Melford Laboratories 
(Chelsworth, UK). Restriction enzymes, DNA ligase and DNA ladder were from New 
England Biolabs (Hertfordshire, UK). Coomassie protein assay reagent (Bradford 
reagent) was from Pierce (Chester, UK). Polyethylenimine (PEI) was from 
Polysciences (Warrington, PA). Skimmed milk (Marvel) was from Premier Beverages 
(Stafford, UK). Taq DNA polymerase in storage buffer A, sequencing grade trypsin 
and nucleotide mix (dNTP) were from Promega (UK). Site-directed mutagenesis was 
carried out using the QuikChange® site-directed mutagenesis method. Plasmid 
Maxiprep kits were from Qiagen Ltd (Crawley, UK). Acetonitrile (HPLC grade) and 
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trifluoroacetic acid (TFA) were from Rathburn Chemicals (Walkerburn, UK). 
Protease inhibitor cocktail tablets and proteinase K were purchased from Roche 
(Lewes, UK). Protran BA nitrocellulose membrane was purchased from Schleicher 
and Schuell (Anderman and Co. Ltd., Surrey, UK). Adenosine 5’-triphosphate sodium 
salt (ATP), anti-HA-agarose, anti-FLAG-agarose, ammonium persulphate (APS), 
ampicillin, benzamidine, benzonase, bovine serum albumin (BSA), bromophenol blue 
(BPB), brilliant blue, doxorubicin, dimethyl pimelimidate (DMP), dimethyl 
sulphoxide (DMSO), ethidium bromide, etoposide glutathione, hydrogen peroxide, 
iodoacetamide, nocodazole, phenylmethanesulphonylfluoride (PMSF), Ponceau S, 
sodium dodecyl sulphate (SDS), sodium tetraborate, thymidine, N, N, N’, N’-
Tetramethylethylenediamine (TEMED), triethylammonium bicarbonate, Triton-X-
100 and Tween-20 were from Sigma-Aldrich (Poole, UK). HRP-conjugated 
secondary antibodies and SuperSignal West Dura extended duration substrate were 
from Thermo-scientific (Essex, UK). P81 paper and 3mm chromatography paper were 
from Whatman International Ltd (Maidstone, UK). Spin-X columns were from 
Corning Incorporated (NY, USA). 
 
2.1.2 In-house reagents 
Primers were synthesised by the University of Dundee oligonucleotide synthesis 
service. Bacterial culture medium Luria Bertani (LB) broth and LB agar plates were 
provided by the University of Dundee media kitchen facility. Substrate peptides for 
kinase activity assays were obtained from GS Biochem (Shanghai, China) or the 
Division of Signal Transduction Therapy (DSTT, University of Dundee). 
 
In addition, purified kinases, phosphatases and other proteins (Table 2.1) and also 
substrate peptides for kinase activity assays were obtained from the Division of Signal 
Transduction Therapy (DSTT, University of Dundee). 
 
2.1.3 Antibodies 
In-house total and phospho-specific antibodies (Table 2.1) were produced by the 
DSTT (University of Dundee). Antisera were raised in sheep by Diagnostics Scotland 
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(Carluke, Lanarkshire, UK). In addition, pre-immune IgG was purified from non-
immunised sheep serum using a protein G-sepharose column. All antibodies were 
affinity purified on CH-sepharose that had been covalently coupled to the appropriate 
antigen. 
Phospho-specific antibodies were generated as follows: first, the peptide immunogen 
was conjugated to BSA and separately to keyhole limpet haemocyanin (KLH). The 
BSA and KLH immunogen carrier protein conjugates were then injected into sheep 
along with Freunds’ Adjuvant. Sheep were injected with a booster 3 weeks later and 
the first bleed was collected after 1 week. This was repeated twice in order to obtain 3 
separate bleeds. Each bleed was allowed to clot overnight at 4 ºC, centrifuged at 1500 
x g for 60 min at 4 ºC and decanted through glass wool prior to storage at -20 ºC. For 
purification, the serum was heated for 20 min at 56 ºC followed by filtration through a 
0.45 µM filter. The anti-serum was diluted 1:1 in 50mM Tris/HCl pH 7.5 with 2% 
Triton X- 100 and purified on a column of the peptide immunogen coupled to 
sepharose. Elution was carried out using 50mM glycine pH 2.5 and dialysed 
overnight into PBS. Total protein antibodies were used at 1 µg/ml in 5% skimmed 
milk in TBS- T. Phosphospecific antibodies were also used at a concentration of 
1µg/ml in the presence of the non-phospho peptide antigen (10 µg/ml) to increase 
specificity. 
The antibodies listed in Table 2.2 were purchased from the indicated sources. 
Antibodies were prepared in either 5% skimmed milk or 5% BSA in TBS-T and used 
at the concentration recommended by the manufacturer as shown. 
 
Antibody Immunogen Sheep 
no. 
Bleed 
No. 
GST GST purified from E. coli S902A 2nd 
TTBK2 Human TTBK2 
[residues 314-385] 
S572C 3rd 
TTBK2 Human TTBK2 
[residues 300-630] 
S533C 3rd 
SV2A GST-SV2A [1-160] S290D 1st 
pSV2A pS42+S45+S47 CKKRVQDEYS*RRS*YS*RFEEEDDKK 
[residues 36 - 54 of human SV2A] 
 
S287D 3rd 
Table 2.1. In-house antibodies 
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Table 2.2 tabulates antibodies obtained from the indicated commercial sources. 
Antibodies were diluted in 5% skimmed milk in TBST or 5% BSA in TBST (which 
was filtered through 0.45µm filter) and used at the concentration recommended by the 
manufacturer.  
 
Antibody Cat No. Company Species 
SV2A ab32942 Abcam rabbit 
Synaptotagmin 1 ab7734 Abcam mouse 
SPTBN2 ab58234 Abcam mouse 
Flag F3165 Sigma mouse 
Table 2.2. Commercial antibodies 
 
2.1.4 cDNA constructs 
 
The DSTT cloning team performed the cloning, subcloning and mutagenesis of the 
constructs described in this thesis.  
TTBK2, CK1δ, SV2A and synaptotagmin 1 constructs are shown in Tables 2.3, 2.4 
and 2.5 respectively. Most of the cDNA constructs were generated by Dr. Maria 
Deak, Dr. Mark Peggie and Mr. Thomas McCartney. The mammalian expression 
vector, pEBG6P, was generated by Dr M. Deak. This is a modified version of the 
pEBG2T vector (Sanchez et al., 1994) that allows the expression of proteins with an 
N-terminal GST tag followed by a PreScission cleavage site.  
The rat Synaptotagmin1-pHluorin (Syt1-pH) construct (Table 2.6) was kindly 
provided by Professor Michael Cousin (University of Edinburgh) and mutagenesis 
was performed by Miss Simone Weidlich (DSTT cloning team). The SV2A-pHluorin 
construct was generated by inserting the superecliptic pHluorin into the first 
intravesicular loop of mouse SV2A. 
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Construct Clone no. Vector 
GST-TTBK2-[1-450]WT DU17397 pEBG6P 
GST-TTBK2-[1-450]KD DU19036 pEBG6P 
GST-TTBK2-[1-316]WT DU38313 pGEX 
GST-TTBK2-[1-316]KD DU38314 pGEX 
GST-CK1δ-[1-294]WT DU19064 pGEX 
Table 2.3. TTBK2 and CK1δ constructs 
 
 
 
 
 
 
Expressed Protein Plasmid DU No. 
GST-SV2A pEBG6P-SV2A (synaptic vesicle glycoprotein 2A) DU38471 
 
GST-SV2A[1-160] pGEX-6-SV2A-[1-160] DU38732 
GST-SV2A[1-160]
 
S42A,S45A,S47A,S62A,S80A,S81A,T84A,S127A 
pGEX-6- SV2A-[1-160] 
S42A,S45A,S47A,S62A,S80A,S81A,T84A,S127A 
DU40838 
Table 2.4. SV2A constructs 
 
 
 
 
 
Expressed Protein Plasmid DU No. 
SYT1-Flag pCMV5 Syt1 C-Flag DU41991 
 
SYT1[K327A]-Flag pCMV5 Syt1 K327A C-Flag  
 
DU44009 
SYT1[T329A]-Flag pCMV5 Syt1 T329A C-Flag  DU44010 
SYT1[K327A+T329A]-Flag pCMV5 Syt1 K327A,T329A C-Flag  DU44012 
Table 2.5. Synaptotagmin 1 (Syt1) constructs 
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cDNA Construct Plasmid DU No. 
Syt1-pH pcDNA3-pHluorin rat SYT1  DU42404 
Syt1[K326A]-pH pcDNA3-pHluorin rat SYT1 K326A DU42411 
Syt1[T328A]-pH pcDNA3-pHluorin rat SYT1 T328A  DU42412 
Syt1[K331A]-pH pcDNA3-pHluorin rat SYT1 K331A DU42420 
Syt1[K326A+T328A+K331A]-pH pcDNA3-pHluorin rat SYT1 
K326A+T328A+K331A  
DU42421 
SV2A-pH pCMVmodified SV2A pHluorin (intra-luminal) DU42855 
SV2AS42A,S45A,S47A-pH pCMVmodified SV2A SV2A S42A,S45A,S47A 
pHluorin (intra-luminal) 
DU42856 
SV2AS80A,S81A,T84A -pH pCMVmodified SV2A SV2A S80A,S81A,T84A 
pHluorin (intra-luminal) 
DU42857 
SV2A6XA-pH pCMVmodified SV2A SV2A 
S42A,S45A,S47A,S80A,S81A,T84A pHluorin 
(intra-luminal) 
DU42858 
Table 2.6. Rat Synaptotagmin1-pHluorin (Syt1-pH) and mouse SV2A-pHluorin 
cDNA constructs 
 
2.1.5 Buffers 
Phosphate buffered saline (PBS): 137mM NaCl, 2.7mM KCl, 8.1mM di-sodium 
hydrogen phosphate, 1.5 mM potassium dihydrogen phosphate pH 7.4. 
Lysis Buffer: 25mM HEPES-KOH pH 7.4, 1mM EGTA, 1mM EDTA, 0.3% (w/v) 
CHAPS (or 1% Triton X-100), 1mM sodium orthovanadate, 10mM sodium-ß-
glycerophosphate, 50mM sodium fluoride, 5mM sodium pyrophosphate, 1µM 
microcystin-LR, 0.27M sucrose, 0.12M NaCl, 0.1% β-mercaptoethanol, 1mM 
benzamidine, 0.1mM phenylmethylsulphonylfluoride (PMSF) and cOmpleteTM 
protease inhibitor cocktail (one “mini” tablet per 10 ml buffer).  
Lysis buffer ensures the immediate inhibition of proteases, protein kinases and 
phosphatases so that the phosphorylation states of proteins in lysates are fixed at the 
levels present in vivo, at the time of extraction. Benzamidine and PMSF or complete 
protease inhibitor tablets were included to prevent the action of metallo-, aspartic, 
cysteine and serine proteases. EGTA chelates Ca2+ ions while EDTA chelates Mg2+ 
ions, which are required for the phosphoryl transfer reaction carried out by protein 
kinases and hence leads to their inhibition. Sodium fluoride, sodium-β-
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glycerophosphate and sodium pyrophosphate inhibit Ser/Thr protein phosphatases 
while sodium orthovanadate inhibits protein Tyr phosphatases. Sodium orthovanadate 
was prepared by several rounds of boiling, cooling to room temperature on ice and 
then adjusted to pH 10. This was repeated until the solution was stable at pH 10 and 
remained colourless. This procedure ensures that the majority of sodium 
orthovanadate is in the monomeric state that favours Tyr phosphatase inhibition 
(Gordon, 1991). 
 
Substrate Lysis Buffer: 25mM HEPES-KOH pH 7.4, 1% Triton X-100, 0.27M 
sucrose, 0.12M NaCl, 0.1% β-mercaptoethanol, 1mM benzamidine, 0.1mM 
phenylmethylsulphonylfluoride (PMSF) and complete protease inhibitor cocktail (one 
“mini” tablet per 10 ml buffer).  
Substrate Lysis buffer was used in experiments where the target protein to be purified 
from cells lysed with the buffer was going to be used as a phosphorylation substrate in 
subsequent in vitro kinase experiments. Omitting phosphatase inhibitors in this buffer 
ensures that endogenous phosphatases dephosphorylate the target protein to a large 
extent, favouring subsequent in vitro phosphorylation reactions. 
 
Buffer A: 50mM Tris-HCl pH 7.5, 0.1mM EGTA, and 0.1% β-mercaptoethanol.  
TBS-Tween buffer (TBST): 50mM Tris-HCl pH 7.5, 0.15M NaCl and 0.1% (v/v) 
Tween-20.  
5X SDS-PAGE Sample Buffer: 5% SDS, 5% (v/v) β-mercaptoethanol, 250mM Tris-
HCl pH 6.8, 32.5% (v/v) Glycerol, Bromophenol Blue. 
 
SDS-PAGE Running Buffer: 25mM Tris-HCl pH 8.3, 192mM Glycine, 0.1% (w/v) 
SDS. 
Western Blotting Transfer Buffer: 48mM Tris-HCl, 39mM Glycine, 20% (v/v) 
Methanol. 
Coomassie staining solution: 45% (v/v) water, 45% (v/v) methanol, 10% (v/v) acetic 
acid, 0.25% (w/v) Brilliant Blue (G-250) 
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Coomassie destaining solution: 45% (v/v) water, 45% (v/v) methanol, 10% (v/v) 
acetic acid 
ECL Solution 1: 0.1M Tris-HCl pH 8.5, 2.5mM Luminol, 0.4mM p-Coumaric acid 
ECL Solution 2: 0.1M Tris-HCl pH 8.5, 5.6mM Hydrogen peroxide. 
Colloidal blue fixing solution: 40% (v/v) water, 50% (v/v) methanol, 10% (v/v) 
acetic acid. 
Colloidal blue staining solution: 55% (v/v) water, 20% (v/v) methanol, 20% (v/v) 
Invitrogen Stainer A, 5% Invitrogen Stainer B. 
2.1.6 Cell lines 
All cell lines were supplied by the MRC Protein Phosphorylation Unit and the 
Division of Signal Transduction Therapy (University of Dundee) with an original 
purchase from ATCC (American Type Culture Collection). 
2.1.7  Instruments 
The Procise 494C Sequenator was from Applied Biosystems (Foster City, USA). 
Centrifuge tubes, rotors and centrifuges were from Beckmann (Palo Alto, USA). 
Trans-Blot Cells, automatic western blot processors and gel dryer apparatus were 
from BioRad (Herts, UK). Speedvacs were from CHRIST (Osterode, Germany). 
HPLC system components were obtained from Dionex (Camberley, UK). 
Thermomixer IP shakers were purchased from Eppendorf (Cambridge, UK). The 
Biofuge microcentrifuge was from Haraeus Instruments (Osterode, Germany). pH 
meters and electrodes were from Horiba (Kyoto, Japan). X-Cell SureLock Mini-cell 
electrophoresis systems and X-Cell II Blot modules were from Invitrogen (Paisley, 
UK). The Polytron was from Kinematica (Brinkmann, CT, USA). X-omat 
autoradiography cassettes, with intensifying screens, were from Kodak (Liverpool, 
UK). The Konica automatic film processor was from Konica Corporation (Japan). 
The LiCOR odyssey infrared imaging system was from LiCOR biosciences 
(Cambridge, UK). CO2 incubators were from Mackay and Lynn (Dundee, UK). 
Tissue culture class II safety cabinets were from Medical Air Technology (Oldham, 
UK). The PCR thermocycler (PTC-200) was from MJ Research. The 96-well 
Versamax plate reader was from Molecular Devices (Wokingham, UK). The Vydac 
218TP54 C18 reverse phase HPLC column was from Separations group. The LTQ-
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orbitrap mass spectrometer and Nanodrop was from Thermo Scientific. The VP-ITC 
machine was from MicroCal and the PheraStar plate reader was from BMG Labtech. 
 
2.1.8 Animals and the generation of the TTBK2-knockin mouse 
Animal studies were approved by the University of Dundee Ethics Committee and 
performed under a U.K. Home Office project license. Animals were obtained from 
Harlan and Taconic Artemis and maintained under specific pathogen-free conditions. 
The knockin mice were generated by Taconic Artemis on an inbred C57BL/6J 
background as described. Genotyping was performed by PCR on DNA extracted from 
ears or embryonic membranes. Primers 1 (5′-CATTTGTTGGCATTATTTCAAAGG-
3′) and 2 (5′-AGTAGTAGTAGTAGTAGTAACATGG-3′) were used to detect the 
wild-type and knockin alleles. The PCR programme consisted of 2 min at 95 °C, 15 s 
at 95 °C, 30 s at 60 °C and 10 s at 72 °C for 35 cycles. 
 
 
2.2  METHODS 
2.2.1 Positional scanning peptide library screen (PSPL) 
PSPL screening was performed as previously described (Mok et al., 2010). Briefly, 
peptides had the sequence Y-A-X-X-X-X-X-S/T-X-X-X-X-A-G-K-K-Biotin), where 
X is generally an equimolar mixture of the 17 amino acid residues excluding Cys, Ser 
and Thr. For each peptide in the set, a single X residue was fixed as one of the 20 
unmodified amino acids, phosphothreonine or phosphotyrosine. Aliquots of peptides 
(0.6mM) were transferred from a 1536-well stock plate to a 1536-well reaction plate 
containing 2µl reaction buffer (50mM HEPES, pH 7.4, 1mM EGTA, 1mM DTT, 
10mM Mg(OAc)2, 0.1% Tween 20) in each well using a pin tool equipped with 200nl 
stainless steel slot pins. Kinase (75 µg of purified GST-TTBK2-[1-450]WT or GST-
TTBK2-[1-450]KD  and radiolabelled ATP (50µM, 0.33 µCi/µl [γ-32P]ATP) were 
added together to each well using a strip of 200nl slot pins, and the plate was sealed 
and incubated at 30 °C for 2 h. Aliquots (200nl) were then transferred using a pin tool 
to a streptavidin membrane, which was washed twice with 0.1% SDS in TBS (10mM 
Tris, pH 7.5, 140mM NaCl), twice with 2M NaCl, and twice with 1% H3PO4 in 2M 
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NaCl. The membrane was then air dried and exposed to a phosphor storage screen to 
visualise radiolabel incorporation. 
 
2.2.2 In vitro kinase assays using synthetic peptides as substrates 
Quantification of peptide substrate phosphorylation was achieved by measuring the 
incorporation of radioactive 32P from [γ32P]-labelled ATP into a substrate peptide. 
Assays were carried out in a final volume of 50µl containing the purified protein 
kinase, the appropriate peptide substrate, 10mM MgCl2 and 0.1mM [γ32P]-labelled 
ATP. Control reactions contained either no purified kinase or kinase-inactive version 
of the kinase. Reactions were incubated on a Thermomixer at 30 ºC for the indicated 
times and terminated by spotting 40µl onto a 2cm square of P81 phosphocellulose 
paper. Paper squares were washed extensively in 75mM orthophosphoric acid to 
remove any ATP which was not incorporated into the substrate peptide and then 
washed in acetone and left to dry. Papers were transferred to 1.5ml eppendorf tubes 
and 32P radioactivity measured by Cerenkov counting on a liquid scintillation counter. 
The protein kinase activity was expressed as specific activity (units of kinase activity 
per milligram of protein). One unit of protein kinase activity was the amount, which 
catalysed the incorporation of 1nmol phosphate into the substrate in 1min. 
 
2.2.3 Transformation of chemically-competent E.coli 
Calcium competent E.coli DH5α cells were provided by the DSTT using a previously 
described method (Inoue et al., 1990). For each transformation, approximately 10 ng 
DNA was added to 35 µl of competent cells and incubated on ice for 5min. Cells were 
then subjected to heat shock at 42 ºC for 90 sec in a water bath to induce the uptake of 
DNA and briefly placed back on ice. Bacteria were streaked onto LB agar plates 
containing 100 µg/ml ampicillin and plates incubated at 37 ºC overnight. 
 
2.2.4 Purification of plasmids from E.coli 
Transformed DH5α E.coli were cultured in 200ml LB containing 200 µg/ml 
ampicillin at 30-37°C while shaking at 200rpm overnight. Cells were pelleted by 
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centrifugation at 6000xg for 15min at 4 ºC. Plasmid DNA was purified using the 
Qiagen plasmid Maxi kit according to the manufacturer’s instructions.  
 
2.2.5 Measurement of DNA concentration 
DNA concentration was measured using NanoDrop instrument as per manufacturer’s 
instructions. The absorbance at 280nm was also measured to allow the calculation of 
the 260nm:280nm ratio, an indicator of DNA purity. A 260:280 ratio greater than 1.6 
is indicative of a highly pure sample. 
 
2.2.6 Agarose gel electrophoresis 
18 g of agarose was boiled in 180 ml of 1X TAE buffer. 10 µl of 10 mg/ml ethidium 
bromide were added after the boiled solution cooled to touchable temperature and 
then poured into a gel casting tray. Electrophoresis was carried out at 150V for 30-
40min.  
 
2.2.7 Site-directed mutagenesis 
Site-directed mutagenesis was performed by the DSTT cloning team using 
QuikChange kit (Stratagene) and KOD polymerase (Novagen). All mutations were 
verified by DNA sequencing. 
 
2.2.8 DNA sequencing 
The sequencing was performed by DNA sequencing service (School of Life Sciences, 
University of Dundee) using DYEnamic ET terminator chemistry kit (Amersham 
Biosciences) on Applied Biosystems automated DNA sequencers. 
 
2.2.9 Cell culture 
All procedures were carried out in aseptic conditions meeting biological safety 
category 2 regulations. Cells were maintained at 37°C in a 5% CO2 water-saturated 
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incubator and allowed to reach 80-90% confluency prior to passaging. For the 
passaging of cells, cells were washed once with sterile PBS and then incubated with 
sterile Trypsin/EDTA. Cells were then resuspended in pre- warmed culture medium 
and centrifuged at 800rpm for 5min. Media/trypsin was aspirated and cells 
resuspended in culture medium and transferred to flasks or dishes as required. 
Human embryonic kidney 293 (HEK293) cells were grown in Dulbecco’s modified 
eagle medium (DMEM) supplemented with 10% (v/v) foetal bovine serum (FBS), 
2mM L-glutamine, 100 U/ml penicillin and 0.1mg/ml streptomycin. Mouse 
embryonic fibroblasts (MEFs) were grown in DMEM containing 10% (v/v) FBS, 
2mM L-glutamine, 100U/ml penicillin and 0.1mg/ml streptomycin, 1X non-essential 
amino acids and 1mM sodium pyruvate. 
2.2.10 Freezing/thawing cell lines 
Cells in a confluent T-75 flask were trypsinised and centrifuged at 800rpm for 5min 
prior to resuspension in 3ml DMEM containing 45% FBS and 10% DMSO. 1ml 
aliquots were stored in cryovials in a polystyrene rack at -80°C prior to long-term 
storage in liquid nitrogen. When required, cells were rapidly thawed in a water bath at 
37ºC and immediately transferred to a T-75 flask containing 15ml media. 
 
2.2.11 Transfection of cells using PEI 
HEK293 cells were cultured in 10cm dishes and transiently transfected using the 
polyethylenimine (PEI) method ((Durocher et al., 2002)). A stock solution of 1mg/ml 
PEI was prepared in 20mM HEPES (pH 7), passed through a 0.22µm filter and stored 
at -80°C. Cells were plated in 10cm dishes 24hrs prior to transfection. For 
transfection of one DNA plasmid, 5µg of DNA was mixed with 15µl 1mg/ml PEI and 
1ml serum-free DMEM and left for 15min at room temperature before being added to 
cells dropwise. For co-transfections, 5µg of each DNA construct (10µg DNA in total) 
was mixed with 30µl PEI and 1ml DMEM. Following transfection, cells were left for 
36hrs prior to harvesting. 
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2.2.12 Cell lysis 
Cells were placed on ice, rinsed once with room temperature PBS and lysed using 
0.5ml of Triton X-100-containing (for routine experiments) or CHAPS-containing 
(for some immunoprecipitation experiments) Lysis Buffer and plastic scrapers. 
Whole-cell lysates were clarified by centrifugation at 12,000rpm for 20min at 4°C, 
the supernatants removed and stored at -80 ºC until required.  
 
2.2.13 Protein concentration estimation using Bradford assay 
The protein concentration of cell lysates and purified proteins was determined using 
the Bradford method (Bradford, 1976). This is based on the fact that when Coomassie 
dye binds to protein in an acidic medium, there is a shift in the absorption maximum 
from 465nm to 595nm and a colour change from brown to blue. A standard curve was 
generated using BSA standards (0, 25, 125, 500, 750, 1500µg/ml). These were 
prepared in water and 5µl of each added to a 96-well plate in duplicate along with 
water as a blank control. 250µl Bradford reagent was added to each well, the mixture 
was allowed to stand for 5min at room temperature prior to measuring the absorbance 
at 595nm using a 96-well plate reader. A standard curve was produced by plotting the 
absorbance values against the BSA concentration. To determine the protein 
concentration, lysates were typically diluted 1:15 in water (purified proteins were not 
diluted) and 5µl added to the wells of a 96-well plate in triplicate along with 250µl 
Bradford reagent. The absorbance values were determined as above and using the 
standard curve, translated into protein concentration. For purified proteins, the purity 
of the sample was also verified by Coomassie staining of a polyacrylamide gel. 
 
2.2.14 Affinity purification of GST-tagged or Flag-tagged proteins from 
HEK293 cells 
HEK293 cells were transfected GST-tagged or flag-tagged constructs and harvested 
48hrs post-transfection in Triton X-100 Lysis Buffer or in Substrate Lysis Buffer, if 
the target protein was going to be used as a substrate in the subsequent in vitro kinase 
reactions. 25ul of glutathione-sepharose or Flag-agarose beads were used per 5mg of 
cleared lysates to bind the target GST-tagged or Flag-tagged protein at 4°C for 2hrs 
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on a rotating platform. The beads were washed 4 times using Lysis Buffer (or 
Substrate Lysis Buffer) supplemented with NaCl for a final concentration of 0.5M and 
twice with Buffer A. GST-tagged proteins were eluted from the resin with an equal 
volume of Buffer A supplemented with 120mM NaCl, 0.27M sucrose and 40mM 
glutathione (pH 7.5-8) for 10min at room temperature on a rotating platform. Flag-
tagged proteins were eluted from the resin with an equal volume of Buffer A 
supplemented with 120mM NaCl, 0.27M sucrose and 1 mg/ml Flag peptide for 10min 
at room temperature on a rotating platform. Elutions were filtered through a 0.22µm 
Spin-X column and 100 µl aliquots were snap-frozen in liquid nitrogen and stored at -
80°C. 
 
2.2.15 Covalent coupling of antibodies 
Protein G, a protein isolated from Group G Streptococci, binds to the Fc region of 
antibodies and can be covalently attached to sepharose beads. This enables the 
immunoprecipitation of specific proteins. Protein G-sepharose was washed 5 times 
with PBS to remove traces of ethanol. The appropriate antibody and Protein G-
sepharose were mixed in a ratio of 1µg antibody to 1µl resin and incubated on a 
rotating wheel at 4 °C for 1-2hrs. The resin was washed twice with PBS. 
Antibodies were then covalently coupled to protein G-sepharose beads using dimethyl 
pimelimidate (DMP), a homo-bifunctional imidoester cross-linker that reacts with 
primary amine groups (Harlow, 1988). The resin was washed three times with 0.1M 
sodium tetraborate (pH 9.0). The resin was resuspended in sodium tetraborate 
containing 20mM DMP and incubated in the dark on a rotating wheel for 30min at 
room temperature. Fresh sodium tetraborate containing 20mM DMP was added for a 
further 30min.The resin was washed three times with 50mM glycine pH 2.5 to 
remove any non-covalently coupled antibody and glycine was neutralised with two 
washes of 0.2M Tris-HCl (pH 8.0). The resin was incubated with for 16 hrs with 
0.2M Tris-HCl (pH 8.0) at 4°C on a rotating wheel to completely quench any residual 
DMP. The resin was rinsed twice with PBS and stored at 4ºC in PBS.  
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2.2.16 Immunoprecipitation of endogenous proteins 
All procedures were carried out at 4 ºC. Typically 5 μg of antibody coupled to 5 μl of 
protein G Sepharose were used for each immunoprecipitation into a microcentrifuge 
tube. Lysate was added to the beads, the quantity depending on which protein was 
being immunoprecipitated. The protein of interest was immunoprecipitated by 
incubating the coupled antibody and lysate for 60 min at 4 ºC on a shaking platform. 
The mixture was centrifuged for 1 min at 13,000 rpm, the supernatant removed and 
the beads washed twice with 1 ml of lysis Buffer containing 0.5 M NaCl. This was 
followed by two washes with 1 ml Buffer A. The immunoprecipitate was then 
assayed for protein kinase activity or treated with LDS Sample Buffer and subjected 
to SDS/PAGE. 
 
2.2.17 Immunoprecipitation of endogenous TTBK2 from mouse brain 
homogenate 
 
The TTBK2 and pre-immune IgG antibodies were covalently coupled to protein G-
Sepharose in a ratio of 1 mg of antibody to 1 ml of resin using a dimethyl 
pimelimidate cross-linking procedure (see 2.2.15). As a pre-clearing step, 50 mg of 
mouse lysate was incubated at 4 ºC for 20 min on a rolling shaker with 0.5 ml of 
protein G-Sepharose. The supernatant was then incubated at 4 ºC for 1h on a rolling 
shaker with 50μl of TTBK2 or IgG-protein G-Sepharose conjugated antibodies. The 
immunoprecipitates were washed four times with 10ml of Lysis Buffer containing 
0.15M NaCl and lacking DTT and twice with 10ml of 10mM Tris-HCl pH 8, 0.1mM 
EGTA. The resin was resuspended in total volume of 0.1ml and 30μl of LDS Sample 
Buffer in the absence of 2-mercaptoethanol. The samples were filtered through a 0.44 
μm Spin-X filter tube, DTT was added to the flow through to a final concentration of 
10mM, then heated for 5 min at 70 ºC and concentrated by speed-vacuum 
centrifugation to 30μl. Samples were next alkylated for 30 min at room temperature 
using 50mM 4-vynilpyridine in 10mM NH4HCO3 then subjected to electrophoresis on 
a 4-12 % gel using MOPS as a running buffer and stained with Colloidal Blue 
Coomassie. The bands were excised, washed and digested with trypsin. Peptides were 
then analysed by mass spectrometry. 
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2.2.18 Lambda phosphatase treatment of SV2A immunoprecipitate 
SV2A was immunoprecipitated from mouse brain lysate as described before. For λ-
phosphatase treatment, immunoprecipitated proteins on beads were washed twice 
with lambda buffer (50 mM Tris-Cl pH 7.5, 100mM NaCl, 0.1mM EGTA, 2mM 
DTT, 0.01% Brij-35). The immunoprecipitate was then split into four aliquots:  
Aliquot 1 was left on ice, aliquot 2 was incubated for 60 min at 30 ºC in lambda 
buffer + 2.5mM MnCl2 without λ -phosphatase, aliquot 3 was treated for 60 min at 30 
°C with 100 U λ -phosphatase in lambda buffer + 2.5 mM MnCl2 and aliquot 4 was 
treated for 60 min at 30 °C with 100 U λ-phosphatase that had been pre-incubated 
with 20mM EDTA, in lambda buffer + 2.5mM MnCl2. After the 60 min incubations, 
the four pellets were washed three times in phosphatase buffer containing 150mM 
NaCl, then resuspended in SDS sample buffer and analysed by immunoblotting. 
 
2.2.19 Resolution of proteins using SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is used to 
separate proteins on the basis of their apparent molecular weight. The anionic 
detergents, sodium dodecyl sulphate (SDS) and lithium dodecyl sulphate (LDS), bind 
to proteins giving them a resulting negative charge that is proportional to their mass. 
As a result, the speed of migration of a protein through a constant gradient 
polyacrylamide gel matrix is a linear function of the logarithm of its molecular 
weight, with small proteins migrating faster than large proteins. 
Separation gels were prepared containing 375mM Tris HCl pH 8.6, 0.1% SDS, 8-15% 
acrylamide (depending on the size of the protein) with N,N,N’,N’- 
tetramethylethylenediamine (TEMED) and ammonium persulphate (APS) used to 
initiate polymerisation. Gels were allowed to polymerise for 30min under 
isopropanol. Stacking gels contained 125mM Tris HCl pH 6.8, 0.1% SDS, 4% 
acrylamide, TEMED and APS. 
 
Cell lysates, immunoprecipitates and purified proteins were prepared in 1XLDS 
sample buffer containing 1X sample reducing agent (for use with pre-cast NuPAGE 
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4-12% Bis-Tris gels) or 1X SDS sample buffer (for use with home- made acrylamide 
gels) and heated to 70°C for 5min. Samples were loaded onto gels along with 
Precision plus protein standards which have apparent molecular weights of 250, 150, 
100, 75, 50, 37, 25, 20, 15 and 10kDa. Electrophoresis was carried out at 90V for 
30min prior to an increase of the voltage to 180V for a further 1hr and gels were 
either stained or transferred for immunoblotting. 
 
2.2.20 Coomassie staining of polyacrylamide gels 
Gels were incubated in Coomassie staining solution for 30 min before being washed 
in destaining solution overnight. Gels used for protein identification by mass 
spectrometry, were stained with Colloidal Coomassie according to the manufacturer’s 
instructions. 
 
2.2.21 Desiccation of polyacrylamide gels 
Gels containing 32P-labelled proteins were dried to improve the autoradiographic 
signal. Gels were transferred to water containing 5% glycerol and sandwiched 
between two sheets of cellophane. The gel was then dried in a GelAir™ Dryer. 
 
2.2.22 Autoradiography  
Coomassie stained gels were placed in an X-Omat autoradiography cassette and 
exposed to Hyperfilm™ for different lengths of time. Typically exposures were 
carried out for between 30min to 48hr in order to detect radioactively labelled 
proteins. For long exposures, the cassette was placed in a -80°C freezer to improve 
the autoradiographic signal. Films were developed using a Konica automatic 
developer. 
 
2.2.23 Transfer of proteins onto nitrocellulose membranes 
Gels that had been subjected to electrophoresis were assembled into a gel- membrane 
sandwich and loaded into a BioRad Mini Trans-blot electrophoretic transfer cell. Prior 
to assembly, nylon sponge pads, Whatman 3mm filter papers and nitrocellulose 
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membranes were soaked in transfer buffer containing 20% (v/v) methanol. The 
transfer cell was submerged in transfer buffer and electrotransfer carried out at 100V 
for 1.5hrs. 
 
2.2.24 Immunoblotting 
Nitrocellulose membranes were briefly stained with Ponceau-S, in order to ensure that 
proteins had been successfully transferred from the gel, before being washed in water. 
Membranes were then blocked for 30min in TBS-Tween buffer containing 5% (w/v) 
skimmed milk and incubated with the appropriate antibody at 4ºC overnight. 
Membranes were washed 6 times with TBS-T, incubated with horseradish peroxidase 
(HRP)-conjugated secondary antibodies for 1hr and washed another 6 times with 
TBS-T using an automatic western blot processor. Finally, membranes were 
incubated with the enhanced chemiluminescence reagent (either in-house or 
commercial reagents) and exposed to X-ray films for different lengths of time. As 
before, films were developed using a Konica automatic developer. 
 
2.2.25 Processing protein bands for analysis by mass spectrometry  
To minimise contamination with proteins such as keratin, sample preparation was 
carried out in a laminar flow hood. Gel pieces were cut into approximately 1mm 
cubes and washed for 10min in water, 50% acetonitrile/water, 0.1M NH4HCO3 and 
50% acetonitrile/50mM NH4HCO3. Washes were carried out in a 0.5ml volume on a 
vibrax shaking platform for 10min and all liquid was removed between washes. The 
final step was repeated until the gel pieces were essentially colourless. Subsequently, 
0.3ml acetonitrile was added and incubated for 15min before the supernatant was 
removed and gel pieces dried in a Speed-Vac. The gel pieces were incubated with 
30µl 25mM Triethylammonium bicarbonate containing 5µg/ml Trypsin at 30°C 
overnight on a shaking platform. Subsequently, an equivalent volume of acetonitrile 
was added for 15min and the supernatant was collected in a clean tube and dried using 
a Speed-vac. Meanwhile 100µl 50% acetonitrile /2.5% formic acid was added to the 
gel pieces, incubated for 15min and the supernatant combined with the first dried 
extract. This was dried in a Speed Vac and stored at -20°C. 
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2.2.26 Mass spectrometry 
LC-MS was performed by Dr D. Campbell and Mr R. Gourlay. Tryptic peptides were 
subjected to LC-MS on a Dionex 3000 nano liquid chromatography system coupled to 
an LTQ-orbitrap mass spectrometer. Results were searched against the IPI-human 
database using the Mascot algorithm (www.matrixscience.com) to identify tryptic 
peptides. 
 
2.2.27 Phosphomapping using HPLC/Edman degradation 
Proteins were phosphorylated in vitro using high-specific activity (~500,000cpm) 
[γ32P]-labelled ATP and resolved on SDS-PAGE. Bands were processed for mass 
spectrometry analysis. Samples were then subjected to HPLC on a Vydac C18 column 
equilibrated in 0.1% (w/v) trifluoroacetic acid (TFA), with a linear acetonitrile 
gradient at a flow rate of 0.2 ml/minute. Fractions of 0.1 ml were collected and 
phosphopeptides were analysed by LC-MS/MS. Individual MS/MS spectra were 
inspected using XCalibur software. The phosphorylated residues were mapped by 
solid-phase Edman degradation. The 32P-labelled peptide was coupled to a Sequelon-
AA membrane and Edman sequencing carried out using an Applied Biosystems 494C 
sequencer. All HPLC and Edman degradation analyses were performed by Dr D. 
Campbell and Mr R. Gourlay. 
 
 
2.3 Biophysical Techniques 
 
2.3.1   Isothermal Titration Calorimetry (ITC) 
Proteins and peptides for calorimetric analysis were dialysed against the same buffer: 
20mM HEPES pH 7.5, 50mM NaCl. All protein solutions were filtered through a 
0.22µm membrane and degassed thoroughly in a vacuum chamber before use.  
ITC experiments were carried out on a Microcal VP-ITC (Milton Keynes, England). 
Figure 2.1 shows a diagram of the equipment used. A series of 30 x 4 µl injections of 
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buffered peptide were made into an isolated chamber containing 1.2 ml of buffered 
protein at various concentrations at a constant temperature of 25 °C. A space of 2 
minutes was allowed between injections to ensure equilibration between reactants. 
The reaction cell was stirred at a constant speed of 300 rpm. 
 
Figure 2.1. Diagram of the MicroCal VP-ITC. The protein for analysis is injected into the sample 
cell and the metal ligand drawn into the syringe. A small amount of sample buffer is then injected into 
the reference cell, in order to provide a reference temperature for the machine to equilibrate with after 
each injection. The chamber is shielded from the outside environment by a double casing. The syringe 
is then locked into place over the sample cell and set to stir the sample at 300rpm. After a period of 
time to allow the entire system to equilibrate, the plunger descends and releases a fixed amount of 
metal into the sample chamber. Any change in heat is then recorded and the system re-equilibrates in 
preparation for the next injection. 
 
Heat changes within the cell were monitored during each injection of metal and 
recorded as the total heat change per second over time. A binding isotherm was then 
fitted to data and expressed as heat change per mole of metal against the metal to 
protein ratio. For each protein and for each condition, at least 2 runs were carried out 
to ensure reproducibility. Between each run, the chamber was thoroughly washed 
with at least 10 chamber volumes of MilliQ (Millipore, England) water and the 
syringe rinsed thoroughly again with at least 10 volumes of MilliQ water. 
From the isothermic data, a regression model was used to predict the number of 
binding sites on the protein involved in the reaction, the dissociation constants of the 
binding (KD) and the change in enthalpies (ΔH).  
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The choice of buffers was based on initial trials, which revealed that these buffers 
offered the minimum of background noise. Each experimental condition had a blank 
run with protein in the chamber replaced with buffer. This data was then subtracted 
from the run with protein present to take into account any energy of dilution or 
metal/buffer reaction.  
2.3.2 Fluorescence Polarisation 
Fluorescence polarisation (FP) or anisotropy can be used to measure protein–protein 
or protein–ligand interactions. Typically one binding partner is labelled with a 
fluorescence probe and the sample is excited with polarised light. The increase in the 
polarisation of the fluorescence upon binding of the labelled protein to its binding 
partner can be used to calculate the binding affinity (Owicki, 2000). 
In broad terms, fluorescence polarisation is relevant where a small (tumbling), 
fluorescent molecule binds a larger target molecule. Thus the observation of small 
fluorescent ligands binding protein molecules are often experiments suitable for this 
type of detection. Fluorescence anisotropy is a method for measuring the binding 
interaction between two molecules, and can be used to measure the binding constant 
(or the inverse, the disassociation constant) for the interaction. The basic idea is that a 
fluorophore excited by polarised light (light whose "waves" only go one direction) 
will also emit polarised light. However, if a molecule is moving, it will tend to 
"scramble" the polarisation of the light by radiating at a different direction from the 
incident light. The "scrambling" effect is greatest with fluorophores freely tumbling in 
solution and decreases with decreased rates of tumbling. Protein interactions can be 
detected when one of the interacting partners is fused to a fluorophore: upon binding 
of the partner molecule a larger, more stable complex is formed, which will tumble 
more slowly (thus, increasing the polarisation of the emitted light and reducing the 
"scrambling" effect). This technique works best if a small molecule is fused to a 
fluorophore and binds to a larger partner (this maximises the difference in signal 
between bound and unbound states). Molecular interactions can thus be analysed 
using this approach where the smaller molecule is fluorescently labelled and the 
concentration of the larger binding partner is varied. An illustration depicting the 
concept of fluorescence anisotropy is shown in Figure 2.2 below. 
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Figure 2.2. Illustration of the concept of fluorescence anisotropy. As molecules tumble in solution, 
the emitted light is depolarised. The depolarisation of the fluorescent molecule is dependent on the size 
and shape of the rotating molecule and also the viscosity of the solution. The smaller the molecule, the 
more rapidly it rotates and the more the light is depolarised and hence the lower the anisotropy. If a 
larger molecule interacts with the fluorescent molecule the rotation of the complex will be slower than 
of the unbound molecules and result in an increase in the fluorescence anisotropy. 
 
2.3.2.1  Labelling peptides with FlAsH 
Peptides were custom-synthesised with a N-terminal CCPGCCGG tetra-cysteine tag 
(Adams et al., 2002), where two glycine residues were added as a linker. This tag 
affords their labelling with FlAsH-EDT2, an arsenic derivative of fluorescein. 
Labelling of N-terminally FlAsH-tagged (CCPGCC) peptides (Adams et al., 2002) 
was performed in 20mM HEPES (pH 7.5), 50mM NaCl and 5mM β‐mercaptoethanol. 
10 nmol of each FlAsH-tagged peptide was incubated with 5µl FlAsH-EDT2 (Lumio 
Green) at room temperature for 2.0 h in the dark. Excess dye was removed by 
overnight dialysis into the above buffer. 
 
2.3.2.2  Equilibrium fluorescence anisotropy measurements 
All binding assays were performed by adding 100nM of labelled peptide to increasing 
concentrations of recombinant protein at room temperature. End point polarisation 
and anisotropy measurements were made using PheraStar plate reader (BMG 
Labtech) using a 485/520 nm fluorescence polarisation module. Data was analysed 
using GraphPad Prism 5 and mean fluorescence anisotropy values (2 measurements) 
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were plotted against protein concentration and the curves fitted to a single-site 
binding model to determine KD values. 
 
2.3.3 Sequence alignments 
Sequence alignments were performed using the ClustalW algorithm for multiple 
sequence alignment and using JalView. 
 
2.3.4 Statistical analysis 
All the experiments presented in this thesis were repeated at least two or three times 
and similar results were obtained. Error bars always indicate the standard error of the 
mean (S.E.M.) and were calculated using GraphPad Prism. 
 
2.4  The use of pHluorins for optical measurements of presynaptic 
acitivity 
 
2.4.1 Hippocampal neuronal cultures and transfections 
Dissociated primary hippocampal neuronal cultures were prepared from E17.5 from 
wild-type embryos of either sex by trituration of isolated hippocampi to obtain a 
single cell suspension, which was plated at a density of 5-10 ×106 cells/coverslip on 
poly-D-lysine and laminin-coated 25 mm coverslips. Cultures were maintained in 
neurobasal media supplemented with B-27, 0.5 mM L-glutamine and 1% v/v 
penicillin/streptomycin. After 72 hours cultures were further supplemented with 1 µM 
cytosine β-d-arabinofuranoside to inhibit glial proliferation. Cells were transfected 
after 7 days in culture with Lipofectamine 2000 according to the manufacturer’s 
instructions, with the following alterations: cells were preincubated in 2ml MEM at 
5% CO2 for 30 min at 37°C, and then incubated for 2 hours with 2µl lipofectamine 
and 1 µg DNA construct/well. Cells were subsequently washed with MEM before 
replacement of conditioned neurobasal media. Cells were imaged after 14-21 days in 
culture. 
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2.4.2 Fluorescent imaging protocols for pHluorin reporters 
Hippocampal cultures were mounted in a Warner imaging chamber with embedded 
parallel platinum wires (RC-21BRFS) and placed on the stage of a Zeiss (Germany) 
Axio Observer D1 epifluorescence microscope. Neurons transfected with pHluorin 
reporters were visualised at 500 nm (all >525 nm emission). In all experiments 
cultures were stimulated with a train of 200 action potentials delivered at 10 Hz (100 
mA, 1 ms pulse width). Cultures were subjected to continuous perfusion with imaging 
buffer (in mM: 136 NaCl, 2.5 KCl, 2 CaCl2, 1.3 MgCl2, 10 glucose, 10 HEPES, pH 
7.4). Fluorescent images were captured at 4 s intervals using a Hamamatsu Orca-ER 
digital camera (Hamamatsu City, Japan) and processed offline using Image J 1.43 
software (NIH, USA). Regions of interest of identical size were placed over nerve 
terminals that displayed an increase on stimulation and the total fluorescence intensity 
was monitored over time. All statistical analyses were performed using Microsoft 
Excel and GraphPad Prism (La Jolla, CA) software. The pHluorin fluorescence 
change was calculated as ΔF/F0 in all cases. 
Estimation of surface Syt1-pHluorin and SV2A-pHluorin was performed by perfusing 
acidic imaging buffer (substituting 20mM MES for HEPES, pH 5.5) over cultures for 
30 seconds (to quench surface Syt1-pHluorin) followed by a 1 min perfusion with 
standard imaging buffer (pH 7.4). Cultures were then subjected to alkaline imaging 
buffer (50mM NH4Cl substituted for 50mM NaCl) for 30 seconds to reveal total Syt1-
pHluorin. The surface fraction of Syt1-pHluorin as a percentage of total was 
estimated using the following equation ((neutral fluorescence – acidic fluorescence / 
alkali fluorescence – acidic fluorescence) × 100). 
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3 Substrate specificity of TTBK2 
 
 
Since its discovery by Japanese scientists in 1995, considerable work has been 
invested in examining TTBK2’s relationship with tau phosphorylation and 
neurodegeneration. However, the validity of these studies has never been 
substantiated in vivo. In 2007, the identification of TTBK2 truncating mutations, as 
the cause of spinocerebellar ataxia type 11 (SCA11), reemphasised that TTBK2 has a 
prominent physiological role in the brain. 
 
Before tackling the pertinent questions regarding TTBK2’s physiological function, 
basic biochemical investigations would require an appropriate tool: an in vitro peptide 
substrate to assay TTBK2’s intrinsic activity. However, a basic biochemical 
characterisation of TTBK2 was never performed before I started my PhD and thus 
nothing was known about TTBK2 substrate selectivity and specificity. In this chapter, 
I present an initial biochemical characterisation of TTBK2. To better understand the 
substrate specificity of TTBK2, I have used a degenerate peptide library approach that 
provides an unbiased evaluation of the importance of the residues surrounding the site 
of phosphorylation for an optimal substrate. This initial analysis of TTBK2 substrate 
specificity has shown that it has a conspicuous preference for a phosphotyrosine 
residue at the +2 position relative to the phosphorylation site. This information was 
used to develop an optimised peptide substrate, TTBKtide, to assess TTBK2 catalytic 
activity.  
 
TTBKtide was subsequently used to evaluate how SCA11 truncating mutations affect 
kinase activity. SCA11 truncating mutations markedly enhance TTBK2 protein 
expression but, however, lead to inhibition of TTBK2 kinase activity. TTBK2-
knockin mice expressing an SCA11 disease-causing mutation were generated and the 
inhibition of endogenous protein kinase activity by the SCA11 truncating mutation 
was confirmed. Also, homozygosity of the SCA11 mutation causes embryonic 
lethality. These findings will provide the tools and the platform for further 
investigations into the function and regulation of TTBK2, as well as its role in 
SCA11. 
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3.1   Expression and purification of GST-TTBK2-[1-450]WT and 
GST-TTBK2-[1-450]D163A (kinase inactive). 
 
To explore TTBK2’s substrate selectivity, recombinant TTBK2 was expressed in 
mammalian cells. HEK293 cells were transfected with GST-tagged constructs 
expressing TTBK2-[1-450]WT and kinase-inactive TTBK2-[1-450]D163A. 36hrs post-
transfection, cells were lysed and GST purifications carried out. Purified proteins 
were subjected to SDS-PAGE and the protein bands visualised using Coomassie 
staining (Figure 3.1). 
 
 
Figure 3.1. Expression and purification of GST-TTBK2-[1-450]WT and GST-TTBK2-[1-450]D163A 
(kinase inactive). HEK293 cells were transfected with GST-tagged constructs expressing TTBK2-[1-
450]WT and kinase-inactive TTBK2-[1-450]D163A. 36hrs post-transfection, cells were lysed and GST 
purifications carried out. Purified proteins were subjected to SDS-PAGE and the protein bands 
visualised using Coomassie staining. 
 
Adequate expression of both GST-TTBK2-[1-450]WT and kinase-inactive GST-
TTBK2-[1-450]D163A was observed as seen in Figure 3.1. The band shift displayed by 
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the wild-type protein compared to the kinase-inactive version is due to auto-
phosphorylation of the active kinase as ascertained by mass spectrometry (data not 
shown). 
 
 
3.2   Analysis of the substrate specificity of TTBK2 by a positional 
scanning peptide library approach 
 
An unbiased positional scanning peptide library (Hutti et al., 2004, Turk et al., 2006) 
approach was initially used to probe the substrate specificity preferences of TTBK2. 
In collaboration with Dr. Lewis Cantley’s laboratory (Harvard Medical School), a 
‘Positional Scanning Peptide Library’ was performed. This assay employs 198 
biotinylated peptide libraries that each contain a 1:1 mixture of serine and threonine at 
the central position and one additional position fixed to one of the 20 amino acids, as 
well as phosphothreonine or phosphotyrosine. Phosphothreonine and phosphotyrosine 
were included to allow substrate specificity analysis of kinases such as CK1, to which 
TTBK2 is related, that have preferences for priming phosphorylation sites. All other 
positions contained an equimolar degenerate mixture of natural amino acids (except 
serine, threonine and cysteine).  
 
The 198 libraries were screened using [γ-32P] ATP and recombinant TTBK2-[1–
450]WT or kinase-inactive TTBK2-[1–450]D163A expressed in HEK-293 cells. 
Biotinylated peptides were then captured on a streptavidin-coated membrane. The 
relative amino acid preference at each position was determined by quantifying 32P-
radioactivity incorporation following phosphoimaging (Figure 3.2).  
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Figure 3.2. Positional scanning peptide library screen. Recombinant HEK-293 purified GST–
TTBK2-[1–450]WT (wild-type) and catalytically inactive GST–TTBK2-[1–450]D163A were used to 
screen a positional scanning peptide library consisting of 198 biotinylated peptide libraries in 
individual kinase assays. Reaction products were bound to streptavidin-coated membrane and, after 
washing, phosphorylation was visualised by phospho-imaging. TTBK2 displayed a conspicuous 
preference for a phosphotyrosine residue at the +2 position, indicated by a red asterisk. 
 
The most salient observation from this peptide library screen was that GST–TTBK2-
[1–450]WT  has a conspicuous preference for a phosphotyrosine residue at the +2 
position downstream from the site of phosphorylation (indicated by a red asterisk in 
Figure 3.2). This finding was consistently observed in two independent experiments. 
 
Apart from the marked incorporation of radioactive ATP for the +2 phosphotyrosine 
peptide library, low levels of phosphorylation were detected in a few other libraries 
e.g. library with serine at -3. However the levels of ATP incorporation in those 
libraries were not as high as in the +2 phosphotyrosine library. For the screen 
undertaken with the kinase-inactive GST–TTBK2-[1–450]D163A overall levels of 
phosphorylation observed were considerably low, and crucially no preference for a +2 
phosphotyrosine was detected. 
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3.3   Elaboration of an optimal TTBK2 peptide substrate, 
TTBKtide. 
 
TTBK2 is a member of the CK1 family of kinases and it was established that it could 
phosphorylate a model peptide substrate termed CK1tide that is frequently employed 
to assess CK1 isoform activity (Marin et al., 1994). CK1δ phosphorylates CK1tide 
(RRKDLHDDEEDEAMS*ITA) at the serine residue marked with an asterisk (Marin 
et al., 1994), and Dr. Michale Bouskila (former postdoc in the lab) confirmed that 
TTBK2-[1–450]WT also phosphorylates CK1tide specifically at this serine residue by 
solid-phase sequencing (data not shown).  
 
To further delineate the substrate selectivity of TTBK2 and to define the optimal 
phosphorylation motif for TTBK2, I sought to analyse the kinetics of phosphorylation 
reactions using a number of different synthetic peptides with variations on the 
CK1tide sequence. A number of peptides were carefully designed, synthesised and 
assayed with recombinant GST-TTBK2 [1-450]WT and GST-TTBK2 [1-450]KD.  
 
Firstly, to test the contribution of the residue at the +2 position to TTBK2 substrate 
recognition and the importance of a phosphotyrosine at this position, three different 
peptides with variations at the critical +2 position in the CK1tide sequence were 
generated: 
 
! RRKDLHDDEEDEAMSITA           (CK1tide) 
          
! RRKDLHDDEEDEAMSIYA           (+2Y peptide) 
 
! RRKDLHDDEEDEAMSIYPA          (+2YP peptide) 
 
! RRKDLHDDEEDEAMSITPA           (+2TP peptide) 
 
 
Those three peptides and CK1tide were assayed with recombinant GST-TTBK2-[1-
450]WT and detailed kinetic analysis to study the relative phosphorylation kinetics of 
each peptide were carried out and are shown in (Figure 3.3) on the next page.  
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Figure 3.3. Phosphorylation kinetics of synthetic peptides by TTBK2. Three CK1tide variants with 
with a phosphothreonine, tyrosine and phosphotyrosine at the +2 position were synthesised, and the 
kinetics of their phosphorylation by GST–TTBK2 [1-450]WT was analysed. Km and Vmax values were 
derived by non-linear regression analysis. Results shown are means±S.D. for three independent 
experiments. 
 
 
Replacement of the +2 threonine residue of CK1tide with a tyrosine did not improve 
the kinetic constants. However, assay of the peptide with a phosphotyrosine at this 
position produced a substantial improvement in the Km value. The Km value of 
TTBK2 with RRKDLHDDEEDEAMSIYPA as the substrate compared to 
RRKDLHDDEEDEAMSIYA was 8-fold lower (141.2 µM compared to 18.0 µM) 
(see table in Figure 3.3) while the Vmax was only marginally enhanced. A 
phosphotyrosine residue at the +2 position was therefore a positive determinant for 
 RRKDLHDDEEDEAMSITA 
(CK1tide) 
  RRKDLHDDEEDEAMSITPA 
 (+2TP) 
RRKDLHDDEEDEAMSIYA 
 (+2Y) 
RRKDLHDDEEDEAMSIYPA 
(+2YP) 
Vmax  
(nmol/mg/min)  
30.0 15.3 32.6 37.5 
Km  (µM)  200.0 361.1 141.2 18.0 
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TTBK2 recognition, and this observation corroborates the finding from the peptide 
library screen. 
 
The peptide RRKDLHDDEEDEAMSITPA gave a lower Vmax and a significantly 
higher Km compared to CK1tide. Thus, introducing a phosphothreonine rather than a 
phosphotyrosine residue at the +2 position failed to enhance TTBK2 activity (Figure 
3.3) indicating the specificity of a phosphotyrosine residue at the +2 position as a 
positive determinant for TTBK2 recognition. 
 
 
3.3.1 Specificity of the +2 position relative to the phosphorylation site 
 
To establish the importance of having a phosphotyrosine residue at the +2 position 
relative to other positions, eight further CK1tide derivatives with varying positions of 
the phosphotyrosine from +4 to -5 relative to the phosphorylatable serine were 
generated. The peptide sequences were as follows: 
 
! RRKDLHDDEEDEAMSITAYP 
! RRKDLHDDEEDEAMSITYP 
! RRKDLHDDEEDEAMSIYPA 
! RRKDLHDDEEDEAMSYPTA 
! RRKDLHDDEEDEAYPSITA 
! RRKDLHDDEEDEYPMSITA 
! RRKDLHDDEEDYPAMSITA 
! RRKDLHDDEEYPEAMSITA 
! RRKDLHDDEYPDEAMSITA 
 
 
TTBK2 assays of those peptides are shown on the next page. 
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Figure 3.4. Potentiation by phosphotyrosine at +2. Peptides with various positions of the 
phosphotyrosine residue from +4 to −5 relative to the phosphorylated serine residue were synthesised 
and analysed for their ability to phosphorylate GST–TTBK2 [1–450]WT purified from HEK-293 cells. 
Km and Vmax values were derived by non-linear regression analysis as described in the Materials and 
methods section. Results shown are means±S.D. for three independent experiments. 
 
Assays of TTBK2 with those nine peptides showed that the rates of phosphorylation 
of those peptides were noticeably lower compared to the peptide with a 
phosphotyrosine at the +2 position (Figure 3.4).  This further substantiated the 
findings of the positional scanning peptide library approach, revealing that 
introducing a phosphotyrosine residue at only the +2 position, but not at any other 
position, strongly enhanced peptide phosphorylation.  
 
Collectively, the results of those peptide assays support the view that the substrate 
recognition of TTBK2 is substantially enhanced by the presence of a phosphotyrosine 
residue and this recognition is exceptionally specific for a phosphotyrosine at the +2 
position. Consequently, the CK1tide peptide with a phosphotyrosine residue at the +2 
position was chosen as the optimal peptide to perform TTBK2 activity assays and 
henceforth named TTBKtide (RRKDLHDDEEDEAMSIYPA).  
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3.4   Residues phosphorylated by TTBK2 
 
To compare the efficiency with which TTBK2 phosphorylates the serine, threonine or 
tyrosine residues, I compared the phosphorylation of three variants of TTBKtide in 
which the phosphorylated residue was either serine or threonine or tyrosine at the 
phosphoacceptor site. The amino acid sequence of the three peptides assayed were as 
follows:  
! RRKDLHDDEEDEAMSIYPA 
! RRKDLHDDEEDEAMTIYPA 
! RRKDLHDDEEDEAMYIYPA 
 
Figure 3.5. Phosphorylation of TTBKtide variants with threonine and tyrosine as the 
phosphoacceptor. Three TTBKtide variants with serine, threonine and tyrosine residues at the 
phospho-acceptor position were synthesised, and the kinetics of their phosphorylation by GST–
TTBK2-[1-450]WT was analysed. Km and Vmax values were derived by non-linear regression analysis. 
NP* denotes that the peptide was phosphorylated too poorly to undertake accurate kinetic analysis. 
Results shown are means±S.D. for three independent experiments. 
 
Substituting the phosphoacceptor serine with a threonine residue did not alter the 
efficacy of the peptide as a TTBK2 substrate, with similar Km and Vmax values (see 
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table in Figure 3.5). However, replacement of the phosphoacceptor site with a 
tyrosine residue resulted in a peptide that no longer served as a TTBK2 substrate 
(Figure 3.5). Thus, TTBK2 showed no preference for serine or threonine residues as 
the phosphoacceptor whereas tyrosine residues are not phosphorylated by TTBK2. 
This result is consistent with the classification of TTBK2 as a serine/threonine kinase. 
 
3.5   Substrate selectivity of CK1 superfamily enzymes 
 
Since TTBK2 is a member of the CK1 superfamily of kinases. I evaluated whether 
other CK1 family enzymes exhibited the same preference for a phosphotyrosine at +2. 
To this end, CK1delta (CK1δ) was assayed against CK1tide, unphosphorylated 
TTBKtide and TTBKtide. The three peptides used were as follows:  
 
! RRKDLHDDEEDEAMSITA 
! RRKDLHDDEEDEAMSIYA 
! RRKDLHDDEEDEAMSIYPA 
 
The three above peptides were assayed with GST-CK1δ-[1-294] expressed in bacteria 
and the kinetics are detailed in Figure 3.6 below. 
 
Assays of those peptides with CK1δ showed that it displayed a higher affinity for 
TTBKtide than for its unphosphorylated derivative; attested by a 2-fold lower Km 
(74.1 µM compared to 172.4 µM). The difference in Vmax between the two peptides 
was clear: a 3-fold higher Vmax was observed for TTBKtide when compared to 
unphosphorylated TTBKtide (563.5 Units/mg compared to 187.2 Units/mg, where 1 
unit is the incorporation of 1 nmol of phosphate per minute).  
 
Importantly, CK1tide was a poorer substrate compared to the other two peptides. 
TTBKtide produced an almost 10-fold higher Vmax (563.5 U/mg compared to 58.1 
U/mg) and a marginally lower Km  (74.1 U/mg compared to 103.1 U/mg) than 
CK1tide. Similar kinetics were observed with other CK1 isoforms, CK1α, CK1γ and 
CK1ε (data not shown). These findings support the notion that a phosphotyrosine at 
+2 may be also be a determinant of substrate recognition by CK1 isoforms. 
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Figure 3.6. Phosphorylation of CK1tide, unphosphorylated TTBKtide and TTBKtide by CK1 
delta. The kinetics of the phosphorylation of the three peptides by GST–CK1δ-[1-294]WT was 
analysed. Km and Vmax values were derived by non-linear regression analysis. Results shown are 
means±S.D. for three independent experiments. 
 
The importance of a phosphotyrosine at +2 had not been previously recognised. 
Historically, CK1tide has been used as the standard peptide used to assay CK1 
activity. TTBKtide is therefore a better in vitro peptide substrate to assay intrinsic 
CK1 activity. 
 
3.6   CK1 consensus phosphorylation motif 
 
Studies utilising peptides based on the amino acid sequence of glycogen synthase 
showed that CK1 preferentially phosphorylates peptides containing a phosphoserine 
residue N-terminal to the Ser/Thr targeted for phosphorylation (Nakielny et al., 1991). 
Other studies using synthetic peptides defined a minimal recognition motif: SP-X-X-
S/T (Kuret et al., 1985, Flotow et al., 1990, Flotow and Roach, 1991). 
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This recognition motif indicates that the phosphorylation of serine and threonine 
residues by CK1 requires the preceding phosphorylation of amino acid residues N-
terminal to the target site. This requirement of a priming phosphorylation of amino 
acid by another kinase restricted CK1 to a function in the hierarchical 
phosphorylation of substrates. However, further studies revealed that a cluster of 
acidic amino acids N-terminal of the target serine/threonine and an acidic amino acid 
in position n-3 could substitute for the phosphoamino acid effectively (Flotow and 
Roach, 1991).  
 
3.6.1 Impact of a phosphoserine residue at -3 on substrate recognition by 
TTBK2 and CK1δ 
 
To compare the requirement for an N-terminal -3 phosphoserine to that of a +2 
phosphotyrosine, four more TTBKtide (RRKDLHDDEEDEAMSIYPA) variants with 
substitutions at the -3 position were designed and assayed. The peptides sequences 
were as follows: 
 
! RRKDLHDDEEDSAMSIYA 
 
! RRKDLHDDEEDSAMSIYPA 
 
! RRKDLHDDEEDSPAMSIYA 
 
! RRKDLHDDEEDSPAMSIYPA 
 
 
Assays of those above four peptides with TTBK2 are shown on the next page. 
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Figure 3.7. Phosphorylation of CK1tide variants with serine/phosphoserine at -3 and 
tyrosine/phosphotyrosine at +2 by TTBK2. Four CK1tide variants with serine/phosphoserine at -3 
and tyrosine/phosphotyrosine at +2 were synthesised, and the kinetics of their phosphorylation by 
GST-TTBK2-[1-450]WT was analysed. Km and Vmax values were derived by non-linear regression 
analysis. Results shown are means±S.D. for three independent experiments. 
 
The Km of the peptide RRKDLHDDEEDSAMSIYPA was similar to that of the 
peptide RRKDLHDDEEDSAMSIYA (65.0 µM compared to 86.1 µM) and the 
change in Vmax values between the two peptides is approximately 1.5-fold. This 
indicates that the presence of a serine residue at -3 (instead of glutamic acid in the 
TTBKtide sequence) weakens the recognition of the +2 phosphotyrosine by TTBK2. 
 
The two peptides with phosphoserine at -3 yielded lower Vmax values than the 
peptides with serine at -3. However, the Km values of those two peptides are 
significantly lower than the peptides with serine at -3 (11.0 µM and 15.3 µM for the 
peptides with phosphoserine at -3 compared to 86.1 µM and 65.0 µM for the peptides 
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with serine at -3). This suggests that the residue at the -3 position influences the 
recognition of the +2 phosphotyrosine.  
 
It is known that a phosphoserine at the -3 position is a critical determinant for 
substrate recognition by CK1 enzymes. To evaluate the impact of a 
tyrosine/phosphotyrosine at +2 on the substrate recognition of CK1, those four 
peptides were also assayed with CK1δ and the results are shown in Figure 3.8 below. 
 
 
Figure 3.8. Phosphorylation of CK1tide variants with serine/phosphoserine at -3 and 
tyrosine/phosphotyrosine at +2 by CK1δ. Four CK1tide variants with serine/phosphoserine at -3 and 
tyrosine/phosphotyrosine at +2 were synthesised, and the kinetics of their phosphorylation by GST–
CK1δ-[1-294]WT was analysed. Km and Vmax values were derived by non-linear regression analysis. 
Results shown are means±S.D. for three independent experiments. ND: not determined. 
 
With CK1δ, the Km of the peptide RRKDLHDDEEDSAMSIYPA was 5-fold higher 
than that of the peptide RRKDLHDDEEDSAMSIYA (187.3 µM compared to 35.4 
µM), which reflects the discrepancy in Vmax values between the two peptides: 
approximately 5-fold (56.6 U/mg compared to 12.7 U/mg). Remarkably, the two 
peptides with phosphoserine at -3 yielded considerably higher Vmax values than the 
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peptides with serine at -3 position. The peptide RRKDLHDDEEDSPAMSIYA had the 
highest Vmax (226.7 U/mg) while the peptide with two phosphorylated residues 
(RRKDLHDDEEDSPAMSIYPA) had an approximately 3-fold lower Vmax (87.9 
U/mg). The difference in Km values between these two peptides is approximately two-
fold (65.2 µM compared to 28.1 µM).  
 
While CK1δ showed a similar preference for a +2 phosphotyrosine, the impact on its 
recognition may vary depending on the residue at the -3 position. The requirement for 
a priming phosphorylation at -3 is known for CK1 kinases and these data suggest that 
a +2 phosphotyrosine may also act as an alternative priming site for substrate 
recognition. 
 
3.7   Molecular basis for phosphate priming 
 
CK1 isoforms possess a well-known requirement for priming phosphorylation 
(Flotow et al., 1990, Flotow and Roach, 1991, Nakielny et al., 1991). The crystal 
structures of yeast CK1 (Xu et al., 1995) (PDB code 1EH4) and human CK1δ 
(Longenecker et al., 1996) (PDB code 1CKI) reveal the presence of a sulphate-
binding groove on the small lobe of the kinase domain, predicted to function as the 
phosphate-priming site (Figure 3.9A). This pocket consists of four highly conserved 
basic lysine and arginine residues on CK1 isoforms and form ionic interactions with 
the sulfate residue (Figure 3.9A). In CK1 those residues are Lys38 (site A), Lys130 
(site B), Arg168 (site C) and Lys171 (site D). Sequence alignments show that three of 
these residues are conserved in TTBK1 and TTBK2 (Lys50, Lys143 and Arg181 in 
the TTBK2 protein sequence). The fourth residue is an alanine in TTBK2 (Ala184) as 
well as in TTBK1 (Figure 3.9B).  
 
To verify whether these residues on TTBK2 could be involved in enhancing the 
recognition and phosphorylation of +2-phosphotyrosine-containing substrates, the 
effect of mutations of Lys50, Lys143, Arg181 and Ala184 on the phosphorylation of 
TTBKtide and its unphosphorylated counterpart was investigated. Mutation of Lys50 
or Lys143 to either glutamic acid or alanine inactivated/destabilised TTBK2 (Figure 
3.10A) and equivalent mutations in CK1δ had similar effects (Figure 3.10B).  
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Figure 3.9. Molecular basis for phosphate priming. (A) High-resolution structure of CK1δ protein 
(from The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.) showing the 
sulphate-binding site on the C-lobe of the kinase domain predicted to function as the phosphate-
priming region (Longenecker et al., 1996). Lys38 (site A), Lys130 (site B), Arg168 (site C) and 
Lys171 (site D) form ionic interactions with the sulphate molecule and are shown in orange. (B) 
Sequence alignment of the indicated species of TTBK1, TTBK2 and CK1 family enzymes showing the 
sequence conservation of the sulphate-binding residues (highlighted in red).  
 
In contrast, mutation of Arg181 or Ala184 did not affect stability (Figure 3.10A) or 
the intrinsic TTBK2 kinase activity as judged by the ability of these mutants to 
phosphorylate a peptide lacking the +2 phosphotyrosine residue (Figure 3.10A). 
However, the ability of TTBK2 [R181A or R181E] or TTBK2 [A184G or A184E] 
mutants to phosphorylate tyrosine-phosphorylated TTBKtide was markedly impaired 
(Km values of 100-150 µM compared with 18 µM for wild-type TTBK2) (Figure 
3.11). Assays of the corresponding CK1 delta mutants yielded similar results (Figure 
A
B
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3.10B). These results suggest that TTBK2 possesses a phosphate-priming groove 
similar to CK1, and that it recognises +2 phosphotyrosine residues as well as N-
terminal phosphoserine/phosphothreonine at -3. 
 
 
Figure 3.10. Expression and activity of phosphate-binding groove mutants of TTBK2 and CK1δ. 
(A) HEK-293 cells were transiently transfected with the indicated forms of GST-tagged TTBK2. After 
36 h of transfection, cells were lysed and the GST-TTBK2 proteins affinity purified on glutathione–
sepharose. Equivalent volumes of GST-TTBK2 [corresponding to 50 ng of wildtype (WT) protein] 
were subjected to a kinase assay employing the indicated dephosphorylated peptide. Results are means 
for triplicate experiments repeated twice with similar results. Equivalent volumes of GST-TTBK2 
(corresponding to 500 ng of wild-type) were subjected to SDS/PAGE and the gels stained with 
Coomassie Blue. The wild-type controls were run on the same gel, but as a space was left in the 
adjacent lane the image was cut, indicated by the dotted line. (B) As in (A) except that CK1δ was 
purified from E. coli. 
A
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C  RRKDLHDDEEDSAMSIYA (non-Phosphorylated TTBKtide or 
+2Y peptide) 
RRKDLHDDEEDSAMSIYPA 
(TTBKtide) 
  Km (µM) Vmax (U/mg) Km (µM) Vmax (U/mg) 
TTBK2 WT WT 141 33 18 38 
TTBK2 
Site C mutants 
R181A 70 26 103 32 
R181E 70 26 150 42 
TTBK2 
Site D mutants 
A184G 149 19 108 22 
A184E 149 16 108 18 
Figure 3.11. The indicated GST–TTBK2-[1–450] mutant proteins expressed in Figure 3.10A were 
tested for their ability to phosphorylate TTBKtide (RRKDLHDDEEDEAMSIYPA) and a variant of 
TTBKtide (RRKDLHDDEEDEAMSIYA) where the tyrosine at the +2 position was not 
phosphorylated. A) Kinetic data from TTBK2 site C mutants; B) Kinetic data from TTBK2 site D 
mutants; C) Table summarising kinetic constants. Km and Vmax values were derived by non-linear 
regression analysis. 
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3.8   Generation of TTBK2-[family-1 mutation]-knockin mice 
 
Knockin mice that precisely mimic the one-base insertion of adenosine in exon 13 at 
nucleotide 1329, observed in SCA11 family 1, were generated by the TaconicArtemis 
company (Bouskila et al., 2011). Heterozygous TTBK2fmly1/+ (where fmly1 is family 
1) mice were viable and fertile. The oldest TTBK2fmly1/+ mice analysed were ~1 year 
of age and display no overt phenotype. Anatomical dissection of 1-year-old mouse 
brains also revealed no discernable abnormality. Breeding of heterozygous 
TTBK2fmly1/+ mice resulted in no homozygous TTBK2fmly1/fmly1 mice being born, 
indicating that the homozygous mutation resulted in embryonic lethality.   
 
Dissection of embryos at different stages of development showed that at E10 
(embryonic day 10) TTBK2fmly1/fmly1 embryos were detected at the expected 
Mendelian frequency (Figure 3.12A), but displayed major abnormalities compared 
with littermate TTBK2fmly1/+ or TTBK2+/+ embryos. By stage E11, no homozygous 
TTBK2fmly1/fmly1 embryos were observed, suggesting that these embryos perished 
before this stage. Homozygous E10-TTBK2fmly1/fmly1 embryos were developmentally 
delayed, lacking prominent subdivisions of the developing brain, and were smaller 
than wild-type littermates (Figure 3.12B). These embryos failed to complete 
embryonic turning movements or undergo normal caudal extension of the body; in 
several cases the rudimentary caudal body, which contained some somites (future 
vertebrae, muscle and dermis) and spinal cord, remained folded back on more rostral 
tissues. This distortion and underdevelopment of the main body axis (Figure 3.12B) 
are the probable causes of embryonic lethality. 
 
3.9   Expression and activity of mutant TTBK2 in tissues and 
fibroblasts derived from knockin mice 
 
Endogenous TTBK2 expression and activity in various mouse tissues was analysed. 
This revealed significantly higher levels of TTBK2 protein and activity in brain and 
testes than other tissues investigated (Figure 3.13A). In wild-type TTBK2+/+ brain and 
testes, TTBK2 migrated on an SDS/PAGE gel at the expected ~150 kDa size. As 
predicted, in tissues of the heterozygous TTBK2fmly1/+ mice, the level of full-length 
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TTBK2 was reduced by ~50% and a truncated form of TTBK2 migrating at ~50 kDa 
that was not seen in the wild-type mice was observed (Figure 3.13B).  
 
 
Figure 3.12. Generation of TTBK2-(family-1 mutation)-knockin mice. (A) TTBK2fmly1/+ mice were 
mated and the progeny genotyped. The number of mice obtained is indicated for each genotype. (B) 
Wild-type and homozygous TTBK2fmly1/fmly1 embryos at E10 were detected at the expected Mendelian 
frequency. Mutant embryos are smaller and developmentally delayed, lacking prominent subdivisions 
of the brain (arrows on the wild-type embryo). Incomplete embryonic turning movements may result in 
failure to extend the body axis. A total of 27 separate E10 TTBK2fmly1/fmly1 embryos were analysed and 
similar phenotypes were observed. 
 
Endogenous TTBK2 catalytic activity after immunoprecipitation from brain and testes 
extracts was assayed against the TTBKtide peptide substrate. These experiments 
revealed that TTBK2 activity was reduced ~40–50% in tissues derived from 
heterozygous TTBK2fmly1/+ compared with wild-type littermate animals, consistent 
with the view that the truncating mutation suppresses TTBK2 catalytic activity 
(Figure 3.13B). 
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Figure 3.13. Study of TTBK2 in wild-type and TTBK2fmly1/+ knockin mice. (A) The indicated tissue 
extracts were generated from wild-type mice. Extracts were immunoblotted for TTBK2 (lower panel) 
or TTBK2 was immunoprecipitated and subjected to a TTBK2 kinase assay employing TTBKtide as 
the peptide substrate (upper panel). Results are means of duplicate experiments that were repeated four 
separate times with similar results. (B) Brain and testes lysates were generated from TTBK2+/+ and 
TTBK2fmly1/+ mice and subjected to immunoblot or TTBK2 kinase assay analysis, as in (A). (C) MEFs 
were generated from TTBK2+/+, TTBK2fmly1/+ and TTBK2fmly1/fmly1 E10 embryos. TTBK2 activity was 
assessed following immunoprecipitation as in (A). Owing to the low levels of TTBK2 protein 
expressed in MEFs and high antibody background in immunoprecipitates, we were unable to detect 
expression of TTBK2 by immunoblot analysis. Results in (B) and (C) are means±S.D.  
 
 
TTBK2 activity in mouse embryonic fibroblasts (MEFs) derived from wild-type 
TTBK2+/+, heterozygous TTBK2fmly1/+ and homozygous TTBK2fmly1/fmly1 littermate 
stage-E10 embryos was also assessed. TTBK2 activity derived from homozygous 
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TTBK2fmly1/fmly1 cells was ~90% lower than activity observed in wild-type TTBK2+/+ 
fibroblasts (Figure 3.13C). The heterozygous TTBK2fmly1/+ displayed intermediate 
TTBK2 activity. 
 
3.10 Discussion 
 
I have undertaken the first characterisation of TTBK2 catalytic activity and substrate 
specificity, and found that it possesses a marked preference for a phosphotyrosine 
residue at the +2 position from the site of phosphorylation (Figure 3.3). The substrate 
selectivity of CK1 superfamily kinases is known to be directed towards phosphate 
groups and one of the most-studied consensus phosphorylation sites for CK1 isoforms 
is SP/TP-X-X-S/T, where SP/TP refers to a phosphoserine or phosphothreonine, X 
refers to any amino acid and the underlined residue refers to the target site (Flotow et 
al., 1990, Flotow and Roach, 1991, Nakielny et al., 1991). In the case of CK1 
isoforms, the priming phosphorylation site is at the -3 position rather than at the +2 
position for TTBK2. If both TTBK2 and CK1 use a similar phosphate-binding site 
within their catalytic domain, there would need to be marked differences in the 
mechanism and orientation at which primed phosphorylated substrates interact with 
CK1 and TTBK2.  
 
Sequence comparisons with CK1 isoforms indicate that TTBK2 possesses a 
phosphate-priming binding site in its catalytic domain equivalent to that in the related 
CK1 isoforms. Mutating two key conserved residues within this putative phosphate-
binding groove (Arg181 or Ala184) did not affect the ability of TTBK2 to 
phosphorylate a non-tyrosine-phosphorylated peptide, but inhibited phosphorylation 
of a tyrosine-phosphorylated peptide (Figure 3.9). The residues making up this 
putative phosphate-binding pocket are conserved on TTBK1, suggesting that this 
isoform may also possess a preference for +2-residue phosphotyrosine priming. The 
key difference in the putative phosphate-binding groove between CK1 and 
TTBK1/TTBK2 is the presence of a non-basic alanine residue in TTBK1 and TTBK2 
rather than a basic lysine residue in all CK1 isoforms. It would be interesting to 
explore whether this contributes towards the preference of TTBK2 for 
phosphotyrosine rather than phosphoserine/phosphothreonine priming in CK1 
isoforms. 
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In future work, it would be interesting to co-crystallise the catalytic domain of 
TTBK2 with a +2-tyrosine-phosphorylated peptide to define the molecular 
mechanism by which TTBK2 interacts with such substrates and establish whether this 
putative phosphate-binding groove is involved. The structure of CK1 bound to an 
SP/TP-X-X-S/T-motif-containing peptide has not been reported, but would be of 
interest to compare it with that of TTBK2. It would also be important to mine 
phosphorylation-site databases for proteins phosphorylated on S/T-X-YP motifs and 
determine whether any of these proteins might comprise physiological substrates for 
TTBK2. 
 
The optimal phosphorylation motif for TTBK2 was determined by oriented peptide 
library screening and the results were corroborated by a detailed kinetic analysis of 
individual peptides containing substitutions at crucial positions. This has enabled the 
elaboration of an optimal peptide substrate for assessing TTBK2 activity (TTBKtide: 
RRKDLHDDEEDEAMSIYPA) that is phosphorylated with a Km of 18µM and a Vmax 
of 38 units/mg.  
 
 
3.10.1 Disease-causing TTBK2 mutations markedly increase protein 
expression and inhibit kinase activity 
 
TTBKtide was used to assay intrinsic TTBK2 activity to determine the effect of 
SCA11 truncating mutations on TTBK2 activity. These activity assays showed that 
two familial SCA11 mutations analysed induce a reduction in TTBK2 protein kinase 
activity. Truncation of TTBK2 at residue 450, in close proximity to where the familial 
TTBK2 truncating mutations occur, suppressed TTBK2 activity. The observations 
that TTBK2 immunoprecipitated from TTBK2fmly1/+ mice possessed ~40% less 
activity (Figure 3.13B) and TTBK2 immunoprecipitated from TTBK2fmly1/fmly1 MEFs 
(Figure 3.13C) had ~10-fold lower activity also support the notion that SCA11 
mutations drastically reduce endogenous TTBK2 activity. Thus these findings 
indicate that loss of TTBK2 activity could underpin the development of SCA11 in 
patients. 
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The developmental delay and small size of homozygous TTBK2fmly1/fmly1 embryos are 
consistent with a role for TTBK2 activity in the regulation of fundamental cellular 
processes, such as cell proliferation. The failure of embryonic turning and 
underdevelopment of the body axis might also lead to a poor placental connection and 
hence embryonic lethality.  
 
 
3.10.2 Signalling specificity of Ser/Thr kinases 
 
As key signalling enzymes, protein kinases participate in the regulation of multiple 
cellular responses and have evolved two properties that are essential for their 
function: sensitive means of regulation and high specificity for substrates. Although 
protein kinase active sites do possess preferred target phosphorylation sequences, this 
stereochemical complementarity is not stringent enough; often they cannot entirely 
explain the in vivo specificity of kinases. 
 
Many protein kinases display clear preferences for the amino acid sequence 
immediately surrounding the phosphorylated residue in the substrate (Kemp et al., 
1975). However, in many cases, these substrate motif preferences are not sufficient to 
predict functional connectivity of kinases: Some ideal motifs do not appear to be 
endogenous substrates, and conversely, some known endogenous substrates do not 
match ideal profiles (Miller, 2003, Biondi and Nebreda, 2003). In addition, certain 
kinases appear to be quite promiscuous for minimal peptide substrates (Biondi and 
Nebreda, 2003). 
 
Protein kinases have evolved several biochemical mechanisms, through which 
specificity is generated during signal transduction.  These include subcellular co-
localisation, interaction with substrates via a scaffolding protein, modular docking 
interactions and specific protein kinase-substrate docking mechanisms (Pawson and 
Nash, 2000). 
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3.10.3 Use of distributed surfaces for recognition 
 
The use of docking site interactions has emerged as a common mechanism used by 
certain Ser/Thr kinases to achieve both selectivity and regulation (Biondi and 
Nebreda, 2003, Holland and Cooper, 1999). Docking interactions involve a docking 
groove on the kinase that is distinct from the active site. The docking groove 
recognises a peptide docking motif, which is distinct from the actual phosphoacceptor 
substrate motif but on the same molecule. Docking interactions appear to function as 
extended recognition surfaces that can increase enzyme-substrate encounters (reduce 
Km) and confer higher specificity than can be achieved by interactions between the 
active site and substrate motif alone. Moreover, such increases in efficiency and 
specificity can be achieved without altering or compromising the function of the 
active site. 
 
Docking grooves are found in several Ser/Thr kinase families, including CK1 
isoforms and the mitogen-activated protein kinases (MAPKs) (Sharrocks et al., 2000, 
Tanoue et al., 2000). The best-characterised MAPK docking motif is referred to as the 
d-box, which is recognised by a conserved groove on the MAPK (Chang et al., 2002). 
The structures of several d-box docking complexes have been solved (Jacobs et al., 
1999, Remenyi et al., 2005), revealing the docking groove is on the opposite surface 
from the active site. Mutation of either the docking groove on MAPKs or of the 
docking motif on substrates disrupts proper signal transmission (Remenyi et al., 2005, 
Grewal et al., 2006). 
 
Many of these kinases show distinct motif-sequence preferences (Remenyi et al., 
2005, Barsyte-Lovejoy et al., 2002). Presumably, the distinct docking and active site 
specificities work together to increase overall selectivity of kinase-substrate 
interactions. 
 
Docking grooves have been identified in several families of Ser/Thr kinases, in 
addition to MAPKs (Biondi and Nebreda, 2003). These docking grooves are 
distributed across the surface of the kinase domain illustrating how much of the 
kinase surface can potentially be tapped for this type of additional recognition 
function. The spatial relationship between the docking groove and active site on the 
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kinase may set the distance constraints between the docking and phosphoacceptor 
sites in substrates. 
 
 
3.10.4 Regulation via docking interactions 
 
In most cases, docking interactions appear to play a relatively passive role as modular 
specificity control elements: They presumably increase the likelihood of enzyme-
substrate encounter. However, in some cases, these interactions appear to regulate 
kinase function directly. For example, there are now several reported cases in which 
peptide binding at the docking groove can allosterically activate kinase function. 
Certain d-box docking site peptides can stimulate MAPK catalytic activity or 
autophosphorylation (Jacobs et al., 1999), whereas others may inhibit activity (Heo et 
al., 2004). FxFP motif binding to ERK appears to be coupled to the positioning of the 
ERK activation loop (Lee et al., 2004). In addition, 3-phosphoinositide-dependent 
kinase-1 (PDK1) interacts with downstream substrate kinases that contain a conserved 
docking motif known as the PDK1 interaction fragment (PIF). Binding of PIF motifs 
to PDK1 increases kinase activity (Biondi et al., 2000). 
 
Another way in which docking motifs can act as regulatory elements is when the 
docking interactions are themselves phosphorylation-dependent. For example, PIF 
motifs must be phosphorylated before they bind effectively to the PIF pocket and 
activate PDK1 (PIF motif: Phe-X-X-Phe-pSer/pThr-Phe/Tyr). Thus, downstream 
substrates must be subjected to a priming phosphorylation prior to the interaction with 
and phosphorylation by PDK1 (Biondi et al., 2002).  
 
A similar priming event is required for phosphorylation of some substrates by 
glycogen synthase kinase-3 (GSK3), which is part of the insulin signalling pathway. 
GSK3 substrates must be phosphorylated on a residue that is C-terminal to the 
Ser/Thr site to be modified by GSK3 (Fiol et al., 1988). This priming phosphorylation 
motif binds to a phospho-recognition docking groove adjacent to the active site 
(Dajani et al., 2001). The priming phosphorylation scheme observed in GSK3 and 
PDK1 pathways provides a mechanism for making signal processing dependent on a 
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sequence of catalytically distinct phosphorylation events, thereby increasing the 
specificity and complexity of control. 
 
 
3.10.5 Substrate selectivity of TTBK2/CK1 conferred by a phosphorylation-
dependent docking mechanism 
 
The structure of CK1δ provides an explanation for the preference of CK1 kinases for 
substrates with -3 priming phosphorylation. Coupled with the observations that 
peptides with a +2 phosphotyrosine or a -3 phosphoserine enhance substrate 
recognition and enzymatic activity, a model analogous to the phosphate-docking 
interactions of GSK3 and PDK1, for the mechanism of substrate recognition by 
TTBK2 (and other CK1 superfamily kinases) emerges.  
 
TTBK2 recognises a primed phosphorylation motif, which binds to a phospho-
recognition docking groove adjacent to the active site (Figure 3.14). 
 
 
3.10.6  Evolution of kinase circuits using docking interactions 
 
The development of substrate recognition sites distinct from the actual 
phosphoacceptor sequence dramatically increases the modularity of kinase 
interactions and connectivities. Related kinases can develop slightly different docking 
grooves, thus allowing them to have distinct specificities without evolutionarily 
taxing the structure and efficiency of the active site. 
 
Nonetheless, docking motifs are limited in their degree of modularity and 
evolvability. The docking grooves are intimately tied to the core catalytic module, in 
this case the catalytic Ser/Thr kinase domain. Thus, although docking motifs can be 
easily transferred to new substrates, the docking grooves cannot be dramatically 
altered or transferred to unrelated catalytic activities. Docking grooves are a step 
toward the separation of recognition and catalysis, but they do not employ generic 
interactions that could be transferred to new functions. Thus, docking grooves may 
represent a more ancestral solution to achieving modular connectivities. Interestingly, 
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although docking interactions are prevalent in many serine/threonine kinases (the 
more ancient eukaryotic protein kinases), similar docking interactions have not been 
identified in the more recently evolved tyrosine kinases. 
 
 
Figure 3.14. Schematic illustration of phosphorylation-dependent substrate interaction with 
TTBK2. TTBK2 possesses a phosphate-binding pocket that is distinct from the active site. This pocket 
acts as a docking groove that recognises a peptide-docking motif, which is distinct from the actual 
phosphoacceptor substrate motif. The docking groove recognises a phosphotyrosine two postions from 
the phosphoacceptor serine or threonine. X: any amino acid. 
 
 
3.11 Conclusions 
 
 
In conclusion, this initial work provides some initial insights into substrate specificity 
of TTBK2 and how SCA11-causing mutations affect kinase activity. In further 
studies, it will be crucial to define the substrates that TTBK2 phosphorylates 
physiologically and subsequently investigate whether aberrantly reduced 
phosphorylation of these targets contributes to the pathogenesis of SCA11. In 
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particular, it would be interesting to determine whether physiological TTBK2 
substrates are primed with a +2 phosphotyrosine and how regulation of tyrosine 
phosphorylation is coupled to the control of these TTBK2 targets. Identifying the key 
targets of TTBK2 could provide vital new insights into the molecular mechanism 
underpinning the development of spinocerebellar ataxia. 
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4 Deciphering the physiological role of 
TTBK2 
 
 
At the physiological and biochemical level, proteins rarely act alone; rather, they 
interact with other proteins to perform particular cellular tasks. To assign cellular 
functions to the TTBK2 protein, and to understand the physiological context in which 
it operates, the identification and analysis of proteins that specifically interact with 
TTBK2 is essential.  
 
Co-immunoprecipitation (co-IP) combined with mass spectrometry (MS) has become 
the method of choice for identifying protein-protein interactions (Free et al., 2009). In 
this experimental strategy, mouse brain tissue was homogenised under non-denaturing 
conditions so that the protein interactions within the cells are not disrupted in the cell 
extract. When the target protein, TTBK2, is captured (immunoprecipitated) with a 
specific antibody bound to protein G sepharose beads, interacting partners of this 
protein may also precipitate. After removing non-specifically bound proteins by 
repeated washing, co-immunoprecipitated interacting partners were eluted from the 
beads using Laemmli buffer, separated by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE), digested in-gel using proteases, and identified by tandem mass 
spectrometry. 
 
4.1   Immunoprecipitation of endogenous TTBK2 from mouse 
brain homogenates 
 
To unequivocally identify proteins that specifically interact with TTBK2 
physiologically, endogenous TTBK2 was immunoprecipitated from mouse brain 
homogenate using two different anti-TTBK2 antibodies and, in a parallel experiment; 
a control immunoprecipitation using a pre-immune (IgG) antibody was performed. 
The three immunoprecipitates samples were subjected to SDS/PAGE, which was then 
stained with colloidal Coomassie (Figure 4.1). The identity of the major bands in the 
TTBK2 and the control immunoprecipitations was established by tryptic-peptide MS 
fingerprinting analysis. 
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Figure 4.1. Immunoprecipitation of endogenous TTBK2. Mouse brain homogenate was subjected to 
immunoprecipitation with a pre-immune antibody (IgG) and two different TTBK2 antibodies. The 
immunoprecipitates were subjected to SDS-PAGE and the protein bands visualised following colloidal 
Coomassie blue staining. The indicated bands were excised, digested with trypsin and identities 
determined by mass spectrometry. The identity of the major bands observed in the TTBK2 are 
indicated on the right hand side. 
 
4.2    Mass spectrometry data analysis 
 
An important issue in the MS-based co-IP approach is how to distinguish the bona 
fide interacting proteins from a large pool of non-specifically bound proteins. Because 
of the significant improvement in detection capability of mass spectrometry, many 
proteins could be detected in a co-IP sample even after the most stringent purification 
processes (Walther and Mann, 2010).  Some identified proteins may, however, be 
non-specifically bound proteins. These background proteins often include abundant 
proteins such as actin and heat shock proteins. In addition, some proteins may bind 
non-specifically to the protein G beads or the antibody. To distinguish these irrelevant 
background proteins, a negative control using serum IgG with the same concentration 
as that of TTBK2 antibody was used in the experiment. Because identical amount of 
IgG was immobilised to G sepharose beads, the negative control provided a similar 
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affinity matrix to which background proteins bound. Also, the comparison of the two 
different immunoprecipitations by the TTBK2 antibodies improved the level of 
confidence of the identified interactors as proteins that were not reproduced by the 
two different antibodies in two independent experiments were filtered out.  
Using the database-searching tool MASCOT, a primary dataset of high-scoring 
peptides present in the three different immunoprecipitates was generated. Non-
specific contaminants were then filtered out using stringent criteria in a manner 
similar to that reported previously (Amoresano et al., 2010). First, the protein 
identification results between the samples and the negative IgG control using the in-
built OLMAT tool of the ProteinGuru online software (www.proteinguru.com) was 
compared. Common non-specific binding proteins such as actin, tubulin, and heat 
shock proteins were identified in all immunoprecipitates, and thus were considered 
background proteins. Secondly, the proteins that were not present in both TTBK2 
immunoprecipitates were filtered out. Thirdly, MASCOT protein scores of a value of 
>24 were considered significant (p<0.05).  
Thus, an unequivocal list of proteins coprecipitated in the TTBK2-specific pull-down 
was compiled. The number of peptides sequenced by MS, protein sequence coverage 
and accession numbers for each protein identified are indicated in Table 4.1. 
. 
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! ! TTBK2!Ab1! TTBK2!Ab2! ! !
Accession(
Number(
MW(Da) MASCOT 
Score 
Peptide  
Hits 
Sequence  
Coverage 
MASCOT 
Score 
Peptide  
Hits 
Sequence  
Coverage Gene Protein Name 
Q9JIS5! 83392 2107 91 36% 1672 71 25% SV2A Synaptic vesicle glycoprotein 2A 
P46096! 47730 1923 103 54% 227 17 21% Syt1 Synaptotagmin-1 
Q6PIC6! 113045 1429 78 45% 1720 97 46% ATP1A3 Sodium/potassium-transporting ATPase subunit alpha-3 
Q3UVR3!!!!!!!!!!!137598 636 48 25% 876 70 35% TTBK2* Tau-tubulin kinase 2 
Q3UVR3! 137598 415 24 15% 200 17 10% TTBK2* Tau-tubulin kinase 2 
Q3UVR3! 137598 250 12 7% 133 14 8% TTBK2* Tau-tubulin kinase 2 
Q62277! 34288 1089 128 20% 354 41 18% SYP Synaptophysin 
O54724! 43927 1377 54 36% 272 22 28% PTRF Polymerase I and transcript release factor 
Q6PIE5! 113457 978 42 19% 865 51 22% ATP1A2 Sodium/potassium-transporting ATPase subunit alpha-2 
P17427! 104017 737 76 39% 773 83 36% AP2a1 AP2 complex subunit alpha 
Q9DBG3! 104583 814 61 42% 424 58 33% AP2b1 AP2 complex subunit beta  
Q8BVE3! 56275 747 44 46% 1313 96 34% ATP6V1h V-type proton ATPase subunit H (VPP1) 
P84091! 49655 30 3 6% 37 12 25% AP2m1 AP2 complex subunit mu-2 
Q9Z0J4! 161740 1281 93 34% 60 18 9% NOS1 Nitric oxide synthase, brain 
P08551! 61528 675 36 37% 248 19 20% NEFLl Neurofilament light polypeptide 
Q8R191! 24774 655 38 23% 253 11 23% Syngr3 Synaptogyrin-3 
O35633! 58313 646 43 37% 495 24 31% SLC32A1 Vesicular inhibitory amino acid transporter 
Q3TXX4! 62312 124 18 13% 104 10 7% SLC17a7 Vesicular glutamate transporter 1 (VGLUT1) 
Q5SSM3! 89564 324 20 21% 26 2 2% Arhgap44 Rho GTPase-activating protein 44 
P61264! 33452 255 24 46% 214 6 14% STX1b Syntaxin-1B 
O35954! 135996 511 42 27% 195 25 13% PITPNM1 Membrane-associated phosphatidylinositol transfer protein 1 
P60879! 23528 502 28 43% 579 24 30% SNAP25 Synaptosomal-associated protein 25 
Q9EP53! 129692 495 51 35% 137 14 10% Tsc1 Hamartin 
O35609! 38772 485 17 22% 107 3 8% SCAMP3 Secretory carrier-associated membrane protein 3 
Q9D0J4! 21022 1270 40 77% 259 9 43% Arl2 ADP-ribosylation factor-like protein 2 
P70704! 130938 236 21 14% 27 3 1% ATP8A1 Probable phospholipid-transporting ATPase IA 
 
 
Table 4.1.-(part 1). Summary of MS data: Proteins co-immunoprecipitating with TTBK2 from mouse brain homogenate. Interacting proteins are listed in decreasing order of 
MASCOT scores obtained from TTBK2 Ab1 immunoprecipitation. Mascot protein score where a value of >24 was considered significant (p<0.05), number of peptides 
sequenced by LC MS/MS, percentage of protein sequence covered (%), accession numbers and molecular weight for each protein identified are indicated. TTBK2, the bait 
protein is shaded in blue and synaptic vesicle membrane proteins are shaded in yellow. 
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! ( TTBK2!Ab1( TTBK2!Ab2( ! (
Accession(
Number(
MW(Da) MASCOT 
Score 
Peptide  
Hits 
Sequence  
Coverage 
MASCOT 
Score 
Peptide  
Hits 
Sequence  
Coverage 
Gene 
 
Protein Name 
O35643! 104768 344 31 21% 262 29 17% AP1b1 AP-1 complex subunit beta-1 
Q61037! 204395 305 20 11% 367 26 9% Tsc2 Tuberin 
Q8R361! 69853 943 19 25% 34 12 16% Rab11FIP5 Rab11 family-interacting protein 5 
Q68FF6! 86046 288 35 34% 27 5 5% Git1 ARF GTPase-activating protein GIT1 
P61264! 33452 255 24 46% 122 7 27% Stx1b Syntaxin-1B 
Q5SX79! 90410 194 15 16% 90 5 6% Shroom1 Protein Shroom1 
Q8C996! 31344 168 5 18% 233 10 23% Tmem163 Transmembrane protein 163 
O88935! 74223 164 10 18% 35 3 5% Syn1 Synapsin-1 
P08553! 95973 150 20 24% 164 33 22% NEFM Neurofilament medium polypeptide 
 
 
Table 4.1 – (part II). Summary of MS data: Proteins co-immunoprecipitating with TTBK2 from mouse brain homogenate. Interacting proteins are listed in decreasing order of 
MASCOT scores obtained from TTBK2 Ab1 immunoprecipitation. Mascot protein score where a value of >24 was considered significant (p<0.05), number of peptides 
sequenced by LC MS/MS, percentage of protein sequence covered (%), accession numbers and molecular weight for each protein identified are indicated. TTBK2, the bait 
protein is shaded in blue and synaptic vesicle membrane proteins are shaded in yellow. *TTBK2, the bait protein was detected by MS in three different gel pieces and the 
MASCOT scores, peptides detected and sequence coverage are indicated for each. 
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4.3  Results of TTBK2 co-immunoprecipitation 
 
Endogenous TTBK2, the bait protein, was predictably detected in three different gel 
pieces with 25%, 15% and 7% sequence coverage with a MASCOT scores of 636, 
415 and 250 with TTBK2 antibody 1 (Ab1). With TTBK2 antibody 2 (Ab2), TTBK2 
was detected with 35%, 10% and 8% sequence coverage with a MASCOT scores of 
876, 200 and 133. 
The number of TTBK2-binding proteins from mouse brain homogenates was high, 
exposed by the number of protein bands visible on the colloidal Coomassie blue-
stained gel of the immunoprecipitates (Figure 4.1). Two high scoring peptide matches 
were (the two proteins with high MASCOT scores) synaptic vesicle glycoprotein 2A 
(SV2A) and synaptotagmin 1. This finding was reproducible by both TTBK2 
antibodies used for immunoprecipitations in two independent experiments. SV2A is 
an integral membrane glycoprotein present in all synaptic vesicles (Bajjalieh et al., 
1992). Synaptotagmin 1 is a calcium-sensing protein, which is also found in the 
membrane of synaptic vesicles (Geppert et al., 1994). This observation may indicate 
that TTBK2 is part of a protein complex that includes SV2A and synaptotagmin 1. 
 
Intriguingly, further evaluation of the list of TTBK2 interactors exposed the presence 
of proteins such as synaptophysin, ATP6V1h (V-type proton ATPase subunit H), 
synaptogyrin 1, synaptogyrin 3, SNAP25 (Synaptosomal-associated protein 25), 
SCAMP1 (Secretory carrier-associated membrane protein 1), Syntaxin-1B, Synapsin 
1, vesicular glutamate transporter (VGLUT1) and Rab proteins, which are all 
members of the unique collection of membrane proteins that typify the synaptic 
vesicle (SV) (shaded in yellow in Table 4.1). Indeed, 12 out of 19 major integral 
synaptic vesicle membrane proteins were identified by mass spectrometry (those 
marked with a red tick in Figure 4.2) as TTBK2 co-immunoprecipitants.  
Another notable group of proteins that co-immunoprecipitated with TTBK2 were 
ATP1A1, ATP1A2 and ATP1A3. These are Na+/K+-ATPases (sodium/potassium 
pumps) and belong to the P-type ATPase group and their function is to establish and 
maintain an electrochemical gradient of sodium and potassium ions across the plasma 
membrane at neuronal synapses (de Carvalho Aguiar et al., 2004).  
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Figure 4.2. A molecular model of a prototypic synaptic vesicle (SV). Takamori et al. (2006) have 
determined the protein and lipid composition; measured vesicle size, density, and mass; calculated the 
average protein and lipid mass per vesicle; and determined the copy number of more than a dozen 
major constituents. The authors constructed this model that integrates all quantitative data and includes 
structural models of abundant proteins. Synaptic vesicles are dominated by proteins, possess a 
surprising diversity of trafficking proteins, and, with the exception of the V-ATPase that is present in 
only one to two copies, contain numerous copies of proteins essential for membrane traffic and 
neurotransmitter uptake. SV proteins marked with red ticks co-immunoprecipitated with TTBK2. 
[Adapted from (Takamori et al., 2006)]. 
 
The TTBK2 immunoprecipitates also contained proteins involved in clathrin-
mediated endocytosis, in particular, the components of the AP2 complex (Adaptor-
related protein complex 2): AP2α2, AP2β2, AP2µ2 and AP2σ2. Synaptic vesicles are 
known to recycle via clathrin-mediated endocytosis (Maycox et al., 1992) and 
evidence for this is provided by the fact that many SV proteins were detected in a 
proteome analysis of brain clathrin-coated vesicles (Blondeau et al., 2004). 
In addition, many other proteins that have been reported to be associated with 
synaptic vesicles e.g., calcium-calmodulin-dependent protein kinase II, MAP6 
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(microtubule-associated protein 6) and amphiphysin were also detected. Some of 
these proteins transiently associate with a subset of vesicles. They are not, however, 
requisite components of all synaptic vesicles. While some of these proteins may 
participate in SV function, such as cytoskeletal proteins (vesicle transport), others 
may be only loosely associated with the vesicle membrane and have crucial roles in 
the trafficking of SVs. 
Viewed collectively, the list of TTBK2 interactors combined was not a random 
collection of proteins. Rather, these proteins all belong to the unique collection of 
membrane proteins that epitomise the synaptic vesicle and other accessory proteins 
involved in their trafficking. Thus, the unifying theme that connects all the TTBK2-
interacting proteins identified by the co-immunoprecipitation of endogenous TTBK2 
from mouse brain homogenate is SV trafficking.  
The salient aspect of the TTBK2 interactors identified is that TTBK2 interacts 
physiologically with a set of genuine SV membrane residents and SV ancillary 
proteins at neuronal synapses. This strongly suggests that TTBK2 participates in the 
protein network regulating synaptic vesicle trafficking and hence a tantalising 
physiological role for TTBK2 at the synapse regulating certain step(s) of the SV cycle 
remains to be uncovered. 
 
4.4   The synaptic vesicle cycle 
 
The key event of the synaptic vesicle (SV) cycle is the fusion of the membrane of 
synaptic vesicles with the presynaptic plasma membrane, a process that is tightly 
regulated by calcium. After exocytosis, vesicles are endocytosed and recycle. As a 
result, synaptic vesicles undergo a cycle of membrane traffic composed of exocytosis, 
endocytosis and recycling (Figure 4.3). More recent studies have further delineated 
the various stages of the synaptic vesicle cycle, including attachment (also called 
docking), prefusion (priming), triggering, recycling and reloading of the vesicles with 
transmitter.   
The synaptic vesicle cycle can be envisioned to start with the uptake of 
neurotransmitters into synaptic vesicles by an energy-dependent step that requires 
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ATP (step 1 in Figure 4.3). Specialised transporter proteins in the synaptic vesicle 
membrane mediate this process.  
 
Figure 4.3.  The synaptic vesicle cycle. Synaptic vesicles are filled with neurotransmitters by active 
transport (step 1) and form the vesicle cluster that may represent the reserve pool (step 2). Filled 
vesicles dock at the active zone (step 3), where they undergo a priming reaction (step 4) that makes 
them competent for Ca2+ triggered fusion-pore opening (step 5). After fusion-pore opening, synaptic 
vesicles undergo endocytosis and recycle via several routes: local reuse (step 6), fast recycling without 
an endosomal intermediate (step 7), or clathrin-mediated endocytosis (step 8) with recycling via 
endosomes (step 9). Steps in exocytosis are indicated by red arrows and steps in endocytosis and 
recycling by yellow arrows. [Adapted from (Sudhof, 2004)]. 
 
Synaptic vesicles filled with neurotransmitters move to the active zone of the 
presynaptic plasma membrane in a translocation process that probably occurs by 
diffusion, although the participation of molecular motors has not been excluded (step 
2). At the active zone the vesicles become attached to the plasma membrane (step 3). 
Attachement (or docking) of the vesicles involves a specific interaction between 
vesicles and the active zone; the vesicles do not attach to any other part of the 
presynaptic plasma membrane except for the active zone. Attached vesicles undergo 
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an ATP-dependent prefusion reaction(s) that primes them for calcium-dependent 
release and may involve a partial fusion process (step 4). Calcium then triggers the 
completion of fusion in a rapid reaction that can occur in less than 0.1 milliseconds 
(Sabatini and Regehr, 1999). Calcium triggering of release involves the binding of 
multiple calcium ions at a calcium-binding site (step 5). 
The synaptic vesicle cycle contains many independent steps, all of which involve 
protein-protein interactions. Vesicle transport, target recognition, docking, and fusion 
each involve the ordered and sequential recruitment of protein complexes from the 
cytoplasm. The membrane constituents SVs are ultimately responsible for 
orchestrating the association of the complex, task execution, and complex 
disassembly.  
 
4.4.1 Medicine Nobel Prize 2013 awarded to discoverers of vesicle 
trafficking system 
 
In October 2013, the Nobel committee recognised the achievements of three 
researchers for their discoveries of machinery regulating vesicle traffic. James 
Rothman of Yale University in New Haven, Connecticut; Randy Schekman at the 
University of California, Berkeley; and Thomas Südhof of Stanford University were 
jointly awarded the Nobel prize for physiology or medicine for 2013. The 
groundbreaking work of these laureates has revolutionised our understanding of a 
basic cellular function - protein and neurotransmitter secretion. 
 
The laboratories of Schekman and Rothman worked out the basic mechanisms of 
vesicle fusion, in which proteins embedded in the membranes of vesicles recognise 
proteins on the membranes of their destination through a lock-and-key mechanism 
that is still being worked out. 
 
Thomas Südhof’s work focused on vesicle fusion in neurons. He identified and 
characterised numerous key components of the synaptic-vesicle fusion apparatus and 
the parallel regulatory machinery that makes synaptic secretion so fast. Of greatest 
importance, he identified the synaptic vesicle protein synaptotagmin, and showed that 
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this protein is the enigmatic calcium sensor that 'turbocharges' synaptic-vesicle 
secretion. 
 
4.5      Synaptic vesicles: Molecular anatomy of an organelle. 
 
 
A fruitful approach to understanding the molecular mechanisms of the synaptic 
vesicle cycle and neurotransmitter release was the characterisation of the proteins 
associated with synaptic vesicles (Sudhof, 1995). Synaptic vesicles are homogeneous 
in size and density, making it relatively easy to isolate large amounts of pure vesicles 
by a combination of density-gradient and size fractionation techniques. The 
characterisation of the proteins localised to synaptic vesicles has opened the door to 
genetic, physiological, and biochemical studies of their functions (Fernandez-Chacon 
and Sudhof, 1999). Through this set of diverse approaches, elaborate and testable 
biochemical models of vesicle attachment and fusion at the nerve terminal are now 
available. 
As judged by electron microscopy, synaptic vesicles are electron-lucent organelles 
that are about 35 nanometres in diameter and may be slightly larger in native 
conditions. Because they are relatively small, synaptic vesicles can accommodate a 
limited number of lipids and proteins. Calculations suggest that each synaptic vesicle 
is composed of approximately 10, 000 molecules of phospholipids and of proteins 
with a combined approximate molecular weight of 5-10 x 103 kDa (Jahn and Sudhof, 
1993). Since an average protein has a molecular weight of around 50 kDa, synaptic 
vesicles contain approximately 200 protein molecules (Sudhof, 2004). The only 
function of synaptic vesicles is their role in uptake and release of neurotransmitters; 
thus they are functionally relatively simple. In principle, the limited number of 
functions and proteins associated with synaptic vesicles should make it possible to 
obtain a complete molecular dissection of these organelles. Indeed, as a result of 
intensive biochemical studies, synaptic vesicles are possibly the best described of all 
organelles. We now know the structures of most vesicle proteins; the functions of 
some of them have been deduced and testable ideas about the functions of others have 
been formulated. 
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Synaptic vesicle proteins can be conceptually divided into two functional classes: 
transport proteins, which mediate the uptake of neurotransmitters and other 
components into synaptic vesicles (step 1 of the vesicle cycle; Figure 4.3), and 
trafficking proteins that participate in synaptic vesicle exo- and endocytosis and 
recycling (steps 2–9 in Figure 4.3).  
The most prominent transport protein of synaptic vesicles is the proton pump (V-
ATPase), which generates the electrochemical transmembrane gradient that fuels 
neurotransmitter uptake and neurotransmitter transporters that mediate the actual 
uptake. A single copy of the proton pump per vesicle is probably sufficient to drive 
neurotransmitter uptake; because of its large size, a single copy would account for 
approximately 10% of the total vesicle protein. One of the determinants of the 
transmitter type that is used by a particular synapse is the class of neurotransmitter 
transporter present in the vesicle. For example, as the neurotransmitter glutamate is a 
universal component of the cytosol, any synaptic vesicle that transports glutamate will 
make the corresponding nerve terminal glutamatergic. In addition to the proton pump 
and neurotransmitter transporters, synaptic vesicles contain ancillary transport 
proteins that mediate zinc transport, chloride flux, and possibly other transport 
activities; which have not yet been identified. 
The trafficking proteome of synaptic vesicles is complex. It includes intrinsic 
membrane proteins; proteins associated via posttranslational lipid modifications, and 
peripherally bound proteins (Figure 4.4). These proteins do not share a characteristic 
that would make them identifiable as synaptic vesicle proteins, and little is known 
about how these proteins are specifically deposited into synaptic vesicles. As 
summarised in Figure 4.4, many but not the entire collection of known synaptic 
vesicle proteins interact with non-vesicular proteins and are linked to specific 
functions. 
There are currently nine families of synaptic vesicle proteins that appear to be 
involved in membrane traffic (Figure 4.4). It is possible that additional proteins of 
synaptic vesicles remain to be identified, but it is unlikely that many proteins are 
missing. In addition to the known proteins, many other proteins have been reported to 
be associated with synaptic vesicles (e.g., calcium-calmodulin-dependent protein 
kinase II, actin, SNAPIN, and dynein). However, these proteins have only rarely been 
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found in highly purified vesicles, and, when present, they were such low abundance in 
the purified vesicles that they cannot be stoichiometric components of all vesicles. 
Although we cannot currently exclude the possibility that some of these proteins 
transiently associate with a subset of vesicles, they are requisite components of all 
synaptic vesicles. 
 
Figure 4.4. Structures, proposed interactions, and putative functions of synaptic vesicle 
trafficking proteins. Proteins are shown schematically (green, intravesicular sequences; orange, 
transmembrane regions; blue, phosphorylation domains; pink, SNARE motifs; red and gray, folded 
domains; yellow, other sequences). The white connecting lines in the intravesicular space identify 
disulfide bonds, and the branched white lines indicate sugar residues. In the boxes corresponding to the 
individual proteins, proposed functions are shown on a white background and purported interactions on 
a black background [adapted from (Sudhof, 2004)]. 
 
As illustrated in Figure 4.4, synaptic vesicle proteins share no common structural 
theme but consist of all types of membrane proteins. The proteins include peripheral 
membrane proteins (e.g., synapsins and rabphilin) and proteins that are attached to the 
vesicles by a post-translational lipid modification (CSP: Cysteine string protein, rab 
proteins) in addition to transmembrane proteins with single (synaptotagmins, 
VAMP/synaptobrevins) or multiple  (synaptophysins, synaptogyrins, SV2s, 
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SCAMPs) transmembrane regions. Interestingly, synaptic vesicles contain three 
families of proteins with 4 transmembrane regions arranged in the same topology 
(synaptophysins, synaptogyrins, SCAMPs) and two families of proteins with 12 
transmembrane regions (SV2s and SVOP) but only a single family of each type I and 
type II transmembrane proteins (synaptotagmin and VAMP/synaptobrevin, 
respectively). 
VAMP/synaptobrevin, syntaxin and SNAP-25 are the founding members of a large 
family of membrane fusion proteins referred to as SNAREs (an acronym derived from 
"SNAP (Soluble NSF Attachment Protein) REceptor"). SNAREs can be divided into 
two categories: vesicle or v-SNAREs, which are incorporated into the membranes of 
transport vesicles during budding, and target or t-SNAREs, which are located in the 
membranes of target compartments (Sudhof et al., 1993). 
 
The primary role of SNARE proteins is to mediate vesicle fusion that mediate 
docking of synaptic vesicles with the presynaptic membrane. These SNAREs are the 
targets of the bacterial neurotoxins responsible for botulism and tetanus. Botulinum 
and tetanus toxins enter nerve terminals and irreversibly inhibit SV exocytosis, 
thereby incapacitating the victim. The toxins are proteases, each of which cleaves a 
single target at a single site (Schiavo et al., 1994).  
 
Most synaptic vesicle trafficking proteins are members of gene families composed of 
closely related isoforms that are on synaptic vesicles. However, the evolutionary 
history of the different vesicle proteins is quite distinct. Some proteins are 
evolutionarily conserved to a high degree (e.g. VAMP/synaptobrevin, 
synaptotagmin). For other proteins (e.g. synapsins and synaptophysin) only distantly-
related homologues can be found in invertebrates, and some proteins such as SV2 are 
absent from invertebrates. These differences in evolutionary conservation indicate 
that some proteins may be components of the basic machinery for release, whereas 
others may have more peripheral regulatory functions that are important in complex 
nervous systems but not in simpler organisms. 
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Taken together, synaptic vesicle proteins are characterised by a great variety of 
structures and topologies (Figure 4.4). The only characteristic that all vesicle proteins 
share is that they lack cleaved signal peptide, usually the most common mechanism of 
membrane protein insertion. Although most transmembrane proteins of synaptic 
vesicles probably include internal signal peptides, the VAMP/synaptobrevins contain 
a C-terminal membrane anchor. As a result protein synthesis is completed before the 
translocation machinery would recognise the hydrophobic sequence. Thus, as 
expected, the transmembrane regions of these proteins are probably inserted into lipid 
bilayers posttranslationally, independent of the translocation apparatus (Kutay et al., 
1995). In spite of this unconventional membrane insertion, the site of the initial 
membrane association of VAMP/synaptobrevins appears to be the endoplasmic 
reticulum; the proteins then flow through the secretory pathway in a normal fashion.  
Although most vesicle proteins are highly concentrated in presynaptic nerve 
terminals, lower levels of these molecules can be found throughout the cell. In 
immature neurons or cells in culture, a considerable concentration of the vesicle 
proteins is found in the Golgi apparatus. Following exit from the trans-Golgi network, 
synaptic vesicle membrane proteins have been proposed to follow constitutive 
vesicular trafficking pathways to the plasma membrane. From the plasma membrane, 
the proteins may be internalised and sorted from other proteins within the endosomal 
system (Johnston et al., 1989). Vesicle proteins travel via fast anterograde axonal 
transport to synaptic sites, assisted by a diverse array of motor proteins. The final 
assembly of a fully mature synaptic vesicle may not occur until further rounds of exo- 
and endocytosis at or close to the synapse, but the exact mechansisms involved are 
obscure. 
Despite a large body of work, the functions of most synaptic vesicle proteins remain 
unknown. For several proteins, a point of action has been identified, but it is unclear 
what exactly these proteins do at that point. A further complicating factor is that the 
relative simplicity of the protein composition of synaptic vesicles suggests that many 
vesicle proteins must have multiple functions. The synaptic vesicle cycle contains 
many independent steps (Figure 4.3), all of which are likely to involve protein-protein 
interactions. These protein-protein interactions must ultimately target synaptic vesicle 
proteins. Since there are only 9 different families of putative trafficking proteins, 
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many proteins must have multiple functions in order to account for all the steps in the 
vesicle cycle.  
Many SV proteins are known to be phosphoproteins, which suggests that their 
functional role is modified by phosphorylation. Modulation of neurotransmitter 
release is brought about by changes in intracellular second messengers that activate 
protein kinases (Greengard et al., 1993). The resultant phosphorylation of synaptic 
vesicle-associated proteins appears to play a key role in regulating neurotransmission. 
The importance of phosphorylation of SV proteins in synaptic membrane traffic is 
well-established. The cycle of synaptic vesicle exo- and endocytosis requires the 
carefully orchestrated formation and dissociation of protein complexes. Regulation of 
the binding affinity through phosphorylation is likely to mediate changes in secretory 
efficiency that contributes to the modulation of synaptic transmission and synaptic 
plasticity (Sudhof, 1995). 
 
 
4.6   Identification of Synaptic Vesicle glycoprotein 2A (SV2A) as 
a TTBK2 substrate. 
 
To investigate whether any of the identified interacting SV proteins is a putative 
substrate for TTBK2, in vitro phosphorylation assays were performed. For this 
purpose, I elected to bacterially express an N-terminal fragment of human TTBK2, 
encompassing residues 1–316, which is a catalytically active proteolytic fragment of 
TTBK2 that has been detected in mouse brain extracts by the discoverers of TTBK2 
as a 36 kDa species and displays in vitro kinase activity towards Tau and Tubulin 
(Takahashi et al., 1995, Tomizawa et al., 2001). A kinase-dead (KD) mutant (D163A) 
of TTBK2 was also purified in parallel, in order to rule out in vitro phosphorylation 
by contaminating kinases co-purifying with TTBK2.  
Similarly, several TTBK2-interacting proteins identified in the co-
immunoprecipitation assays were expressed as GST fusion proteins in E.coli or 
HEK293 cells. GST fusion proteins, thus expressed and purified, were incubated with 
GST-TTBK2 [1-316]WT and GST-TTBK2 [1-316]KD  in the presence of 100 µM [γ-
32P] ATP for 30 min at 30°C. The reaction mixtures were subjected to SDS-PAGE, 
and phosphorylated proteins were imaged by autoradiography. 
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All the proteins tested as substrates showed no phosphorylation at all, except one. 
Only SV2A (Synaptic Vesicle glycoprotein 2A) displayed substantial phosphorylation 
by TTBK2 in vitro (Table 4.2). SV2A was significantly phosphorylated by TTBK2 in 
vitro (Figure 4.5), with an incorporation of more than 4.0 moles phosphate per mole 
of SV2A, indicating multiple phosphorylation sites.  
Gene Protein name In vitro Phosphorylation by 
TTBK2 
SV2A Synaptic vesicle glycoprotein 2A Substantial Phosphorylation 
Syt1 Synaptotagmin-1 No Phosphorylation 
ATP1A3 
Sodium/potassium-transporting ATPase 
subunit alpha-3 
No Phosphorylation 
SYP Synaptophysin No Phosphorylation 
ATP6V1h V-type proton ATPase subunit H No Phosphorylation 
NSF N-ethylmaleimide sensitive factor No Phosphorylation 
SLC32A1 Vesicular inhibitory amino acid transporter  No Phosphorylation 
SNAP25 Synaptosomal-associated protein 25 No Phosphorylation 
SCAMP3 
Secretory carrier-associated membrane 
protein 3 
No Phosphorylation 
STX1b Syntaxin-1B No Phosphorylation 
Table 4.2. Table listing the synaptic proteins tested as a TTBK2 substrate. 
 
The generic 26 kDa substrate histone H1 was used as a positive control for the kinase 
reaction. Histone H1 was well phosphorylated by TTBK2 indicating that reaction 
conditions used were permissive to kinase reactions. On SDS-PAGE, GST-TTBK2 
[1-316] migrates like a protein of about 70 kDa and thus the phosphorylation detected 
in the wild-type kinase reactions below the 75 kDa mark corresponds to 
autophosphorylation of the TTBK2 kinase.  
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Figure 4.5. SV2A is an in vitro TTBK2 substrate. In vitro phosphorylation of recombinant GST-
SV2A by either GST-TTBK2 [1-316]WT or GST-TTBK2 [1-316]KD or kinase buffer alone. The left 
panel shows the CBB staining of the SDS-PAGE gel and the right panel shows the result of 
autoradiography. The autoradiogram (right) shows two diffuse bands running at 100 and above 250 
kDa, corresponding to two different forms of SV2A. Diffuse bands are observed due to the 
glycosylation of SV2A. SV2A migrates in two different forms of distinctive molecular weights. The 
lower band corresponds to GST-SV2A and the upper band matches to GST-SV2A complexed with 
laminin proteins. Arrows indicate SV2A bands, autophosphorylation of TTBK2 and histone H1. 
Histone H1 was used as a positive control for the kinase reaction.!
 
As shown in Figure 4.5 above GST-SV2A was profusely phosphorylated by GST-
TTBK2 [1-316]WT but not by GST-TTBK2 [1-316]KD. The autoradiogram shows two 
distinct diffuse bands running at 100 and above 250 kDa, typical of SV2A (Figure 
4.5). The diffuse appearance of the bands is possibly due to the glycosylation of 
SV2A. SV2A migrates in two different forms of distinctive molecular weights. The 
lower band corresponds to GST-SV2A and the upper band matches to GST-SV2A 
complexed with laminin (Son et al., 2000), an extracellular matrix protein. The 
interaction of SV2A with laminin is strong in that it resists dissociation by high pH 
and detergents (Son et al., 2000). No phosphorylation was detected in the kinase-dead 
reactions. 
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4.7       Initial discovery of SV2A 
 
Synaptic vesicle protein 2 (SV2) was discovered with a monoclonal antibody 
prepared against cholinergic vesicles from the electric organ of the marine electric ray 
Discopyge ommata (Buckley and Kelly, 1985). Immunolocalisation by electron 
microscopy revealed that this antibody recognised an epitope on the cytoplasmic face 
of synaptic vesicles. Biochemical evidence suggested that SV2 is a membrane-
associated glycoprotein of approximately 80 kDa. The SV2 epitope was present in 
fish, amphibians, and mammals and is specifically localised to neural and endocrine 
cells. Immunohistochemical studies demonstrated that the SV2 epitope was not 
limited to neurons that contain a specific neurotransmitter but was detected in all 
neuronal and endocrine cells surveyed (Buckley and Kelly, 1985, Floor and Feist, 
1989, Lowe et al., 1988).  Its presence across a wide range of species, from 
elasmobranchs to mammals, suggests that it plays a critical role in vesicle 
functioning.  
 
cDNAs encoding SV2 were cloned by screening a rat brain library with DNA probes 
based on amino acid sequence (Bajjalieh et al., 1992) and by screening for 
immunoreactivity in cells transfected with the cDNA (Feany et al., 1992). 
Computational analyses of the predicted protein sequence revealed that SV2 has 12 
putative membrane-spanning domains.  
 
SV2 (Synaptic Vesicle Protein 2) was found to be a family of membrane 
glycoproteins specific to the secretory vesicles of neurons and endocrine cells in 
vertebrates (Buckley and Kelly, 1985). Mammals have three SV2 genes that encode 
the three isoforms SV2A, SV2B, and SV2C (Bajjalieh et al., 1993, Bajjalieh et al., 
1992, Feany et al., 1992, Janz et al., 1998). Of these, SV2A is the most broadly 
expressed, and is present in essentially all neurons (Bajjalieh et al., 1994). Notably, it 
is the only isoform expressed in many inhibitory, GABAergic neurons (Bajjalieh et 
al., 1994, Gronborg et al., 2010). 
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4.7.1 SV2A domain architecture 
 
All SV2 proteins contain 12 transmembrane regions (TMRs) with N- and C-terminal 
cytoplasmic sequences and a large intravesicular loop that is N-glycosylated (Figure 
4.6). Comparisons of different SV2 isoforms show that the TMRs and cytoplasmic 
loops are highly conserved, while the intravesicular loop, although N-glycosylated in 
all SV2 isoforms, exhibits little homology (Janz and Sudhof, 1999). While SV2A is 
expressed ubiquitously, SV2B is present in a more restricted forebrain pattern 
(Bajjalieh et al., 1994), and SV2C is concentrated in caudal brain regions (Janz and 
Sudhof, 1999). A distantly related synaptic vesicle protein called SVOP (SVtwo-
related protein) contains a similar transmembrane structure as SV2, but lacks its long 
cytoplasmic and highly glycosylated intravesicular loops (Janz et al., 1998).  
 
 
 
Figure 4.6. Domain structure of SV2A. Schematic diagram of the structure of the SV2A protein. 
Amino acids residues in the primary sequence of SV2A are indicated by circles, with 12 potential 
transmembrane regions (TMRs). Branched lines show positions of N-linked carbohydrates. N and C 
termini are identified by letters. 
 
SV2s share significant sequence homology to a large family of transport proteins. 
Included in this family are bacterial and fungal proteins that co-transport protons with 
sugars, citrate, and drugs, and mammalian facilitative glucose transporters 
Synaptic Vesicle Lumen  
N C aa1
aa160
aa742
Cluster-1
Cluster-2
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(Henderson and Maiden, 1990, Maiden et al., 1987). This similarity to a large class of 
transport proteins suggested that SV2 might be a transporter specific to synaptic 
vesicles and initially investigators thought that SV2A may be a neurotransmitter 
transporter, but its presence in nerve terminals with distinct neurotransmitters 
dispelled this idea (Bajjalieh et al., 1994). 
 
Despite many hypotheses, SV2A has no validated function as a transporter or 
otherwise. Much of the data regarding the function of SV2A comes from studies 
using SV2A and SV2A/B knockout mice. SV2A is indispensable for survival in mice. 
Mice with knock out of one allele of SV2A have an elevated incidence of epileptic 
seizures, and mice with both copies knocked out have very severe epileptic seizures 
after the first postnatal week and die by the third week (Crowder et al., 1999), 
primarily because of fulminant epilepsy. SV2B knock out (KO) mice, however, are 
phenotypically unremarkable and SV2C KO mice have not been reported yet. 
 
4.8   Mapping of TTBK2 phosphorylation sites on SV2A 
 
To map TTBK2 phosphorylation sites, GST-SV2A [1-160] was maximally 
phosphorylated with either TTBK2 [1-316]WT or TTBK2 [1-316]KD. Five reactions 
were set up in a 40 µl volume of Buffer A containing 1 µg GST–TTBK2 [1–316], 1 
µg GST-SV2A (full-length), 10 mM MgCl2, 0.1 µM [γ-32P] ATP. After incubation for 
60 min at 30 °C, incorporation of phosphate was determined after electrophoresis of 
samples on a NuPAGE® Bis-Tris 10%-polyacrylamide gel and autoradiography of 
Coomassie Blue-stained gels. The protein bands corresponding to SV2A were 
excised, and phosphate incorporation was quantified on a scintillation counter. After 
tryptic digestion, more than 86% of the 32P radioactivity incorporated into the gel 
band was recovered and the samples were chromatographed on a reverse-phase Vydac 
218TP5215 C18 HPLC column to isolate 32P-labelled phosphopeptides. The HPLC 
trace obtained is shown in Figure 4.7. Under the conditions employed, SV2A was 
phosphorylated by wild-type TTBK2 to ~ 4.0 mol of phosphate/mol of SV2A, 
indicating multiple phosphorylation sites. 
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Figure 4.7. Full-length SV2A was phosphorylated by TTBK2 [1-316]WT for 60 minutes. The 32P-
labelled SV2A was isolated by SDS-PAGE, digested with trypsin and the resulting peptides were 
chromatographed on a C18 column. Fractions containing the major 32P-labelled peptides are marked 
(P1-P4). 
 
Peptide analysis of the fractions corresponding to the major 32P-containing peaks was 
performed using an Applied Biosystems 4700 Proteomics Analyser (MALDI-
TOF/TOF) and solid-phase Edman degradation on an Applied Biosystems 494C 
sequenator of the peptide coupled to Sequelon-AA membrane. 32P radioactivity was 
measured after each cycle of Edman degradation and the deduced amino acid 
sequences of peptides P1, P2, P3 and P4 are shown below in Table 4.3. 
 
Table 4.3.The indicated peptides were analysed by MALDI-TOF/TOF MS. The phosphorylated 
residues in each peptide were determined by solid-phase Edman sequencing in which 32P radioactivity 
was released is indicated. The deduced amino acid sequences of peptides P1, P2, P3, and P4 are 
indicated; the phosphorylated residues are underlined. 
P1 
P2 
P3 
P4 
Sample 
ID 
Phosphopeptide Cycle of 
32P 
release 
Phosphorylation 
site 
P1 VQDEYSRR 6 S42 
P2 GGLSDGEGPPGGR 4 S127 
P3 SYSRFEEEDDDDDF 3 S47 
P4 VQDEYSRRSYSRFEEEDDDDDFPAPSDGY 6,9,11, 
26 
S42,S45,S47 
S62 
P4 GEGTQDEEEGGASSDATEGHDEDDEIYEGEYQGIPR 13,14, 
17 
S80,S81,T84 
  120 
Eight potential phosphosites were identified: Ser42, Ser45, Ser47, Ser62 and Ser127. 
Ser42 and Ser45 theoretically comprise the canonical CK1 consensus sequence 
(SP/TP-X-X-S/T). Notably, all the identified TTBK2 phosphosites on SV2A are all 
located on the cytosolic N-terminus of the protein, corresponding to amino acids 1 to 
160 (Figure 4.6). 
 
4.9   Expression and phosphorylation of the cytosolic N-terminal 
fragments of SV2A, SV2B and SV2C. 
 
As previously mentioned, the TTBK2 phosphosites on SV2A are all located on the 
cytosolic N-terminus of the protein. Since very low levels of expression of full-length 
recombinant SV2A were observed, the cytosolic amino terminus of SV2A (amino 
acids 1-160) was subcloned and expressed in bacterial cells. The corresponding 
regions of SV2B and SV2C: SV2B [1-103] and SV2C [1-146] (see alignment in 
Figure 4.8 on next page), were also cloned and expressed.  
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Figure 4.8. Multiple sequence alignment of the human SV2A, SV2B and SV2C. The amino 
terminal sequences of the SV2 isoforms illustrating the similarity between SV2A and SV2C, and the 
divergence of SV2B. Conserved phosphorylation sites are highlighted in red. Red arrowed line 
indicates the boundary between the cytosolic portion of the proteins and the first membrane-spanning 
domain, corresponding to residues 160 for SV2A, 103 for SV2B and 146 for SV2C. 
 
The in vitro phosphorylation of the N-terminal fragments; SV2A [1-160] and SV2B 
[1-103] and SV2C [1-146] by TTBK2 was evaluated by autoradiography and the 
resulting autoradiogram is shown below (Figure 4.9). All three SV2 isoforms were 
profusely phosphorylated by TTBK2 with similar stoichiometry. 
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Figure 4.9. Phosphorylation of SV2 isoforms was determined after SDS-PAGE and autoradiography 
(right panel) of the Coomassie Blue-stained bands (left panel). TTBK2-[1–316]WT or kinase-dead (KD) 
[D163A] TTBK2-[1–316]KD was incubated with the indicated proteins SV2A-[1-160], SV2B-[1-103], 
SV2C-[1-146] in the presence of Mg2+ and [γ-32P] ATP. 
 
4.10 Mapping TTBK2 phosphorylation sites on SV2A, SV2B 
and SV2C. 
 
SV2A [1-160], SV2B [1-103] and SV2C [1-146] were found to be very potent in vitro 
substrates for TTBK2 and phosphosite mapping was performed on those N-terminal 
fragments of SV2A, SV2B and SV2C. 
To map the TTBK2 phosphorylation sites in SV2A-[1-160], SV2B-[1-103], and 
SV2C-[1-146], the three SV2 isoforms were phosphorylated by TTBK2-[1–316]WT 
and TTBK2 [1-316]KD as a control as described previously. Under these conditions, 
SV2A, SV2B and SV2C were phosphorylated with similar stoichiometries.  
HPLC, peptide analysis and Edman degradation was carried out as described 
previously. The HPLC traces, resulting peptide analyses and Edman sequencing 
results for SV2A-[1-160], SV2B-[1-103] and SV2C-[1-146] are detailed below.  
 
 
 
GST$TTBK2([1$316](WT( GST$TTBK2([1$316](KD( GST$TTBK2([1$316](WT( GST$TTBK2([1$316](KD(
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4.10.1 TTBK2 phosphosite mapping of SV2A[1-160] 
 
 
  
Figure 4.10. SV2A-[1-160] was phosphorylated by TTBK2-[1-316]WT for 60 minutes. The 32P-labelled 
SV2A was isolated by PAGE, digested with Asp-N and the resulting peptides were chromatographed 
on a C18 column. Fractions containing the major 32P-labelled peptides are marked. 
 
Edman sequencing of the phosphopeptides P1, P2, P3 and P4 (Figure 4.10) are 
summarised in Table 4.4. 
 
Table 4.4. The indicated peptides were analysed by MALDI-TOF/TOF MS. The phosphorylated 
residues in each peptide were determined by solid-phase Edman sequencing in which 32P radioactivity 
was released is indicated. The deduced amino acid sequences of peptides P1, P2, P3, and P4 are 
indicated; the phosphorylated residues are underlined. 
 
There is significant overlap between the two phosphomapping datasets (full-length 
SV2A and SV2A[1-160]. All the phosphosites identified previously on full-length 
SV2A: Ser42, Ser45, Ser47, Ser80, Ser81 and Thr84 were exposed on the N-terminal 
P1 
P2 
P3 
P4 
Sample ID Phosphopeptide Cycle of 32P 
release 
Phosphorylation site(s) 
P1 VQDEYSRR 6 S42 
P2 GEGTQDEEEGGASSDATEGHDEDD 13,14,17 S80,S81,T84 
P3 GEGTQDEEEGGASSDATEGHDEDD 13,14,17 S80,S81,T84 
P4 SYSRFEEEDDDDDFPAPSDGYYR 1,3 S45,47 
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fragment SV2A [1-160]. However, Ser62 and Ser127 were not detected on SV2A [1-
160]. 
 
Cumulatively, the mapping of TTBK2 phosphosites on SV2A revealed eight potential 
phosphorylation sites: Serines 42, 45, 47, 62, 80, 81, 127 and Threonine 84.  
 
4.10.2 TTBK2 phosphosite mapping of SV2B[1-103] 
 
Figure 4.11.SV2B-[1-103] was phosphorylated by TTBK2-[1-316]WT for 60 minutes. The 32P-labelled 
SV2B was isolated by PAGE, digested with Asp-N and the resulting peptides were chromatographed 
on a C18 column. Fractions containing the major 32P-labelled peptides are marked P1 and P2. 
 
Edman sequencing of the phosphopeptides P1 and P2 (Figure 4.11) are summarised in 
Table 4.5. 
 
Table 4.5. The indicated peptides were analysed by MALDI-TOF/TOF MS. The phosphorylated 
residues in each peptide were determined by solid-phase Edman sequencing in which 32P radioactivity 
was released is indicated. The deduced amino acid sequences of peptides P1 and P2 are indicated; the 
phosphorylated residues are underlined. 
The two peptides sequenced for SV2B were identical. Two phosphorylation sites 
were identified for SV2B: Ser33 and Thr36. 
 
Sample ID Phosphopeptide Cycle of 
32P release 
Phosphorylation site(s) 
P1 DAQSDVTEGH      4,7 S33, T36 
P2 DAQSDVTEGH      4,7 S33, T36 
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4.10.3 TTBK2 phosphosite mapping of SV2C[1-146] 
 
 
Figure 4.12.SV2C-[1-146] was phosphorylated by TTBK2-[1-316]WT for 60 minutes. The 32P-labelled 
SV2c was isolated by PAGE, digested with Asp-N and the resulting peptides were chromatographed on 
a C18 column. Fractions containing the major 32P-labelled peptides are marked. 
 
Edman sequencing of the phosphopeptide P1 (Figure 4.12) are summarised in Table 
4.6. 
 
Table 4.6. The indicated peptide was analysed by MALDI-TOF/TOF MS. The phosphorylated residues 
in the peptide were determined by solid-phase Edman sequencing in which 32P radioactivity was 
released is indicated. The deduced amino acid sequences of peptide P1 is indicated; the phosphorylated 
residues are underlined. 
 
The sequence of only one peptide was obtained for SV2C and revealed two 
phosphorylation sites: Thr42 and Ser47. 
 
4.11 Confirmation of accuracy of SV2A phosphomapping 
 
I next assessed how mutation of these eight residues affected the phosphorylation of 
SV2A [1-160]. I compared phosphorylation of SV2A [1-160]WT and  
Sample ID Phosphopeptide Cycle of 
32P 
release 
Phosphorylation 
site(s) 
P1 DEYTQRSYSRFQ 4,9 T42, S47 
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SV2A [1-160]8XA, which is an SV2A mutant in which Ser42, Ser45, Ser47, Ser62, 
Ser80, Ser81, Thr84 and Ser127 are mutated to alanines by TTBK2 [1-316]WT and 
TTBK2 [1-316]KD using autoradiography (Figure 4.13).  
 
 
Figure 4.13. Autoradiogram comparing the phosphorylation of SV2A-[1-160]WT and SV2A[1-
160]8XA by TTBK2-[1-316]WT and TTBK2-[1-316]KD. GST-SV2A-[1-160]WT and GST-SV2A-[1-
160]8XA were incubated with recombinant either GST-TTBK2-[1-316]WT or GST-TTBK2-[1-316]KD 
and Mg2+-[γ-32P]ATP for 30 mins and subjected to SDS-PAGE and autoradiography. 
 
As shown by the autoradiogram in Figure 4.13, TTBK2-[1-316]WT 
autophosphorylates and phosphorylates SV2A-[1-160]WT. Mutations of Ser42, Ser45, 
Ser47, Ser62, Ser80, Ser81, Thr84 and Ser127 to alanines completely abolished 
phosphorylation of SV2A by TTBK2 (Figure 4.13), while the level of TTBK2 
autophosphorylation detected remains identical. This adds further support to the view 
that all prospective phosphosites have been accurately mapped.  
37#
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4.12 Conservation of phosphosites between SV2 isoforms 
 
The three SV2 proteins are differentially expressed in brain. SV2A is present in 
almost all neurons, SV2B exhibits a more restricted distribution in retinal 
photoreceptors (Bajjalieh et al., 1994), and SV2C is present only in a small subset of 
neurons in the basal forebrain and caudal brain regions (Janz and Sudhof, 1999). 
SV2A is by far the most widely expressed isoform. 
SV2A and SV2C are larger proteins than SV2B (742, 727 and 683 amino acids 
respectively) and the residues preceding the first transmembrane domain constitute 
the most divergent region between isoforms (Figure 4.8). Whereas the membrane 
spanning domains are 73% identical in SV2A and SV2B, the amino termini are only 
34 % identical. SV2A and SV2C are more similar, sharing 50% identity in the amino 
terminal region. The most striking difference between SV2A/C and SV2B are the 49 
amino acids present at the very amino terminus of SV2A/C, a region that contains 
multiple stretches of identical residues. 
 
Accordingly, SV2A and SV2C share similar phosphorylation sites. The corresponding 
residues of SV2A Ser42, Ser45 and Ser47 in SV2C are Thr42, Ser45 and Ser47. Our 
phosphomapping, however, did not show phosphorylation of SV2C Ser45. This may 
be due to a miscleavage of the phosphopeptide. SV2B does not possess equivalent 
residues (Figure 4.8).  
 
The other notable phosphosites identified on SV2A were Ser80, Ser81 and Ser84; 
which correspond to SV2C Ser75, Ser76 and Thr79. These phosphosites were not 
detected on SV2C due to poor detection of phosphopeptides by mass spectrometry. 
SV2B, on the other hand, possesses phosphosites Ser33 and Thr36; which parallel 
Ser81 and Thr84 of SV2A (Figure 4.8). The conservation of certain phosphosites 
between SV2 isoforms may point to common generic regulatory mechanisms 
modulated by those sites. 
 
Ser62 is shared between SV2A and SV2B but is not present in the SV2C sequence. 
Ser127 is only present in SV2A and not in SV2B or SV2C. The dearth of 
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conservation of those two sites suggests that they may not be important for SV2 
function. 
 
4.13 Conservation of SV2A phosphosites in SV2A orthologues 
 
To identify which of the identified human phosphosites are conserved in distantly 
related model organisms and thereby likely to be essential for fundamental cellular 
activities, I investigated the conservation of protein phosphorylation events i.e. sites 
that are conserved at similar positions in orthologous proteins between human, mouse, 
rat, cow and Xenopus (Figure 4.14). Assessment of conservation showed that Ser62 is 
not conserved at all in other species, while Ser127 was conserved in human, mouse 
and rat orthologues but not in lower species (highlighted in green in Figure 4.14).  
The six remaining phosphorylation sites (Ser42, Ser45, Ser47, Ser80, Ser81 and 
Thr84) identified in human SV2A are well conserved in not only the human and 
mouse proteins, but also in lower organisms including Xenopus Tropicalis 
(highlighted in red in Figure 4.14). The degree of conservation of those phosphosites 
implies that they are vital for the function of SV2A. 
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Figure 4.14. Multiple sequence alignment of human SV2A and SV2A from selected species. Ser62 
and Ser127 are highlighted in green; Ser62 is not conserved among other species, while Ser127 was 
conserved in human, mouse and rat but not in lower species. Ser42, Ser45 and Ser47 were collectively 
referred to as cluster-1. Similarly, Ser80, Ser81 and Thr84 were jointly designated as cluster-2. Cluster-
1 and cluster-2 residues are highlighted in red, emphasising their inter-species conservation. 
 
The positions of those phosphosites on the cytoplasmic N-terminus of SV2A showed 
that they were clustered within two motifs of six and five amino acids respectively. 
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The three phosphosites: Ser42, Ser45 and Ser47 were henceforth collectively referred 
to as cluster-1. Similarly, Ser80, Ser81 and Thr84 were jointly designated as cluster-2. 
 
4.14 Functional importance of phosphorylation sites 
 
The synaptic vesicle cycle at the nerve terminal consists of vesicle exocytosis with 
neurotransmitter release, endocytosis of empty vesicles, and regeneration of fresh 
vesicles.  Of all the cellular transport pathways, the synaptic vesicle cycle is the 
fastest and the most tightly regulated.  The cycle of synaptic vesicle exo- and 
endocytosis requires the carefully orchestrated formation and dissociation of protein 
complexes. Vesicle transport, target recognition, docking, and fusion each involve the 
ordered and sequential recruitment of protein complexes from the cytoplasm. Much of 
this temporal and spatial control is achieved through phosphorylation-dependent 
protein-protein interactions, allowing the formation and dissociation of complexes to 
be regulated through the action of kinases and phosphatases.  
I hypothesised that the cytoplasmic N-terminus of SV2A constitutes a domain that 
participates in phosphorylation state-dependent protein-protein interactions intrinsic 
to its physiological function in the synaptic vesicle trafficking cycle. The 
identification of protein-protein interactions of SV2A that depend on the 
phosphorylation state of SV2A at cluster-1 or cluster-2 is likely to shed light on the 
normal physiological function of SV2A phosphorylation as well as identify potential 
roles for SV2A in the SV cycle. 
To identify protein-protein interactions that are potentially regulated by the SV2A 
phosphorylation sites at cluster-1 and cluster-2, I undertook a mass spectrometric 
analysis of brain protein complexes that could be pulled down in vitro by peptides 
encoding the phosphorylated motifs, cluster-1 and cluster-2 of SV2A.  
Mass spectrometric analysis of protein-protein interactions offers a uniquely unbiased 
tool for elucidating the components of protein complexes. This targeted mass 
spectrometry-based functional proteomics approach was used to identify and compare 
qualitative and relative quantitative differences in protein-protein interactions of non-
phosphorylated, singly-phosphorylated, doubly-phosphorylated and triply-
phosphorylated peptides encompassing the amino acid sequences spanning the 
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cluster-1 and cluster-2 motifs and flanking sequences  (Table 4.7 and Figure 4.6). 
Those biotinylated peptides were employed in pull-down experiments from mouse 
brain homogenates to identify protein interactors by mass spectrometry and to assess 
the phosphorylation-dependence of those interactions.  
 
4.15 Quantitative analysis of proteins pulled-down by 
differentially phosphorylated SV2A cluster-1 peptides 
 
Eight biotinylated peptides (Table 4.7) corresponding to residues 28 to 61 of human 
SV2A, plus 4 Arginine residues added to the C-terminus to promote solubility, were 
custom-made by GL Biochem (Shanghai, China). The identity, purity and 
phosphorylation status of the peptides were ascertained by mass spectrometry.  
 Cluster-1 peptides 
Phosphorylation 
status Peptide Sequence 
NPCluster-1 BIOTIN-KKVVKGLDRVQDEYSRRSYSRFEEEDDDDDFPAPRRRR 
SV2A pS42 BIOTIN-KKVVKGLDRVQDEYSPRRSYSRFEEEDDDDDFPAPRRRR 
SV2A pS45 BIOTIN-KKVVKGLDRVQDEYSRRSPYSRFEEEDDDDDFPAPRRRR 
SV2A pS47 BIOTIN-KKVVKGLDRVQDEYSRRSYSPRFEEEDDDDDFPAPRRRR 
SV2A pS42+pS45 BIOTIN-KKVVKGLDRVQDEYSPRRSPYSRFEEEDDDDDFPAPRRRR 
SV2A pS42+pS47 BIOTIN-KKVVKGLDRVQDEYSRRSPYSPRFEEEDDDDDFPAPRRRR 
SV2A pS45+pS47 BIOTIN-KKVVKGLDRVQDEYSPRRSPYSRFEEEDDDDDFPAPRRRR 
SV2A 
pS42+pS45+pS47 
BIOTIN-KKVVKGLDRVQDEYSPRRSPYSPRFEEEDDDDDFPAPRRRR 
Table 4.7. Cluster-1 peptides used in pull-down experiments. Cluster-1 biotinylated peptides 
correspond to residues 28 to 61 of human SV2A; 4 Arginine residues have been added to the C-
terminus to promote solubility. Each of the 8 peptides has a different phosphorylation status, indicated 
in the first column of the table. Phosphorylated residues are highlighted in red. 
 
For Cluster-1, bait peptides consisted of amino-terminally tagged biotinylated 
peptides (GL Biochem, Shanghai, China) (Table 4.7). The peptides used were as 
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follows: the non-phosphorylated amino acids corresponding to residues 28 to 61 of 
human SV2A, plus 4 Arginine residues added to the C-terminus to promote solubility  
(NP1); the NP1 peptide phosphorylated either at Ser42 (pS42) or at Ser45 (pS45) or at 
Ser47 (pS47), respectively; the NP1 peptide phosphorylated either at Ser42 and at 
Ser45 (pS42+45), or at Ser42 and at Ser47 (pS42+47), or at Ser45 and at Ser47 
(pS45+47); and the NP1 peptide phosphorylated at Ser42, Ser45 and Ser47 
(pS42+45+47). 
For each affinity peptide pull-down, 10 mg of mouse brain homogenate in CHAPS 
lysis buffer was pre-cleared five times with 10µl of streptavidin sepharose beads to 
eliminate proteins that bind non-specifically to the resin. 3µg of each peptide was then 
incubated to 10 mg of pre-cleared mouse brain lysate for 10 minutes at 4 0C. 20µl of 
1:1 streptavidin bead slurry was then added to each mixture for 5 minutes. Samples 
were washed three times in lysis buffer containing 0.15 M NaCl. Bound proteins were 
eluted from the immobilised peptides with 1 % Rapigest and processed for mass 
spectrometry analysis. 
Mass spectrometry data for each peptide pull-down was then analysed to distinguish 
proteins binding with different affinities to each peptide. Relative protein 
quantification was determined using peptide hits quantification and MASCOT scores 
are shown in Table 4.8. I applied stringent thresholds to decide on the inclusion of 
proteins. Firstly, only proteins binding with high affinity with a MASCOT score of 
higher than 100 were included. Secondly, for the affinity to be preferential, it was 
essential that there were more peptide hits and higher MASCOT scores depending on 
the phosphorylation status of the peptide. The number of peptide hits, sequence 
coverage and MASCOT scores were all considered for confirmation of preferential 
affinity. 
Enrichment or depletion of a particular protein in a pull-down with either the 
phosphorylated or non-phosphorylated bait peptides was assessed using the ratio of 
normalised peptide hits for the peptides of that protein obtained using the bait 
peptides. Enrichment was arbitrarily defined as a 2-fold greater number of normalised 
peptide hits or normalised ion currents for the phosphorylated versus non-
phosphorylated bait peptide or vice versa.  
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4.15.1 Results of cluster-1 peptide pull-downs 
 
For cluster-1, there were several proteins that showed different binding affinities in 
pull-downs depending on the phosphorylation status of the peptide used as bait. To 
tease out which of the interactions were phosphorylation-dependent, I stratified the 
highest-scoring proteins into discrete functional groupings and analysed the number 
of peptides hits, sequence coverage and MASCOT scores for those proteins in each 
peptide pull-down (Table 4.7).  
 
A major class of proteins that were pulled down by the cluster-1 peptides was all four 
subunits of the clathrin adaptor AP2 complex (adaptor-related protein complex 2).  
AP2 is the best-characterised member of the family of heterotetrameric clathrin 
adaptor complexes that play pivotal roles in many vesicle trafficking pathways within 
the cell. The AP2 adaptor complex works on the plasma membrane to internalise 
cargo in clathrin-mediated endocytosis (Pearse et al., 2000). AP2 is a heterotetrameric 
protein, which is made up of four different subunits. Each subunit is called an adaptin, 
and each adaptin is named after a Greek letter—α, β, µ, and σ adaptin subunits (            
Figure 4.15) (Collins et al., 2002). The AP2 complexes which function both as a 
linker between the plasma membrane and the clathrin lattice and as a sorter for some 
proteins to be internalised, comprise two large subunits of 100–130 kDa (α and β2), a 
medium subunit of ∼50 kDa (µ2), and a small subunit of 17–20 kDa (σ2) 
(Kirchhausen, 1999).  
 
One striking finding was that all four subunits of the AP2 complex (AP2α, AP2β2, 
AP2µ2 and AP2σ2) (Table 4.8) were present in all 8 peptide pull-downs. However, 
the comparison of the number of peptide hits, sequence coverage and MASCOT 
scores for each subunit indicated that the affinity was dependent on the 
phosphorylation status of the peptide used as bait. Intriguingly, the affinity of the AP2 
complex appeared to decrease upon phosphorylation of cluster-1. The highest number 
of peptide hits and MASCOT scores for AP2 subunits were seen with the 
dephosphorylated cluster-1 peptide (NP1). 
  134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.8. Proteins with differential affinities for SV2A cluster-1 depending on its phosphorylation status. Comparisons are shown only for proteins identified with a MASCOT score of 100 or 
more. The MASCOT scores for each protein for each peptide pull-down are shown. The number of peptide hits for each protein is shown between parentheses.
SV2A Cluster-1 peptide pull-downs 
   MASCOT scores (number of peptide hits) 
   Peptide pull-down 
UniProtKB/Swiss-Prot 
entry name 
Primary 
accession 
number 
Gene name NP1 pS42 pS45 pS47 pS42+pS45 pS42+pS47 pS45+pS47 pS42+pS45+pS47 
Spectrin β chain, brain 
2 
Q68FG2 
 
SPTBN2 
 
45  
(10) 
- 140  
(17) 
27  
(16) 
- - 56  
(8) 
1376  
(42) 
AP2 complex 
subunit α1 P17426 AP2A1 848 (33) 
1191 
(56) 
854 
(40) 
151 
(17) 
606  
(36) 
268  
(17) 
904 
(41) 
737 
(24) 
AP2 complex 
subunit α2 P17427 AP2A2 291 (16) 
1026 
(51) 
442 
(29) 
101 
(13) 
659 
(36) 
222 
(15) 
757 
(41) 
416 
(21) 
AP2 complex 
subunit β-2 Q9DBG3 
 
AP2B1 310 
(29) 
819 
(46) 
435 
(24) 
76 
(11) 
549 
 (32) 
207 
 (27) 
522 
(34) 
172 
(11) 
AP2 complex 
subunit µ-2 P84091 
 
 
AP2M1 783 
(37) 
1068 
(71) 
709 
(43) 
133 
(22) 
377 
(34) 
416 
(34) 
456 
(29) 
343  
(20) 
AP2 complex 
subunit σ-2 P62743 
 
AP2S1 - 36 
(5) 
- - 52  
(6) 
- 26  
(6) 
28  
(3) 
Na/K-transporting 
ATPase subunit alpha-3 Q6PIC6 
 
ATP1A3 133 
(10) 
37 
(6) 
355  
(16) 
712 
(42) 
- 220 
(5) 
310 
(20) 
682 
(21) 
Actin, α1 
 P62737 
 
ACTA1 - - 677 
(31) 
642 
(32) 
- 428 
(23) 
- - 
β-actin  P60710 
 
ACTB 657 
(31) 
807 
(35) 
1244  
(61) 
1463  
(69) 
334 
(16) 
876 
(46) 
- 2273 
(89) 
CaM kinase II α chain P11798 
 
Camk2a 897 
(39) 
846 
(28) 
559  
(25) 
884 
(42) 
400  
(18) 
687  
(26) 
420 
 (21) 
235 
(18) 
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Lower scores were observed with the singly-phosphorylated and doubly-
phosphorylated peptides and the lowest scores was seen with the triply-phosphorylated 
peptide (Table 4.8), indicating that phosphorylation of cluster-1 impedes the 
interaction of SV2A with the AP2 complex. 
 
 
4.15.1 The clathrin adaptor AP2 complex 
 
The AP2 complex is a stable complex of four subunits called adaptins which give rise 
to a structure that has a core domain and two appendage domains attached to the core 
domain by polypeptide linkers (Figure 4.15). These appendage domains are sometimes 
called ‘ears’. The core domain binds to the membrane and to cargo destined for 
internalisation. The alpha and beta appendage domains bind to accessory proteins and 
to clathrin. Their interactions allow the temporal and spatial regulation of the assembly 
of clathrin-coated vesicles and their endocytosis. 
 
 
            Figure 4.15. The AP2 adaptor complex.  
Left Panel: The structure of the free AP2 complex. There are 4 different subunits (as illustrated in the 
model above based on the crystal structure) and thus they are sometimes called polymeric or 
hetrotetrameric adaptors. The trunk domain binds to membranes and to cargo via the µ and β subunits. 
The appendage domains (sometimes called ‘ears’) bind to accessory proteins. Structures of a number of 
appendage domains have been solved and binding motifs and partners characterised. The hinge domains 
bind to clathrin terminal domains. Right Panel: structure of AP2 as bound to a vesicle. The AP2 
adaptor complex works on the plasma membrane to internalise cargo. In the above picture the beta-
appendage is bound to the clathrin cage while the alpha-appendage is free to recruit accessory proteins. 
The AP2 complex is critical in synaptic vesicle recycling. (adapted from www.endocytosis.org). 
 
AP2 was previously reported to interact with the amino-terminus of SV2A (Yao et al., 
2010). SV2A has been shown to serve as a receptor for clathrin adaptor proteins via a 
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tyrosine-based endocytosis motif (Yao et al., 2010). SV2A contains two tyrosine-based 
endocytosis motifs, termed YXXΦ motifs, where Y denotes tyrosine, X denotes any 
amino acid, and Φ denotes a hydrophobic amino acids. The first endocytosis motif is at 
amino acids 46-49 with sequence Y46S47RF, which is in SV2A's cytoplasmic amino 
terminus. The serine residue, Ser47, in the endocytic motif is a major site of 
phosphorylation and so are two other adjacent serine residues, Ser42 and Ser45. Those 
three phosphosites were collectively grouped as cluster-1. Importantly, Tyr46 appeared 
to be a major determinant of the interaction because binding was substantially lost 
upon mutagenesis of this residue to alanine (Yao et al., 2010). The endocytosis motif 
of SV2A thus has the highest affinity for endocytosis-related proteins, particularly the 
clathrin adaptor complex AP2 (Yao et al., 2010). This high affinity binding to AP2 is 
consistent with SV2A acting at the point of cargo recognition that ensures synaptic 
vesicle retrieval by endocytosis.  
 
All the four subunits of the AP2 complex were also detected in TTBK2 co-
immunoprecipitations from mouse brain homogenate (Table 4.1), indicating their 
physiological association with SV2A and possibly other SV proteins. Phosphorylation 
of the serine residues of cluster-1 adjacent to Tyr46 is likely to act as additional 
specificity determinants of this interaction. 
 
4.15.2 Spectrin B2 
 
Another major group of proteins enriched in pull-downs with certain phosphorylated 
SV2A cluster-1 peptides were a number of presynaptic cytoskeletal elements, 
particularly the brain-specific βIII spectrin (SPTBN2) when SV2A was phosphorylated 
at cluster-1. Enrichment for α-actin and β-actin was also observed. These proteins are 
present in the presynaptic portion of neurons and form a dense presynaptic cytoskeletal 
structure known as the presynaptic particle web involved in the stabilisation of the 
synapse (Phillips et al., 2001).  
SPTBN2 was not present in pull-downs with NP1 or singly-phosphorylated peptides. It 
was only observed in pull-downs with three peptides as bait: two doubly-
phosphorylated peptides (pS42+45 and pS42+47) and the triply-phosphorylated 
peptide. Comparison of the number of peptide hits, sequence coverage and MASCOT 
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scores revealed that SPTBN2 binding was significantly enhanced by the triply-
phosphorylated peptide (Table 4.8), indicating that phosphorylation of cluster-1 may 
induce SPTBN2 binding to SV2A. 
4.15.3 ATP1A3 and Camk2a 
 
Two other proteins were observed consistently in these peptide pull-downs, but their 
binding affinities were independent of the phosphorylation status of the bait peptide. 
These two proteins were ATP1A3 and CamK2a (Calcium/Calmodulin-Dependent 
Protein Kinase II Alpha). 
ATP1A3 is an α subunit of the Na+/K+ ATPase pump that is partly responsible for 
establishing and maintaining electrochemical gradients of sodium and potassium ions 
across the plasma membrane of neurons (de Carvalho Aguiar et al., 2004). Mutations 
in ATP1A3 have been shown to cause rapid-onset dystonia-parkinsonism (DYT12) 
(Blanco-Arias et al., 2009). More recently, de novo ATP1A3 mutations have been 
identified as the primary cause of alternating hemiplegia of childhood (AHC) thus 
expanding the spectrum of phenotypes associated with mutations in ATP1A3.  
 
CamK2a belongs to the serine/threonine protein kinases family, and to the 
Ca2+/calmodulin-dependent protein kinases subfamily. CamK2a is crucial for calcium 
signalling in several aspects of plasticity at glutamatergic synapses. Both Camk2a and 
ATP1A3 also co-immunoprecipitate with endogenous TTBK2 from mouse brain 
homogenate, indicating that they may in a protein complex with SV2A in the brain. 
However, comparison of the MASCOT scores from the peptide pull-downs indicates 
that the associations of SV2A cluster-1 to these two proteins are not phospho-
dependent. 
 
4.16 Quantitative analysis of proteins pulled-down by 
differentially-phosphorylated SV2A cluster-2 peptides 
 
Similarly, eight cluster-2 peptides (Table 4.9) corresponding to residues 67 to 98 of 
human SV2A in which 4 Arg residues have been added to the C-terminus to promote 
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solubility were used to assess phosphorylation-dependent binding to Cluster-2. 
For Cluster-2, the peptides used were as follows. The non-phosphorylated amino acids 
corresponding to residues 67 to 98 of human SV2A, plus 4 Arginine residues added to 
the C-terminus to promote solubility (NP2 peptide); the NP2 peptide phosphorylated 
either at Ser80 (pS80) or at Ser81 (pS81) or at Thr84 (pT84), respectively; the NP2 
peptide phosphorylated either at Ser80 and at Ser81 (pS80+pS81), or at Ser80 and at 
Thr84 (pS80+pT84), or at Ser81 and at Thr84 (pS81+pT84); and the NP2 peptide 
phosphorylated at Ser80, Ser81 and Thr84 (pS80+pS81+pT84). The identity, purity 
and phosphorylation status of the peptides were verified by mass spectrometry. 
 Cluster-2 peptides 
Phosphorylation 
status 
Peptide Sequence 
NP2   Biotin—RGEGAQDEEEGGASSDATEGHDEDDEIYEGEYRRRR           
SV2A pS80  Biotin—RGEGAQDEEEGGASPSDATEGHDEDDEIYEGEYRRRR           
SV2A pS81  Biotin—RGEGAQDEEEGGASSPDATEGHDEDDEIYEGEYRRRR           
SV2A pT84  Biotin—RGEGAQDEEEGGASSDATPEGHDEDDEIYEGEYRRRR           
SV2A pS80+81 Biotin—RGEGAQDEEEGGASPSPDATEGHDEDDEIYEGEYRRRR           
SV2A pS80+pT84  Biotin—RGEGAQDEEEGGASPSDATPEGHDEDDEIYEGEYRRRR           
SV2A pS81+pT84  Biotin—RGEGAQDEEEGGASSPDATPEGHDEDDEIYEGEYRRRR           
SV2A 
pS80+pS81+pT84 
 Biotin—RGEGAQDEEEGGASPSPDATPEGHDEDDEIYEGEYRRRR           
Table 4.9. Cluster-2 peptides used in pull-down experiments. Cluster-2 biotinylated peptides 
correspond to residues 67 to 98 of human SV2A plus 4 Arginine residues have been added to the C-
terminus to promote solubility. Each of the 8 peptides has a different phosphorylation status, indicated in 
the first column of the table. Phosphorylated residues are highlighted in red. 
The dataset for the Cluster-2 peptides was analysed using the same stringent criteria 
used for the analysis of cluster-1 peptide pull-downs. The data is summarised in Table 
4.10 (on the next page). Several presynaptic cytoskeletal elements were seen to bind to 
the cluster 2 peptides. γ-actin, WDR11 (WD repeat-containing protein 11) and 
neurofilament medium polypeptide (NEFM) were observed with all 8 cluster-2 
peptides. However, similar number of peptide matches and MASCOT scores were 
  139 
observed for those proteins in all 8 peptide pull-downs signifying that the binding 
affinities were independent of the phosphorylation status of the bait peptides. Whilst 
the interaction of SV2A with those cytoskeletal elements may be critical for SV2A’s 
function in the SV cycle, they are not regulated by phosphorylation of cluster-2. 
Nevertheless, further inspection of these pull-downs revealed that synaptotagmin 1 
(Syt1), another SV membrane protein, binds to the triply-phosphorylated cluster-2 
peptide with very high affinity and was conspicuously not retrieved by the rest of the 
peptides from mouse brain homogenate. This finding strongly suggests that 
phosphorylation of SV2A at Ser80, Ser81 and Thr84 may regulate the interaction of 
SV2A with Syt1. Synaptotagmins are SV proteins present in multiple isoforms (Li et 
al., 1995). Syt1 is one of the most abundant SV proteins. A typical SV contains 15 
synaptotagmin 1s, accounting for ≈7% of the total SV protein content (Takamori et al., 
2006). 
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SV2A Cluster-2 peptide pull-downs 
   MASCOT scores (number of peptide hits) 
   Peptide pull-down 
UniProtKB/Swiss-
Prot entry name 
Primary 
accession 
number 
Gene name NP2 pS80 pS81 pT84 pS80+pS81 pS80+pT84 pS81+pT84 pS80+pS81+pT84 
actin P68033 
 
ACTC 1267 
(56) 
1098 
(40) 
1078 
(46) 
1276 
 (57) 
1238 
(54) 
822 
(45) 
845 
(44) 
820 
(41) 
Neurofilament 
medium 
polypeptide 
 
P08553 
 
NEFM 33 
(14) 
355 
(36) 
253 
(26) 
144 
(19) 
166 
 (28) 
156 
 (22) 
191 
(23) 
147 
(17) 
Vacuolar protein 
sorting-associated 
protein 13C 
 
Q8BX70 
 
VPS13C 486 
(56) 
1540 
(94) 
861 
(59) 
368 
(51) 
944 
(71) 
1731 
(16) 
1061 
(79) 
1259 
(102) 
WD repeat-
containing 
protein 11 
 
Q8K1X1 
 
WDR11 124 
(9) 
22  
(1) 
66 
(6) 
36 
(5) 
198 
(11) 
- 288 
(11) 
606  
(36) 
Synaptotagmin 1 
 
P46096 
 
Syt 1 - - - - - - - 157 
(12) 
Table 4.10. Proteins with differential affinities for SV2A cluster-2 depending on its phosphorylation status. Comparisons are shown only for proteins identified with a 
MASCOT score of 100 or more. The MASCOT scores for each protein for each peptide pull-down are shown. The number of peptide hits for each protein is shown between 
parentheses
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4.17 Confirmation of quantitative mass spectroscopy by 
immunoblotting 
 
 
I used immunoblotting of the mixture of proteins pulled down by all 16 bait peptides 
as an independent method of assessing the validity of the mass spectrometry results. 
As shown in Figure 4.16, SPTBN2 did not bind NP1 or any of the singly-
phosphorylated cluster-1 peptides. Low-level binding to the two of the doubly-
phosphorylated peptides (pS42+pS45 and pS45+pS47) was detected by 
immunoblotting. The triply-phosphorylated cluster-1 peptide was able to bind 
SPTBN2 with higher affinity than the other two peptides as shown in Figure 4.16. 
None of the cluster-2 peptides bound SPTBN2. This pattern of enrichment of 
SPTBN2 was in complete agreement with the mass spectrometric analysis.  
 
 
Figure 4.16. Composite of immunoblots confirming peptide pull-down mass spectroscopy data. 
Each lane is labelled with a bait peptide with different phosphorylation status that was used in pull-
down experiments. Eluted proteins bound to each peptide were separated by SDS-PAGE and 
immunoblot analysis was performed with antibodies against SPTBN2 and Syt1. 
 
Immunoblotting all the peptide pull-downs for Syt1 corroborates the previous 
observation that only the SV2A cluster-2 triply-phosphorylated peptide binds Syt1 
with very high affinity Figure 4.16, while none of the other peptides retrieved Syt1 
from mouse brain lysate. This observation adds further support to the notion that the 
phosphorylation of the three cluster-2 residues modulates the binding of SV2A to 
Syt1. 
IB:$Synaptotagmin$1$
250 
50 
IB:$Spectrin$$B2$
kDa 
Cluster-1 Cluster-2 
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4.18 Validation of phosphorylation-dependence of 
interactions  
 
These observations suggest that a phosphorylation-dependent mechanism modulates 
the association of SPTBN2 and Syt1 to the amino-terminus of SV2 via cluster-1 and 
cluster-2 respectively. To test the phosphorylation-dependence of those interactions in 
vivo, I carried out a λ-phosphatase treatment on endogenous SV2A 
immunoprecipitates. 
SV2A was immunoprecipitated from mouse brain lysate as described before. For λ-
phosphatase treatment, immunoprecipitated proteins on beads were washed twice 
with lambda buffer (50mM Tris-Cl pH 7.5, 100mM NaCl, 0.1mM EGTA, 2mM DTT, 
0.01% Brij-35). The immunoprecipitate was then split into four aliquots (Figure 
4.17A):  Aliquot 1 was left on ice, aliquot 2 was incubated for 60 min at 30 ºC in 
lambda buffer + 2.5mM MnCl2 without λ -phosphatase, aliquot 3 was treated for 60 
min at 30 °C with 100 U λ -phosphatase in lambda buffer + 2.5mM MnCl2 and 
aliquot 4 was treated for 60 min at 30 °C with 100 U λ-phosphatase that had been pre-
incubated with 20mM EDTA, in lambda buffer + 2.5mM MnCl2. After the 60 min 
incubations, the four pellets were washed three times in phosphatase buffer containing 
150mM NaCl, then resuspended in SDS sample buffer and analysed by 
immunoblotting. 
Immunoblot analysis of SV2A treated with λ-phosphatase induced the 
dephosphorylation of SV2A as shown by the blot using the SV2A pS42,45,47 
phosphospecific  antibody (Figure 4.17B). The phosphatase treatment resulted in a 
nearly complete loss of the interactions with SPTBN2 and Syt1. These observations 
confirm the findings from the peptide pull-downs and definitively show that these 
interactions can be modulated by phosphorylation. Thus, a model whereby 
phosphorylation of SV2A by TTBK2 confers binding to SPTBN2 via cluster-1 and 
Synaptotagmin 1 via cluster-2 can be envisioned.
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Figure 4.17. Experimental strategy and composite of immunoblots verifying the phosphorylation-dependence of SPTBN2 and Synaptotagmin 1 binding to SV2A. 
(A) Endogenous SV2A was immunprecipitated from 40 mg of mouse brain homogenate. The immunoprecipitate was then split into four aliquots, which were the subjected to 
the indicated reaction conditions. (B) After washes, each reaction was subjected to SDS-PAGE and immunoblotting in duplicate using the indicated antibodies.   
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4.19 Synaptotagmin 1 
 
Synaptotagmins (Syts) make up a family of vesicle membrane proteins that includes 
more than 17 isoforms with diverse functions and tissue-specific expression patterns 
(Ullrich et al., 1994, Schiavo et al., 1998). Synaptotagmin 1 (Syt1), the best-
characterised isoform, is expressed abundantly in neurons and is essential for fast 
Ca2+-triggered neurotransmitter release (Chapman, 2008). 
Syt1 is thought to function in several distinct steps during the synaptic vesicle cycle 
(Chapman, 2002). Among these functions, Syt1 might operate as a Ca2+- sensor that 
triggers rapid exocytosis (Augustine, 2001). The molecular mechanism by which Syt1 
transduces Ca2+ signals to the opening and/or dilation of fusion pores has therefore 
emerged as a crucial question in the study of synaptic transmission. 
Syt1 is anchored to the membrane of synaptic vesicles via a single transmembrane 
domain near its N-terminus (Figure 4.18a). The most interesting feature of Syt1 is the 
presence of tandem C2 domains that make up its cytoplasmic domain; these are 
designated C2A and C2B (Perin et al., 1990) (Figure 4.18a). C2 domains are 
conserved motifs of ∼135 amino acid residues that often serve as Ca2+ and/or effector 
binding domains. The name is derived from conserved or constant sequence 2 among 
isoforms of protein kinase C that are regulated by Ca2+ and phosphatidyl serine 
(PtdSer) (Nalefski and Falke, 1996). Early studies revealed that Syt1 binds Ca2+ and 
PtdSer-containing membranes in a mutually dependent way (Brose et al., 1992). 
Subsequent studies showed that isolated C2A directly binds Ca2+ and PtdSer 
(Chapman, 2002) and C2B was also later shown to be a Ca2+-sensing module (Desai 
et al., 2000). Similar to C2A (Sutton et al., 1999), C2B is a compact β-sandwich 
formed by two four-stranded β-sheets with loops emerging from the top and bottom 
(Fernandez et al., 2001, Sutton et al., 1999) (Figure 4.18b). Nuclear magnetic 
resonance (NMR) studies indicate that C2B binds two Ca2+ ions (Fernandez et al., 
2001), whereas C2A binds three Ca2+ ions (Ubach et al., 1998). In each C2 domain, 
five conserved acidic residues (Asp) in two flexible loops play crucial roles in 
coordinating Ca2+ (Sutton et al., 1995, Fernandez et al., 2001, Sutton et al., 1999) 
(Figure 4.18b). 
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Figure 4.18. Structure of synaptotagmin 1 (Syt1). (a) Syt1 is anchored to the vesicle membrane via a 
single transmembrane domain (TMD) near its N terminus. The cytoplasmic domain of syt1 is 
composed of two conserved motifs called C2 domains (C2A and C2B). To generate this image, the 
crystal structure of the cytoplasmic domain of SytIII was used as a template (Sutton et al., 1995). (b) 
3D structures of C2A (Shao et al., 1998) and C2B (Fernandez et al., 2001). Red spheres represent 
multiple Ca2+ ions bound to loops 1 and 3. Ca2+-binding loops 1 and 3 are shown as green ribbons. Five 
acidic residues (D1-D5) in each domain (C2A: D172, D178, D230, D232, D238; and C2B: D303, 
D309, D363, D365, D371) that coordinate Ca2+ ions are shown as ball-and-sticks. Positively charged 
residues in each C2 domain that have been shown to play roles in mediating the binding of Ca2+ and 
effectors (C2A, R233; and C2B, K366) (Fernandez-Chacon et al., 2001) are also shown as ball-and-
sticks. [adapted from (Bai and Chapman, 2004)]. 
 
Syt1 operates as the Ca2+-sensor during neuronal exocytosis. Ca2+ thus has a crucial 
regulatory role and alters the interaction of Syt1 with effector molecules on a 
microsecond time-scale to drive neurotransmitter release (Bai and Chapman, 2004).  
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4.20 Activities of the C2 domains of Syt1 
 
The C2A domain of Syt1 is considered to be a calcium sensor, because the binding 
between phospholipids and the C2A domain is Ca2+-dependent (Geppert et al., 1994). 
The C2A domain also binds to syntaxin, a plasma membrane presynaptic protein, in 
the presence of Ca2+ (Shao et al., 1997, Chapman et al., 1995); an interaction that is 
necessary for SV exocytosis. 
The C2B domain engages a wider array of effector molecules than the C2A domain. 
Several proteins, such as clathrin adaptor protein-2 (AP2) (Zhang et al., 1994), 
soluble NSF attachment protein (β-SNAP) (Schiavo et al., 1995), SNAP-25, and N-
type calcium channels (Schiavo et al., 1997), bind to different sites in the C2B 
domain. AP2 is the multimeric protein complex that participates in cargo protein 
internalisation during the clathrin-mediated endocytosis of synaptic vesicles on the 
plasma membrane. The interaction between the C2B domain and AP2 was reported to 
play an important role in synaptic vesicle endocytosis. An in vivo study in 
Caenorhabditis elegans suggests that the C2B domain may function as a high-affinity 
docking site for AP2 and serve as a bridge between endo- and exocytosis in the 
synaptic vesicle cycle (Mizutani et al., 1997). It was also reported that the C2B 
domain binds inositol polyphosphates [IHPS, including inositol 1,3,4,5-
tetrakisphosphate (IP4), inositol 1,3,4,5,6-pentakisphosphate (IP5), and inositol 
hexakisphosphate (IP6)] and phosphoinositide polyphosphates (PtdInsPn) (Fukuda et 
al., 1994). This binding is Ca2+ concentration-dependent. The binding module was 
determined using a liposome model system (Schiavo et al., 1996). 
IP6 is generally considered to be an antinutrient because of its ability to chelate 
divalent minerals and reduce the extent of their absorption (Xu et al., 2008). IP6 was 
shown to inhibit free radical formation and weaken the lipid peroxidation catalysed by 
iron and ascorbic acid in human erythrocytes (Xu et al., 2008). A neuroprotective 
effect for IP6 was suggested because of its antioxidant effects and its ability to alter 
the cell signalling pathways that detoxify reactive oxygen species (ROS). A cell line 
assay using squid giant synapses indicated that the serial microinjection of IP6 into 
the presynaptic terminal inhibited synaptic transmission; this inhibition could be 
released by the co-injection of antibodies that recognise the C2B domain (Llinas et 
al., 1994). In addition, IP6 also plays an essential role in regulating the inhibition of 
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neurotransmitter release, and this effect might partially be due to the inhibition of the 
interaction between Syt1 and AP2, which blocks endocytosis (Mizutani et al., 1997). 
 
4.21 Domain architecture and NMR structure of 
Synaptotagmin 1 C2B-IP6 complex 
 
To understand the interactions between the C2B domain of Syt1 and IP6 at the 
molecular level, Joung et al. (2012) have used a variety of biophysical methods 
including isothermal titration calorimetry (ITC), circular dichroism (CD) 
spectrometry, and multidimensional NMR, to characterise the molecular interaction 
between C2B and IP6. 
 
Figure 4.19. NMR structure of the C2B domain of synaptotagmin 1 complexed with IP6. A 
magnified view of the C2B-IP6 complex showing the binding region and the corresponding residues 
involved in intermolecular interaction with three phosphate groups indicated by pink dotted lines 
[reproduced from (Joung et al., 2012)]. 
 
IP6 binds strongly to the C2B domain and it inhibits the fusion step of Ca2+-regulated 
exocytosis (Mochida et al., 1997, Fukuda and Mikoshiba, 1997). Therefore, IP6 was 
assumed to be a potential regulator of neurotransmitter release and the elucidation of 
the structural interactions between the IP6 and C2B domain at the molecular level 
provided the mechanistic information needed to understand how IP6 acts as an 
inhibitor of neurotransmitter release. It has been reported that point mutants in the 
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polybasic Lys residues (K324–K327) (see sequence alignment in Figure 4.20) within 
the C2B domain decreased the binding affinity of the C2B domain for IP6 (Fukuda et 
al., 1995).  
 
 
Figure 4.20. Multiple sequence alignment of human Syt1 and Syt1 from selected species. 
Sequence alignment showing the high degree of conservation of the Syt1 protein sequence especially in 
the C2A domain (residues 157-245) and the C2B domain (residues 287-422). The three charged and 
polar amino acids that are critical for binding three phosphate groups of IP6 are highlighted in red.  
 
In addition, the isothermal titration calorimetry (ITC) data suggested a one-binding 
site mode for the C2B–IP6 complex (Joung et al., 2012). The exact binding region of 
IP6 on C2B was determined by the solution structure of the C2B–IP6 complex using 
intermolecular nuclear Overhauser enhancement (NOE) data and chemical shift 
perturbation data. The four intermolecular NOEs between the C2B domain and IP6 
are illustrated in Figure 4.19. Residues K327, T329, and K331 in the C2B domain 
exhibited intermolecular NOEs with IP6. The authors thus identified a conserved 
cluster of charged and polar amino acids, that provide generic interactions with three 
phosphate groups (Figure 4.19).  Those residues are therefore candidates for 
phosphorylation-dependent interactions with other proteins or molecular effectors. 
 
 
4.22 How does the phosphorylated SV2A cluster-2 bind Syt1? 
 
I postulated that those three residues could possibly be the critical binding sites of the 
three phosphate groups of SV2A cluster-2. To verify that those key phosphate-
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interacting residues are required for mediating the phospho-dependent SV2A/Syt1 
interaction, I mutated two of the residues predicted to be the binding sites of 
phosphate groups to alanine and assessed their ability to bind the triply-
phosphorylated cluster-2 peptide.  
 
Figure 4.21.  Wild-type Syt1 is retrieved by the triply-phosphorylated cluster-2 peptide but not 
the K327A mutant or the T329A mutant. Wild-type Syt1 with a C-terminal flag tag, single amino-
acid substitution mutants (K327A and T329A) and a double amino-acid substitution mutant 
(K327A+T329A) were transiently expressed in HEK293 cells. Transfected cell lysates were incubated 
with the cluster-2 triply-phosphorylated peptide or the NP2 peptide immobilised on streptavidin beads. 
Proteins bound to beads were eluted and separated by SDS-PAGE. Immmunoblots were performed on 
whole cell lysates with anti-flag and anti-Syt1 antibodies (top two panels). Syt1 proteins bound to 
peptides were detected with an anti-Flag antibody. 
 
cDNA constructs to express Syt1-Flag fusion proteins carrying a lysine-to-alanine or 
a threonine-to-alanine mutation in one or both of these critical IP6-binding residues 
were generated. The two key residues were Lys327 and Thr329 of the C2B domain of 
human Syt1.  The resulting proteins, Syt1[K327A]-Flag, Syt1[T329A]-Flag and 
Syt1[K327A+T329A]-Flag Wild-type and mutant (K327A and T329A) were transiently 
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expressed in HEK293 cells along with Syt1[WT]-Flag. Wild-type and mutant fusion 
proteins were all produced by HEK293 cells (Figure 4.21).  
The biotinylated cluster-2 triply-phosphorylated phosphopeptide affinity-retrieved 
Syt1[WT]-Flag from HEK293 cell lysate. Remarkably, alanine mutations of either 
K327 or T329 within the C2B domain of Syt1 ablated the capture of Syt1 by the 
phosphopeptide (Figure 4.21). 
As shown in Figure 4.21, mutation of either Lys327 or Thr329 in Syt1 completely 
abrogates the interaction with the triply-phosphorylated cluster-2 peptide, suggesting 
that these two residues are critical determinants for the SV2A/Syt1 interaction. This 
observation argues that K327 and T329 could provide generic interactions with 
phosphate groups of SV2A cluster-2 and is therefore critical for the phospho-
dependent interaction of SV2A with synaptotagmin 1. 
 
4.23 Discussion 
 
As a means to understand the role of phosphorylation-dependent interactions imparted 
by the cytosolic N-terminus of SV2A, I employed a proteomic study to identify 
proteins and pathways that physically interact with the phosphorylated motifs of 
SV2A. In this chapter, I have described the phosphorylation-dependent interactions 
between SV2A and SPTBN2 via cluster-1 and the interaction between SV2A and 
Syt1 via cluster-2. Another noteworthy observation was that phosphorylation of the 
three serine residues of cluster-1, which are situated in the vicinity of SV2A’s 
tyrosine-based endocytosis motif (amino acids 46-49), hinders the interaction between 
SV2A and adaptor-related protein complex 2, AP2. 
 
4.23.1 AP2 clathrin adaptor complex 
 
AP2 was previously reported to interact with the amino-terminus of SV2A (Yao et al., 
2010). SV2A has been shown to serve as a receptor for clathrin adaptor proteins via a 
tyrosine-based endocytosis motif (Yao et al., 2010). SV2A contains two tyrosine-
based endocytosis motifs, termed YXXΦ motifs, where Y denotes tyrosine, X denotes 
any amino acid, and Φ denotes a hydrophobic amino acids. The first endocytosis 
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motif is at amino acids 46-49 with the amino acid sequence Y46S47RF, which is in 
SV2A's cytoplasmic amino terminus. The serine residue, Ser47, in the endocytic 
motif is a major site of phosphorylation and so are two other neighbouring serine 
residues, Ser42 and Ser47: the three phosphosites that were previously identified and 
collectively grouped as cluster-1.  
 
Importantly, Tyr46 appeared to be a major determinant of the interaction because 
binding was substantially lost upon mutagenesis of this residue to alanine (Yao et al., 
2010). In that study, the endocytosis motif of SV2A (YSRF) was found to have the 
highest affinity for endocytosis-related proteins, particularly the clathrin adaptor 
complex AP2 (Yao et al., 2010). This high affinity binding to AP2 is consistent with 
SV2A acting at the point of cargo recognition in the SV cycle that ensures synaptic 
vesicle retrieval by endocytosis. Phosphorylation of the serine residues of cluster-1 is 
likely to act as additional specificity determinants for the temporal and spatial 
modulation of this interaction. Precedence for this supposition is provided by studies 
of the phospho-dependent binding of the clathrin adaptor AP2 to the GABAA receptor 
(GABAAR) γ subunit isoforms. 
 
Kittler et al. (2008) performed molecular analyses to delineate the amino acids 
responsible for binding to the µ2 subunit of AP2 (µ2–AP2) in the the GABAA 
receptor (GABAAR) protein. This resulted in the identification of a classical tyrosine-
based binding motif (YXXφ, where φ is a hydrophobic amino acid) centred on 
Tyr367 in the (Y365GY367ECL) in the γ2 subunit of  GABAAR (Kittler et al., 2008). 
Significantly, both Tyr367 and the adjacent tyrosine residue Tyr365 are the principal 
sites of phosphorylation for Src family members in GABAARs (Brandon et al., 2001). 
Using surface plasmon resonance (SPR) coupled with crystallography, it was evident 
that this motif bound µ2–AP2 with an affinity of 40 nM, an interaction critically 
dependent on Tyr367 (Kittler et al., 2008). Phosphorylation of either Tyr365 or 
Tyr367 ablated the interaction of µ2–AP2 to the γ2 subunit of GABAAR .  
 
The interaction of SV2A with AP2 is critically dependent Tyr46 (Yao et al., 2010), 
which is a potential site of phosphorylation for a tyrosine kinase. Hypothetically, 
there are two separate phospho-dependent mechanisms regulating the interaction of 
SV2A with AP2. The fact that AP2-binding motifs are regulated by different kinases 
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suggests that this mechanism may have evolved as a scheme to allow for tight 
regulation of AP2 binding, and therefore internalisation kinetics, by multiple 
signalling cascades that converge at the level of direct receptor phosphorylation.  It 
will be interesting to dissect the role that phosphorylation of the three cluster-1 
residues of SV2A by TTBK2 plays in regulating the binding of SV2A to µ2–AP2 by 
biophysical and structural approaches. 
 
4.23.2 SPTBN2 (β-III spectrin gene) 
 
The finding that the brain specific β-III spectrin (SPTBN2) interacts with SV2A in a 
phosphorylation-dependent manner via cluster-1 is biologically intriguing in the 
context of SCA pathogenesis as mutations in SPTBN2 cause spinocerebellar ataxia 
type 5 (SCA5) (Ikeda et al., 2006).   
Spectrins, heterotetramers consisting of two α and two β subunits, are important 
structural components of the plasma membrane skeleton and are thought to play a 
significant role in restricting and stabilising membrane-spanning proteins within 
specific subdomains of the plasma membrane.  
The core structural element of spectrins and a few other proteins, including spectrin 
family proteins (e.g. α-actinin, dystrophin), is a helical repeating unit referred to as a 
spectrin repeat (Figure 4.22B). Typically, 20 complete repeats can be found in α-
spectrin, while β-spectrins contain 16 (or 29 in the case of β-heavy isoforms). Full 
sequence analysis of both spectrin subunits confirmed that the size of such segments 
varies in the range between 99 and 114 amino acid residues and the sequence 
homology between them does not exceed 30% (Leluk et al., 2001). Nevertheless, 
there is a common structural fold shared by all the spectrin repeats consisting of three 
helices, of which A and C are parallel and B is antiparallel. Spectrin repeats are 
typically found together with actin-binding calponin-homology (CH) domain, SH3 
(Src homology 3) domain, PH (Pleckstrin homology) domain, EF hand type motifs; 
calcium-binding motifs and various signalling domains (Figure 4.22A). 
β-III spectrin is primarily expressed in the nervous system with highest levels of 
expression in the cerebellum, where it is found in Purkinje cell soma and dendrites 
(Sakaguchi et al., 1998, Jackson et al., 2001). β-III spectrin interacts with EAAT4 
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(excitatory amino acid transporter 4), the glutamate transporter predominately 
expressed in Purkinje cells, and stabilises it at the plasma membrane (Jackson et al., 
2001). This implicates β-III spectrin in clearance of glutamate from the synaptic cleft, 
and consequently both modulation of glutamatergic neurotransmission and prevention 
of glutamate-mediated neurotoxicity. Other investigators have shown β-III spectrin 
interacts with ARP1 (actin-related protein1) (Figure 4.22B) and is found in a complex 
with dynactin (Holleran et al., 2001). Since dynactin is the accessory protein that 
mediates the association of dynein with cytoplasmic vesicles, another suggested 
function of β-III spectrin is to facilitate protein trafficking by linking the microtubule 
motor to vesicle-bound cargo. An earlier study also suggested that β-III spectrin 
associates with Golgi and cytoplasmic vesicles (Stankewich et al., 1998).  
The importance of the spectrin skeleton in the vertebrate nervous system is 
underscored by the discovery that mutations in human β-III spectrin cause 
spinocerebellar ataxia type 5 (SCA5) (Ikeda et al., 2006). SCA5 results in Purkinje 
cell loss, cerebellar cortical atrophy, and neuromuscular defects (Ikeda et al., 2006). 
The characterisation of a mouse model in which β-III spectrin expression is disrupted 
has been reported (Perkins et al., 2010). The functional β-III spectrin knockout mouse 
(β-III−/−) develops characteristic features of cerebellar ataxia including progressive 
motor incoordination, a wider hind-limb gait, tremor, cerebellar atrophy and Purkinje 
cell loss, thus resembling the human clinical cases. The β-III−/− mouse was used as a 
new model of cerebellar ataxia and further investigations of the ataxic phenotype 
implicated several physiological defects: ion channel dysfunction, glutamate-
mediated excitotoxicity, and vesicle-trafficking deficits, all arising from loss of β-III 
spectrin in disease pathogenesis.  
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Figure 4.22.  Structural and functional features of the spectrin dimer. (A) The domains of spectrin 
are: CH domain (PDB ID: 1BKR), SH3 domain (PDB ID: 1U06), PH domain (PDB ID: 1WJM), EF 
hands; major structural elements are spectrin repeats (structure of repeats 15, 16 and 17 of brain alpha 
spectrin PDB ID: 1U4Q; structure of erythroid spectrin tetramerisation complex PDB ID: 3LBX; 
structure of repeats 13, 14 and 15 of erythroid beta spectrin in complex with ZU5 domain of erythroid 
ankyrin; ribbon representations of helices of repeats of beta spectrin are in red and of alpha spectrin are 
blue). (B) Schematic representation of the domain structure of spectrin heterodimer together with 
examples of binding partners for each of the spectrin subunits ascribed to certain parts of the molecules 
(solid rectangles); double colour dashed rectangles represent binding partners of unassigned specificity 
to a certain part of a dimer. [adapted from (Machnicka et al., 2013)]. 
 
In Drosophila, spectrin function at the synapse has been extensively studied in motor 
neurons (Featherstone et al., 2001, Pielage et al., 2005). These studies first 
characterised pre- and postsynaptic spectrin localisation and function during motor 
neuron synaptogenesis in Drosophila. Loss of presynaptic spectrin reportedly 
eliminates several essential cell adhesion molecules from synaptic sites and leads to 
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defects in neurotransmission and the disassembly and elimination of synapses at the 
neuromuscular junction (Pielage et al., 2005, Pielage et al., 2006). In addition, the 
RNAi depletion of presynaptic β-spectrin has been reported to disrupt microtubule 
organisation at the synapse, to generate large accumulations of synaptic vesicles with 
motor axons, and to reduce the accumulation of synaptic vesicles within the terminal 
boutons. Thus, in the case of Drosophila and also Caenorhabditis elegans, which only 
have one form of β-spectrin, loss of β-spectrin causes an uncoordinated phenotype, 
which is a consequence of the destabilisation of the neuromuscular junction through 
loss of synaptic cell-adhesion molecules (Pielage et al., 2005) and axonal breakage 
(Hammarlund et al., 2007), respectively. These latter studies proposed a link between 
spectrin and vesicle transport either through a direct role in motor-based transport or 
an indirect effect on cytoskeletal organisation.  
Spectrins are present in the presynaptic portion of neurons and form a dense 
presynaptic cytoskeletal structure known as the presynaptic particle web involved in 
the stabilisation of the synapse (Phillips et al., 2001). The newly identified phospho-
dependent interaction between SV2A and βIII-spectrin could promote the tethering of 
SV2A to the pre-synaptic cytoskeleton, thereby targeting SV2A to certain membrane 
proteins in the neuronal plasma membrane or within specific subdomains of the 
plasma membrane. 
Given that the spectrin cytoskeleton is required for the organisation of a diverse set of 
membrane proteins, including ion channels, receptors, and cell adhesion molecules, 
the emerging paradigm for ataxia pathogenesis follows. This paradigm is dissolution 
of the spectrin cytoskeleton, which causes a failure in the cellular localisation of 
certain membrane proteins resulting in the loss of their physiological interactions with 
other proteins, which leads to neuronal dysfunction that can cause ataxia. 
 
4.23.3 Synaptotagmin 1 
 
Several investigators have studied the physical and functional interaction between 
SV2A and synaptotagmin 1 previously. This interaction is direct and mediated by the 
amino terminus of SV2A and the C2B domain of synaptotagmin 1 (Schivell et al., 
1996). It is also known to be influenced by calcium and modulated by 
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phosphorylation of SV2A (Pyle et al., 2000). However, the precise position of the 
binding site i.e. the critical SV2A phosphorylation sites that confer binding Syt1 had 
not been defined. 
 
I have shown that phosphorylation of SV2A at the three cluster-2 residues (Ser80, 
Ser81and Thr84) confers binding to synaptotagmin 1. I have also presented evidence 
that the phosphorylation of cluster-2 plays a modulatory role in binding to 
synaptotagmin 1 as the dephosphorylation of native SV2A leads to the dissociation of 
synaptotagmin 1, indicating that the SV2A-synaptotagmin 1 interaction may be 
regulated in vivo through changes in SV2A phosphorylation.  
 
The region of synaptotagmin 1 that mediates its interaction with SV2A is the second 
protein kinase C homology domain, the C2B domain (Schivell et al., 1996). The 
critical residues within the C2B domain that provide generic interactions with the 
phosphate groups of cluster-2 were mapped using previously published structural 
data. This information will be particularly useful for future biophysical, structural and 
functional investigations of the SV2A-synaptotagmin 1 interaction. 
 
The SV2A-synaptotagmin 1 interaction is inhibited by calcium (Schivell et al., 1996) 
and this regulation is most likely mediated by calcium-induced conformational 
changes in synaptotagmin 1 (Davletov and Sudhof, 1994). The C2B domain is known 
to interact with several proteins in a calcium-independent manner. Several proteins, 
such as clathrin adaptor protein-2 (AP2) (Zhang et al., 1994), soluble NSF attachment 
protein (β-SNAP) (Schiavo et al., 1995), SNAP-25, and N-type calcium channels 
(Schiavo et al., 1997), bind to different sites in the C2B domain.  
In addition, the C2B domain is extremely important functionally. Microinjection of 
peptides corresponding to a region of the C2B domain were more efficacious in 
disrupting neurotransmission in the squid giant synapse than peptides corresponding 
to the analogous region of the C2A domain (Bommert et al., 1993). Furthermore, 
mice in which synaptotagmin 1 has been disrupted in the C2B domain lack the fast, 
low calcium-affinity component of regulated secretion (Geppert et al., 1994), 
suggesting that the C2B domain may mediate Syt1’s role as a low affinity calcium 
sensor. 
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The SV2A-synaptotagmin 1 interaction may provide calcium-regulated modulation of 
one or both proteins' actions. There are at least three ways in which this interaction 
may function. First, synaptotagmin 1 may regulate a putative transporter or channel 
function of SV2A. This model predicts that association with synaptotagmin 1 either 
inhibits or promotes transport by SV2A, with reversal of this regulation at high 
calcium concentrations during exocytosis. Interestingly, expression of 
synaptotagmin's C2B domain transforms an endogenous choline transport activity in 
Xenopus oocytes to one with the characteristics of neuronal choline transporters, 
indicating that C2B domains can regulate transporters (O'Regan et al., 1995). 
Moreover, the effect of C2B on transport activity in this system was eliminated by 
high calcium concentrations, a result which parallels the inhibitory effect of calcium 
on the SV2A-synaptotagmin interaction. In the synapse, synaptotagmin may activate 
SV2A-mediated transport of a common vesicle constituent during resting conditions. 
With calcium influx, the proteins dissociate, turning off SV2A activity during 
exocytosis and recycling. 
A variation of this model incorporates another hypothesised function of SV2A; that it 
serves as a component of the fusion pore that mediates the initial events of transmitter 
release. In this model, Syt1, via its interactions with SNARE proteins, would regulate 
targeting of SV2A to its counterpart in the plasma membrane. This model is 
consistent with Syt1’s proposed role as a calcium-regulated inhibitor of synaptic 
transmission (Nonet et al., 1993). It suggests that synaptotagmin 1 provides a “dock 
and hold” mechanism for the placement of SV2A. This hypothesis is also consistent 
with the observation that Syt1 knockout mice lack the fast component of 
neurotransmitter release. SV2A in these mice would not be ushered to the proper 
region of the plasma membrane; therefore fusion pore preassembly would be absent. 
An alternative model is one in which SV2A regulates the action of synaptotagmin 1, 
perhaps as a function secondary to its activity as a transporter. In this model of SV2A-
synaptotagmin 1 interaction, SV2A inhibits the availability of synaptotagmin 1 to 
form protein complexes that mediate synaptic vesicle fusion until calcium 
concentrations rise in response to membrane depolarisation.  
I have presented evidence implicating SV2A and synaptotagmin 1 in a 
phosphorylation-dependent interaction. The phosphorylation of SV2A at cluster-2 
may provide a temporal regulatory control of its association with the C2B domain of 
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synaptotagmin 1. Ca2+ also modulates this association as high Ca2+ concentrations 
induce conformational changes in Syt1 that mediate its dissociation from SV2A. 
Further insights into the SV2A-Synaptotagmin 1 interaction could be gained by co-
crystallising the C2B domain of Syt1 in complex with the triply-phosphorylated 
SV2A cluster-2 peptide. This can reveal further insights into the binding sites and 
how this interaction is modulated in vivo. 
 
4.24 Implications for SV2A’s physiological function 
 
Based on its structure, SV2A has been proposed to perform several actions, including 
transport of ions or small molecules into vesicles (Janz et al., 1999), providing the 
glyco-matrix to the vesicle lumen (Reigada et al., 2003), modulating the endocytosis 
of vesicle proteins including synaptotagmin 1 (Haucke and De Camilli, 1999), serving 
as a receptor for clathrin adaptor proteins and contributing to the proper trafficking of 
the vesicle protein synaptotagmin 1 (Yao et al., 2010). 
Mutation of Tyr46, which is part of a canonical YXXΦ adaptor-binding site (Owen 
and Evans, 1998) in the amino terminus of SV2A, produced a protein that trafficked 
to synapses but did not support normal neurotransmission. In comparison to wild-type 
SV2A, SV2AY46A demonstrated significantly reduced binding to AP2 (Yao et al., 
2010). Consistent with reduced binding to the AP2 mediators of endocytosis, the 
Tyr46Ala mutation resulted in lowered internalisation of SV2A. Because SV2A 
contains an YXXΦ motif in its cytoplasmic N-terminus, those results suggested that 
the amino terminal endocytosis motif in SV2A plays a dominant role in its 
endocytosis.   
Disruption of the endocytosis motif in SV2A's amino terminus by mutating Tyr46 to 
Ala resulted in a higher proportion of synaptotagmin 1 on the plasma membrane. This 
finding is consistent with SV2A playing an important role in the endocytosis of 
synaptotagmin 1. When viewed in light of the finding that synaptic vesicles from 
SV2A/B knockout mice contained significantly lower amounts of synaptotagmin 1, 
the most compatible conclusion is that SV2A regulates the endocytosis of 
synaptotagmin 1. Synaptotagmin 1 has been proposed to be required for normal 
vesicle endocytosis (Nicholson-Tomishima and Ryan, 2004) and to be a clathrin 
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adaptor receptor (Yao et al., 2010, Diril et al., 2006). Therefore, SV2A contributes to 
any role synaptotagmin plays in endocytosis.  
SV2A influences the endocytosis of synaptotagmin 1 because peptides corresponding 
to the endocytosis domain of SV2A increase binding of synaptotagmin to AP2 
clathrin adaptors (Haucke and De Camilli, 1999). Moreover, synaptic vesicles isolated 
from SV2A KO mice contain lower levels of synaptotagmin 1 than wild-type mice 
(Yao et al., 2010). Thus, SV2A appears to play a specific role in trafficking of 
synaptotagmin 1 and it also appears to exert a selective effect on the expression of 
synaptotagmin 1. Collectively, these observations support the view that SV2A plays a 
major role in regulating the amount of the synaptotagmin 1 protein in synaptic 
vesicles. 
SV2A is essential for normal neurotransmission. In its absence, synaptic release 
probability decreases, a result that leads to a severe seizure phenotype and premature 
death (Crowder et al., 1999, Janz et al., 1999). The functional lesion in synapses 
lacking SV2A occurs after vesicle docking (Custer et al., 2006) and before the 
formation of tightly-associated SNARE complexes (Xu and Bajjalieh, 2001), 
indicating that SV2A contributes to the process that renders vesicles competent for 
calcium-stimulated fusion. Altered endocytosis could produce this phenotype by 
changing the protein composition of vesicles.  
In the absence of SV2A, synaptotagmin 1 trafficking to synaptic vesicles becomes 
more random (Yao et al., 2010), leading to fewer vesicles with enough of the calcium 
sensor to trigger calcium-stimulated fusion. Thus this action of SV2A can explain the 
neurotransmission deficit observed in SV2A knockout mice. Changes in vesicle 
protein expression have been noted in several nervous system pathologies, including 
schizophrenia (Mirnics et al., 2000), epilepsy (Matveeva et al., 2007, Matveeva et al., 
2008, Matveeva et al., 2003) and Alzheimer’s disease, where changes in vesicle 
protein expression precede loss of synapses and changes in cognitive functioning 
(Yao, 2004, Yao et al., 2003). Protein sorting during synaptic vesicle endocytosis 
represents a potential point of regulation in neurotransmission because it dictates the 
protein composition of synaptic vesicles, the organelle that mediates neurotransmitter 
release. 
The number and variability of each protein in synaptic vesicles has implications for 
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hypotheses of protein action at the synapse. Four SV proteins: SV2A, H+/ATPase, V-
glut1 and synaptotagmin 1, show little variation in number of copies per vesicles 
(Mutch et al., 2011), indicating that they are sorted to vesicles with high precision. 
This was seen despite the fact that the vesicles analysed represented all 
neurotransmitter classes. This finding supports a model in which protein complexes 
with a fixed stoichiometry interact with clathrin adaptor proteins in a stereotypical 
manner. In this way, vesicle protein content could be encoded into protein interactions 
that result in the self-assembly of vesicles with uniform protein content. This model is 
consistent with the report that SV2A, the most monodispersed of the vesicle proteins, 
regulates the amount of synaptotagmin 1 in synaptic vesicles (Yao et al., 2010). 
Based on the findings presented here, a theoretical model emerges in which SV2A, 
via its phospho-dependent interactions with AP2 clathrin adaptors, βIII-spectrin and 
synaptotagmin 1 regulates the trafficking of synaptotagmin 1 and hence the vesicle 
content of synaptotagmin 1. SV2A impacts on the endocytosis of synaptotagmin 1 
because peptides corresponding to the endocytosis domain of SV2A increase binding 
of synaptotagmin to AP2 clathrin adaptors (Haucke and De Camilli, 1999). However, 
the endocytosis of synaptotagmin 1 is also modulated by another protein called stonin 
2 (Diril et al., 2006), a homolog of the µ2 subunit of AP2. SV2A’s ability to influence 
synaptotagmin 1’s endocytosis may therefore be through regulating synaptotagmin 
1’s ability to bind stonin 2. Alternatively, by simultaneously engaging AP2 clathrin 
adaptors through its YXXΦ motif and interacting with synaptotagmin 1 bound to 
stonin 2 via cluster-2, SV2A may help concentrate clathrin adaptors in a way that 
insures the inclusion of synaptotagmin 1 in vesicles.  
This likely scenario may involve the coordination of the phosphorylation of SV2A at 
cluster-1 and cluster-2. It will be interesting to investigate the spatio-temporal 
regulation of SV2A phosphorylation by TTBK2 in vivo. Phosphorylation of SV2A at 
cluster-1 and cluster-2 must be tightly-coordinated to ensure the correct sequential 
orchestration of SV2A’s interactions with AP2, β2-spectrin and synaptotagmin1 to 
ensure the fidelity and precise stoichiometry of protein sorting during endocytosis. 
Clues to SV2A's molecular action have come largely from its structure. SV2A's most 
striking feature is its structural similarity to major facilitator transporters (Pao et al., 
1998), which has led to the widely held hypothesis that it transports something across 
the vesicle membrane. Despite exhaustive efforts, the transporter function of SV2A 
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has never been validated (Chang and Sudhof, 2009). The fact that it affects the 
expression and endocytosis of synaptotagmin 1 supports the conclusion that 
modulation of endocytosis is an essential action of SV2A. 
 
4.25 Enigmatic role of SV2A in clinical epilepsy and the 
treatment of epilepsy with Levetiracetam 
 
The involvement of SV2A in clinical epilepsy remains unclarified. Mice with knock 
out of one allele of SV2A have an elevated incidence of epileptic seizures, and mice 
with both copies knocked out have very severe epileptic seizures after the first 
postnatal week and die by the third week (Crowder et al., 1999), primarily because of 
fulminant epilepsy. 
According to the world health organisation (WHO), about 50 million people 
worldwide have epilepsy, and nearly 80% of epilepsy occurs in developing countries 
(WHO, 2012). Epilepsy becomes more common as people age (Brodie et al., 2009). 
Epileptic seizures may occur in recovering patients as a consequence of brain surgery. 
Epilepsy is usually managed with medication, but not cured. 
There is no silver bullet for the medical treatment of epilepsy. Specifically, there is no 
single defect that can be targeted to correct the hyperexcitability and hypersynchrony 
that are the hallmarks of epileptic brain circuits. Vast numbers of proteins regulating 
neuronal excitability interact in an extraordinarily complex manner to govern cellular 
and network behaviour. Among the current antiepileptic therapies, only a very few 
proteins (e.g., voltage-gated sodium channels, GABAA receptors) have been targeted, 
while many potential molecular candidates for antiepileptic drug development remain 
unexplored. For example, a large number of proteins govern the synaptic vesicle cycle 
and, consequently, the strength of synaptic transmission. Once an action potential 
reaches the axon terminal, rather than an all-or-nothing phenomenon, these proteins 
regulate the probability that a vesicle will fuse and release its contents. Vesicles are 
filled with neurotransmitter, dock, are primed, and finally, fuse at the release site 
when Ca2+ enters the terminal. The rate at which vesicles cycle through these various 
stages helps to determine how synaptic responses change during repetitive activity. 
Thus, an ideal antiepileptic drug would not target a protein integral to the release 
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process, which would disrupt normal neurotransmission, but rather would be directed 
at a modulatory protein that regulates the vesicle cycle during high activity (e.g., a 
seizure).  
 
In 1992, the potent effect of the pyrrolidone drug Levetiracetam (LEV) was 
discovered. By random screening, scientists at UCB (Union Chimique Belge), a 
Belgian biopharmaceutical company, found that this (S)-configurated ethyl derivative 
((2S)-α-ethyl-2-oxo-1-pyrrolidine acetamide) of piracetam possesses pronounced 
anticonvulsive effects, which became evident by tests involving acoustically induced 
seizures in sound-sensitive mice (Gower et al., 1992). LEV underwent clinical trials 
and eventually was approved by the Food and Drug Administration (FDA) under the 
trade name Keppra® in November 1999. At that time, not much was known regarding 
the molecular mechanism of action and the target of LEV, which was supposed to be 
a highly abundant protein located in synaptic vesicle membranes of the central 
nervous system (Noyer et al., 1995). Five years after its approval, in 2004, this site 
was identified as the synaptic vesicle protein, SV2A (Lynch et al., 2004). Today, 
Keppra® is one of the most successful anti-epileptic drugs, being widely prescribed 
for partial as well as generalised seizures, as a monotherapy and as an add-on 
medication (De Smedt et al., 2007). 
 
LEV represents a new class of drug for the treatment of neurological and psychiatric 
disorders. LEV is currently widely-used for the treatment of epilepsy, though it also 
shows promise in the treatment of anxiety disorders (Kinrys et al., 2007, Kinrys et al., 
2006, Zhang et al., 2005), pain (Enggaard et al., 2006, Dunteman, 2005, Price, 2004), 
dyskinesias (Bushara et al., 2005, McGavin et al., 2003, Woods et al., 2008, Zivkovic 
et al., 2008, Striano et al., 2009), and post-traumatic stress disorder (Kinrys et al., 
2006).  
 
SV2A is the molecular target of the anti-epileptic drug LEV (Lynch et al., 2004). 
SV2A is both necessary and sufficient for LEV binding (Lynch et al., 2004). In 
addition, mice heterozygous for the SV2A gene disruption show reduced response to 
drug treatment (Kaminski et al., 2009), consistent with SV2A being required for 
levetiracetam action. Thus, levetiracetam appears to act by modulating the action of 
SV2A, though its mechanism of action remains unknown. Currently, SV2A is the 
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only synaptic vesicle protein known to be a drug target. LEV, the first agent in this 
new class of antiepileptic drugs with unknown mechanism of action, illustrates the 
promises and challenges faced in searching for antiepileptic medications with novel 
molecular targets. 
 
Crowder et al. (1999) showed that mice with knock out of one allele for SV2A have 
an elevated incidence of seizures, and mice with both copies knocked out have severe 
seizures after the first postnatal week and die by the third week (Crowder et al., 
1999). Action potential-independent release of vesicles from inhibitory neurons (i.e., 
spontaneous release of vesicles) is normal in hippocampal slices from SV2A-deficient 
mice, but action potential-dependent release (i.e., Ca2+-triggered release) is markedly 
reduced. These findings suggested that SV2A is involved in the coupling of Ca2+ 
entry and vesicle release at inhibitory synapses i.e. in the final step in which docked 
vesicles are readied for rapid release in response to Ca2+ influx. In other words, SV2A 
may regulate neurotransmission indirectly by controlling the vesicle’s ability to detect 
changes in presynaptic calcium. 
 
Several studies report a correlation between increased SV2A expression and changes 
in synaptic functioning. Kindling of seizures in rats results in increased expression of 
several synaptic vesicle proteins including SV2A (Matveeva et al., 2007, Matveeva et 
al., 2003), and SV2A is at the hub of seizure-dependent changes in protein co-
expression (Winden et al., 2011). In addition, mRNA encoding SV2A is a primary 
target of a microRNA whose expression is sensitive to changes in synaptic activity 
(Cohen et al., 2011). Together these findings indicate that altered expression of 
SV2A, is a molecular signature of altered synaptic activity. 
 
In animals subjected to seizure kindling protocols, treatment with LEV blocks both 
the development of a seizure phenotype and increases in SV2A expression (Ohno et 
al., 2009, Matveeva et al., 2008). In hippocampal slices from non-epileptic animals, 
treatment with levetiracetam reduces neurotransmission in response to fast stimulus 
trains (Yang et al., 2007), consistent with the drug blocking SV2A's effects on vesicle 
priming. Most interestingly, the latency of drug action is much shorter when neurons 
are stimulated (Meehan et al., 2011), suggesting that LEV preferentially targets 
hyperactive synapses. 
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LEV treatment of neurons overexpressing SV2A decreased the amount of Syt1 at 
synapses but did not alter the ratio of SV2A/Syt1 at synapses (Nowack et al., 2011). 
Considered together these findings are consistent with the interpretation that the 
amount of Syt1 at synapses tracks the amount of SV2A, and LEV results in a 
reduction in the amount of both proteins available to support calcium-triggered 
exocytosis. The fact that both increased and decreased levels of SV2A and Syt1 are 
associated with reduced release probability suggests that optimal levels of these 
proteins are required for normal neurotransmission, a conclusion consistent with the 
recent observation that the number of SV2s and synaptotagmins per vesicle is tightly 
regulated (Mutch et al., 2011).  
 
LEV had no effect on neurons that lacked SV2A, consistent with the conclusion that 
the drug acts by binding SV2A. Because SV2A expression is limited to presynaptic 
terminals, this means that LEV affects presynaptic events that regulate synaptic 
vesicle release. Given that LEV restored the concentration of SV2A at the synapse to 
control levels without affecting total SV2A per length of neurite, it is most likely that 
LEV affects the ability of SV2A to concentrate in synapses (Nowack et al., 2011). 
This is most consistent with the drug altering SV2A's ability to bind to proteins that 
influence protein trafficking or localisation, for example binding to clathrin adaptor 
proteins or proteins of the cytoskeleton. 
 
The effects of LEV, in combination with the observation that LEV blocks kindling-
induced increases in SV2A (Matveeva et al., 2008), suggest that levetiracetam may 
act by reversing the effects of increased SV2A expression. In the case of SV2A 
overexpression, levetiracetam may inhibit inappropriate interactions that occur when 
SV2A is over-abundant. What is clear is that LEV’s action on protein levels at 
synapses represents a novel drug action.  
 
Because SV2A’s function inherently involves its phosphorylation-modulated 
interactions with AP2 clathrin adaptors, spectrin β2 and synaptotagmin 1, one 
possible mechanism of drug action is that it modulates SV2A phosphorylation, which 
in turn impacts on SV2A protein interactions. A direct implication of my findings 
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would be to investigate the effect of LEV on SV2A phosphorylation by TTBK2 in 
vivo. 
 
Future work into the mechanisms by which LEV produces the effects will provide 
insight into the aetiology of nervous system disorders that are based in aberrant SV 
protein expression/function. Elucidating the mechanism by which LEV and SV2A 
interact to prevent seizures will undoubtedly open doors to the investigation of 
potential novel target proteins involved in the synaptic vesicle cycle. 
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5 Characterisation of SV2A/Syt1 
interaction using biophysical and 
functional methods 
 
The data presented in chapter 4 indicate that the interaction between SV2A and Syt1 
is regulated by the phosphorylation of the three residues (Ser80, Ser81 and Thr84) 
collectively designated as SV2A cluster-2. This interaction is direct and mediated by 
the cluster-2 of SV2A and the C2B domain of synaptotagmin 1 (Syt1). The critical 
residues within the C2B domain that provide generic interactions with the phosphate 
groups of cluster-2 were mapped using previously published structural data. Support 
for the notion that a cluster of highly conserved charged and polar amino acids (K327, 
T329, K332) in the C2B domain Syt1 were critical in binding the three phosphate 
groups of SV2A cluster-2 was provided by the inability of the triply-phosphorylated 
SV2A cluster-2 peptide to retrieve Syt1-Flag proteins harbouring an alanine mutation 
of either residue. This is indicative of a phosphospecific physical and functional 
association between the two proteins.  
The structural basis for phospho-dependent association of the amino-terminus of 
SV2A to the C2B domain of Syt1 may be determined by solving the high-resolution 
X-ray crystal structure of this complex. The resolution of the C2B domain of Syt1 in 
complex with the SV2A triply-phosphorylated cluster-2 phosphopeptide will provide 
a molecular rationale for this phosphospecific association of SV2A and Syt1. 
 
Nevertheless, before this goal is reached, methods for determining biophysical 
quantitative data relating to this complex are important. Biophysical methods were 
employed to achieve a critical objective: an ab initio method of predicting the binding 
interface. Supporting biophysical studies are often invaluable both for sample 
characterisation before starting structural studies as well as for investigating structure-
function relationships after structural information is available. In addition, a plethora 
of questions can be addressed through biophysical studies in the absence of any 
structural information. 
 
To investigate the SV2A/Syt1 interaction in more detail, two independent biophysical 
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methods were employed: Isothermal titration calorimetry (ITC) and fluorescence 
polarisation anisotropy (FP) were used for quantitative analyses of the SV2A/Syt1 
phosphospecific interaction. 
  
 
5.1   Expression and purification of GST fusion Syt1 fragments  
for biophysical studies 
Syt1 recombinant GST fusion proteins were expressed in BL21 DE3 strain of E. coli 
as described before in the ‘Materials and Methods’ section. Initial pilot expression of 
Syt1 fragments showed that GST-Syt1 encompassing residues 246-422 expressed 
very well. This fragment includes the C2B domain of Syt1 with approximately 40 
residues flanking it on either side.  
For the purposes of ITC and FP experiments, three different versions of GST-Syt1 
[246-422] were expressed: GST-Syt1[246-422]WT,  GST-Syt1[246-422]K327A, GST-
Syt1[246-422]T329A. Figure 5.1 shows a Coomassie-stained gel of those expressed 
fragments together with BSA (Bovine Serum Albumin) standards used to gauge the 
concentrations of each protein. 
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Figure 5.1. GST-Syt1[246-422] for biophysical binding studies. Coomassie Blue staining of 0.5 µg 
and 1.0 µg of each expressed protein fragment: GST- Syt1 [246-422]WT, GST-Syt1 [246-422]K327A and 
GST-Syt1 [246-422]T329A.  
 
5.2   Isothermal Titration Calorimetry (ITC) 
Isothermal Titration Calorimetry (ITC) is considered as the most quantitative 
technique available for measuring the thermodynamic properties of protein–protein 
interactions and is a useful tool for protein–protein complex structural studies. This 
technique relies upon the accurate measurement of heat changes that follow the 
interaction of protein molecules in solution, without the need to label or immobilise 
the binding partners, since the absorption or production of heat is an intrinsic property 
of virtually all biochemical reactions. ITC provides information regarding the 
stoichiometry, enthalpy, entropy, and binding kinetics between two interacting 
proteins (Velazquez-Campoy et al., 2004). 
Isothermal titration calorimetry provides a direct route to the complete 
thermodynamic characterisation of protein interactions. A typical ITC experiment is 
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carried out by the stepwise addition of one of the reactants (1-10 µl per injection) into 
a cell (≈ 1.4 mL) containing the other reactant. In this context, a syringe of ITC 
containing a ligand (peptide) is titrated into a cell containing a protein solution. As the 
two elements interact, heat is released or absorbed and this can be related to the extent 
of binding that occurs. When the protein in the cell becomes saturated with the added 
ligand, the heat signal diminishes until only the background heat of dilution is 
observed. Measurement of this heat allows for the accurate determination of binding 
constants (KD), reaction stoichiometry (n), and a thermodynamic profile of the protein 
interaction that includes the observed molar calorimetric enthalpy (ΔH), entropy (ΔS), 
and change in free energy (ΔG) according to the equation: ΔG = −RT!LnK = !ΔH − TΔS , 
where R is the gas constant (8.3144 J K−1 mol−1 equal to 1.9872 cal K−1 mol−1), T is 
the absolute temperature (Kelvin), K is the association constant, whereas ΔH, ΔS and 
ΔG denote, respectively, the changes in enthalpy, entropy and binding free energy 
upon complex association. 
Unlike other methods, ITC does not require immobilisation and/or modification of 
proteins since the absorption or production of heat is an intrinsic property of virtually 
all biochemical reactions (Lakey and Raggett, 1998). 
 
5.2.1 ITC experiments 
 
All protein solutions for calorimetric experiments were filtered through a 0.22 µm 
membrane and degassed thoroughly in a vacuum chamber before use. Peptide 
solutions were prepared by dissolving the same buffer as protein samples. Protein and 
peptide samples were prepared in 20mM HEPES pH 7.5, 50mM NaCl and 0.5mM β-
mercaptoethanol. The choice of buffer was based on initial trials, which revealed that 
this buffer offered minimal background noise and precipitation 
 
ITC experiments were carried out on a Microcal VP-ITC (Milton Keynes, England) as 
described in the ‘Materials and Methods’ section. A typical experiment involved 30 
serial 4 µl injections of the SV2A cluster-2 phosphopeptide or dephosphopeptide (10-
  170 
100 µM) into a sample cell containing 25 µM of purified GST-Syt1 [246-422]WT or 
GST-Syt1 [246-422]K327A protein. A space of 2 minutes was allowed between 
injections to ensure equilibration between reactants. The reaction cell was stirred at a 
constant speed of 300 rpm. 
 
Heat changes within the cell were monitored during each injection of peptide and 
recorded as the total heat change per second over time. A binding isotherm was then 
fitted to data and expressed as heat change per mole of peptide against the peptide to 
protein ratio. For each protein and for each condition, at least 2 runs were carried out 
to ensure reproducibility. Between each run, the chamber was thoroughly washed 
with at least 10 chamber volumes of MilliQ (Millipore, England) water and the 
syringe rinsed thoroughly again with at least 10 volumes of MilliQ water. Each 
experimental condition had a blank run with protein in the chamber replaced with 
buffer. This data was then subtracted from the run with protein present to take into 
account any energy of dilution or peptide/buffer reaction.  
 
From the isothermic data, a regression model was used to predict the number of 
binding sites on the protein involved in the reaction, the disssociation constants of the 
binding (KD). 
 
5.2.2 The thermodynamics of cluster-2 triply phosphorylated peptide 
binding to the C2B domain of synaptotagmin 1 
 
ITC experiments were conducted on a Microcal VP-ITC instrument. The binding of 
the non-phosphorylated and triply-phosphorylated cluster-2 peptides to the C2B 
domain of Syt1 were thus examined. A series of injections of each peptide were made 
into an isolated chamber containing the protein: GST-Syt1[246-422]WT or GST-Syt1 
[246-422]K327A at a constant temperature of 30 °C. Heat changes within the cell were 
monitored during each injection of peptide and recorded as the total heat change per 
second over time.  
The peptides loaded into the syringe were at a concentration of 2mM. Injection 
parameters for the ligand were 4 µl/injection with time spacing of 200–700 seconds 
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depending on the progress of the titrations. The final protein concentrations used for 
the experiments were 26 µM concentration of Syt1[246-422]. 
Different concentrations were used to ensure that results were repeatable over a 
variety of conditions. During each experiment, 30 × 4 µL doses of peptide were 
injected into the chamber with protein, which was stirred constantly at 300 rpm. Each 
injection was followed by a 2 min period to ensure equilibration of the solution.  
All the experiments presented were conducted at 30°C. The buffer used was 20mM 
HEPES, pH 7.5, 0.05M NaCl, 0.5mM β-mercaptoethanol. The peptides were 
reconstituted in the same buffer. Multiple titrations were carried out at various 
concentrations to optimise the conditions. The peptides taken in the syringe were at a 
concentration of 1 to 2.0 mM. Injection parameters for the ligand (peptide) were 4 
µl/injection with time spacing of 200–700 seconds depending on the progress of the 
titrations.  
The final protein concentrations used for the experiments were 26 µM of Syt1[246-
422] and 1 µM peptide. Four sets of peptide titrations were performed; 1) cluster-2 
phosphopeptide titration on GST-Syt1 [246-422]WT, 2) cluster 2 dephosphopeptide 
titration on GST-Syt1 [246-422]WT, 3) cluster 2 phosphopeptide titration on GST-Syt1 
[246-422]K327A, and 4) cluster 2 dephosphopeptide titration on GST-Syt1 [246-
422]K327A.  
The results of the titration curves were corrected using a buffer–protein control. 
Initially, the buffer alone was titrated, using the cluster-2 phosphopeptide as the 
ligand. The same procedure was repeated with the protein dissolved in the buffer. The 
heat change of the first experiment (buffer titrated with phosphopeptide) was 
subtracted from that of the second (protein dissolved in buffer titrated with 
phosphopeptide). Finally, the Origin software supplied by Microcal was used to 
analyse these data. 
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Figure 5.2. ITC Titration of SV2A peptide titrations on Syt1. Raw data are shown in the upper 
panels and integrated heat changes shown in the lower panels as solid squares.  
(A) The triply-phosphorylated SV2A cluster-2 peptide solution was titrated into a solution containing 
GST-Syt1 [246-422]WT. Each downward deflection corresponds to one injection. The area represents 
the heat exchanged. The total heat exchanged during each injection is fit to a single-site binding 
isotherm with KD and ΔH° as independent parameters, where KD = 312 nM. 
(B) The triply-phosphorylated SV2A cluster-2 peptide solution is titrated into a solution containing 
GST-Syt1 [246-422]K327A, showing no detectable binding to Syt1. 
(C,D) The dephosphorylated SV2A cluster-2 peptide solution is titrated into a solution containing 
GST-Syt1 [246-422]WT (C) and GST-Syt1 [246-422]K327A (D) showing no detectable binding of the 
dephosphopeptide to Syt1. 
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The raw data (upper panels in Figure 5.2) consists of peaks of heat output generated 
by successive injections of peptide and, when integrated, these provide the total heat 
output per injection. Once the protein is saturated, the residual heat effects originate 
from dilution of the peptide and also from mechanical effects associated with the 
injection. Lower panels represent the data after non-specific buffer interactions have 
been subtracted. 
 
In Figure 5.2A (lower panel), a clear traceable pattern of binding was observed. The 
heat transfer associated with each injection is plotted as a function of the peptide-to-
protein concentration ratio. The Origin 7 software’s non-linear regression fitting was 
used and fit to an equation that incorporates the enthalpy and affinity of a single 
phosphopeptide binding event. A single set of sites based on a MicroCal model was 
found to produce the lowest χ2 values and error dependency. The binding isotherm 
indicates that the cluster-2 triply phosphorylated peptide bound extremely tightly to 
the C2B domain of Syt1 with a KD of 312 nM. The fit corresponds to stoichiometry of 
binding n=1, and the data shows a two-stage binding event with one dependent site. 
The binding reaction is endothermic, which means that the interaction between SV2A 
and Syt1 is not enthalpically favoured.  
 
Strikingly, no binding at all was observed for between triply-phosphorylated peptide 
and Syt1[246-422]K327A, signifying that mutation of Lys327 to alanine abrogates 
phosphopeptide binding. In addition, none of the proteins bound to the 
nonphosphorylated peptide (panels C and D). 
Collectively, those results show that the C2B domain of Syt1 binds with affinity the 
specific phosphopeptide encoding SV2A cluster-2 but not its unphosphorylated 
derivative, reiterating the absolute dependence of the tight association between the 
two proteins on the three SV2A cluster-2 residues being phosphorylated.  
The ITC data also confirms the importance of residue K327 of the C2B domain of 
Syt1 in mediating this interaction and argue that K327 is a critical determinant of the 
binding specificity.   
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5.3   Fluorescence polarisation 
 
Fluorescence polarisation (FP) or anisotropy can be used to measure the affinity of 
protein–protein or protein–ligand interactions. Typically, one binding partner is 
labelled with a fluorescence probe and the sample is excited with a specific frequency 
of light. The increase in the polarisation of the emission spectra upon binding of the 
labeled protein to its binding partner can be used to calculate the binding affinity 
(Owicki, 2000). 
In broad terms, fluorescence polarisation is relevant where a small (tumbling), 
fluorescent molecule binds a larger target molecule. Thus the observation of small 
fluorescent ligands binding protein molecules are often experiments suitable for this 
type of detection. Fluorescence anisotropy is a method for measuring the binding 
interaction between two molecules, and can be used to measure the binding constant 
(or the inverse, the disassociation constant) for the interaction. The basic idea is that a 
fluorophore excited by polarised light (light whose "waves" only go one direction) 
will also emit polarised light. However, if a molecule is moving, it will tend to 
"scramble" the polarisation of the light by radiating at a different direction from the 
incident light (Figure 5.3). The "scrambling" effect is greatest with fluorophores 
freely tumbling in solution and decreases with decreased rates of tumbling. Protein 
interactions can be detected when one of the interacting partners is fused to a 
fluorophore: upon binding of the partner molecule a larger, more stable complex is 
formed, which will tumble more slowly (thus, increasing the polarisation of the 
emitted light and reducing the "scrambling" effect). This technique works best if a 
small molecule is fused to a fluorophore and binds to a larger partner (this maximises 
the difference in signal between bound and unbound states). Molecular interactions 
can thus be analysed using this approach where the smaller molecule is fluorescently 
labeled and the concentration of the larger binding partner is varied. The concept of 
fluorescence anisotropy is depicted in Figure 5.3 below. 
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Figure 5.3. The concept of fluorescence anisotropy. As molecules tumble in solution, the emitted 
light is depolarised. The depolarisation of the fluorescent molecule is dependent on the size and shape 
of the rotating molecule and also the viscosity of the solution. The smaller the molecule, the more 
rapidly it rotates and the more the light is depolarised and hence the lower the anisotropy. If a larger 
molecule interacts with the fluorescent molecule the rotation of the complex will be slower than of the 
unbound molecules and result in an increase in the fluorescence anisotropy. 
 
5.3.1 Labelling peptides with FlAsH 
 
The FlAsH-EDT2 labelling reagent emits a green (FlAsH) fluorescent signal when 
excited at the appropriate wavelength. The fluorescent excitation and emission spectra 
for the FlAsH reagent are shown in Figure 5.4 below. It has a maximum excitation of 
508 nm and an emission maximum of 528 nm.  
 
 
Figure 5.4. Fluorescence Excitation/Emission spectra of FlAsH-EDT2 (Lumio green).  
[adapted from http://www.lifetechnologies.com/order/catalog/product/T34563] 
 
Peptides encoding the SV2A cluster-2 motif, with different phosphorylation status, 
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were custom-synthesised (Table 5.11) with a N-terminal CCPGCCGG tetra-cysteine 
tag (Adams et al., 2002), where two glycine residues were added to the C-terminus as 
a linker. This tag affords their labelling with FlAsH-EDT2, an arsenic derivative of 
fluorescein. Labelling of N-terminally FlAsH-tagged (CCPGCC) peptides (Adams et 
al., 2002) was performed in 20mM HEPES (pH 7.5), 50mM NaCl and 5mM β‐
mercaptoethanol. 10nmol of each FlAsH-tagged peptide was incubated with 5µl 
FlAsH-EDT2 (Lumio Green) at room temperature for 2.0 h in the dark. Excess dye 
was removed by overnight dialysis into the above buffer. 
 Peptides for Fluorescence Polarisation 
Phosphorylation 
status 
Peptide Sequence 
fNP2 CCPGCCGGGGRGEGAQDEEEGGASSDATEGHDEDDEIYEGEYRRRR 
fSV2ApS80 CCPGCCGGGGRGEGAQDEEEGGAS*SDATEGHDEDDEIYEGEYRRRR         
fSV2ApS81 CCPGCCGGGGRGEGAQDEEEGGASS*DATEGHDEDDEIYEGEYRRRR         
fSV2ApT84 CCPGCCGGGGRGEGAQDEEEGGASSDAT*EGHDEDDEIYEGEYRRRR         
fSV2ApS80+81 CCPGCCGGGGRGEGAQDEEEGGAS*S*DATEGHDEDDEIYEGEYRRRR       
fSV2ApS80+pT84 CCPGCCGGGGRGEGAQDEEEGGAS*SDAT*EGHDEDDEIYEGEYRRRR       
fSV2ApS81+pT84 CCPGCCGGGGRGEGAQDEEEGGASS*DAT*EGHDEDDEIYEGEYRRRR       
fSV2ApS80+81+pT84 CCPGCCGGGGRGEGAQDEEEGGAS*S*DAT*EGHDEDDEIYEGEYRRRR     
Table 5.11. Peptides for fluorescence polarisation.  SV2A Cluster-2 peptides correspond to residues 
67 to 98 of human SV2A where 4 Arginine residues have been added to the C-terminus to promote 
solubility and the tetracysteine tag (CCPGCCGGGG) has been added to the N-terminus to enable 
Lumio green labelling. Each of the 8 peptides has a different phosphorylation status, indicated in the 
first column of the table. Phosphorylated residues are highlighted with an asterisk in red. 
 
5.3.2 Equilibrium fluorescence anisotropy measurements 
 
All binding assays were performed by adding 100 nM of labelled peptide to 
increasing concentrations of recombinant GST-Syt1 [246-422]WT or GST-Syt1 [246-
422]K327A. End point polarisation and anisotropy measurements were made using 
PheraStar plate reader (BMG Labtech) using a 485/520 nm fluorescence polarisation 
module. Data was analysed using GraphPad Prism 5 and mean fluorescence 
anisotropy values (2 measurements) were plotted against protein concentration and 
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the curves fitted to a single-site binding model to determine KD values. 
 
Figure 5.5. Specificity of SV2A cluster-2-encoding peptides binding to GST-Syt1[246-422]WT. 
Binding affinities of GST-Syt1[246-422]WT for FlAsH-labelled SV2Acluster-2-derived peptides were 
determined by fluorescence polarisation. Only the triply-phosphorylated peptide incorporating all three 
cluster-2 phosphorylation sites, shows significant binding affinity (250 nM). No detectable binding was 
observed for the dephosphopeptide, singly-phosphorylated peptides and doubly-phosphorylated 
peptides. The calculated KD (shown on the graph) indicates a phosphospecific interaction. For 
calculation of KD see ‘Materials and Methods’ section.  
 
The binding of the eight labelled peptides shown in Table 5.11 to GST-Syt1 [246-
422]WT was first quantitated by FP. The triply-phosphorylated SV2A cluster-2 peptide 
showed very tight binding to the Syt1 protein with a KD of 250 nM (Figure 5.5), 
comparable to the KD obtained by ITC (312 nM). Notably, none of the 
dephosphorylated, singly-phosphorylated and doubly-phosphorylated peptides 
showed any demonstrable binding to Syt1, reemphasising the unconditional 
dependence of the tight association of SV2A to Syt1 on the concerted 
phosphorylation of the three SV2A cluster-2 residues.  
 
Subsequently, the binding affinities of GST-Syt1 [246-422]WT and GST-Syt1 [246-
422]K327A for the triply-phosphorylated peptide and dephosphopeptide were 
determined. In excellent agreement with the previous ITC data, the K327A mutant 
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protein displayed extremely weak binding to the triply-phosphorylated peptide, with a 
KD several-fold higher than that observed with the wild-type protein (Figure 5.6). 
 
 Syt1[246-422]WT/ 
fpS80+pS81+pT84 
Syt1[246-422]K327A/ 
fpS80+pS81+pT84 
Syt1[246-422]WT/ 
fNP2 
Syt1[246-422]K327A/ 
fNP2 
KD (nM) 252 ND ND ND 
Bmax  (AU) 700 196 45 44 
Figure 5.6. Binding of SV2A cluster-2-derived peptides to GST-Syt1 [246-422]WT and GST-Syt1 
[246-422]K327A. The affinity of the phosphospecific interaction of GST-Syt1[246-422]K327A is 
substantially reduced as compared to GST-Syt1[246-422]WT , indicating that the Lys327 residue of the 
C2B domain of Syt1 is a critical determinant of this interaction. The SV2A cluster-2 dephosphopeptide 
showed no significant ability to bind to either GST-Syt1[246-422]WT or GST-Syt1[246-422]K327A. A 
dissociation constant could not be calculated for binding assays marked ND. ND: not determined; AU: 
arbitrary units. 
  
Taken together, these data substantiate the importance of three phosphorylation sites 
(Ser80, Ser81 and Thr84) of SV2A, SV2A cluster-2, in the phosphospecific 
interaction with the C2B domain of Syt1.  
Moreover, mutation of Lys327 of Syt1 to alanine abrogates phosphopeptide binding 
in perfect agreement with the previous ITC data and corroborates the observation that 
Lys327 is a critical in mediating this interaction. 
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5.4   Discussion 
 
I have shown that the phosphorylated SV2A cluster-2 motif binds the C2B domain of 
synaptotagmin 1 with high affinity and specificity. The dissociation constant for the 
interaction between purified GST-Syt1[246-422]WT  and the triply-phosphorylated 
SV2A cluster-2 peptide was determined by ITC and FP. A KD of 312 nM was 
obtained by ITC and 250 nM by FP. The submicromolar affinity of this interaction is 
comparable to other interactions of established biological importance.  
The tight association of the two proteins is phospho-dependent as the 
dephosphorylated cluster-2 peptide showed no detectable binding to GST-Syt1[246-
422]WT by ITC. To confirm this unique phospho-dependent binding selectivity, eight 
peptides encoding SV2A cluster-2 with different phosphorylation statuses (Table 
5.11) were generated and their interaction with GST-Syt1[246-422]WT was examined 
by FP. None of those peptides displayed appreciable binding to GST-Syt1[246-
422]WT, except the triply-phosphorylated SV2A cluster-2 peptide. Collectively, these 
results showed that the C2B domain of Syt1 binds with high affinity to the 
phosphorylated SV2A cluster-2 motif but not to its unphosphorylated, singly-
phosphorylated and doubly-phosphorylated motifs. This provides strong support to 
the notion that Syt1 binds SV2A by direct recognition of the SV2A cluster-2 
phosphoepitope in vivo.  
Based on the previously-published NMR structure of the C2B-IP6 complex, three 
critical residues (K327, T329 and K332) were predicted to provide the generic 
interactions with the three phosphate groups of SV2A cluster-2. GST-Syt1[246-422] 
fusion proteins harbouring K327A or T329A mutations were also tested for their 
ability to bind SV2A cluster-2 peptides. Consistent with the peptide pull-down assays 
described in chapter 4, ITC showed that GST-Syt1[246-422]K327A did not bind the 
triply-phosphorylated cluster-2 peptide. Similar results were obtained by FP, which 
showed that neither GST-Syt1[246-422]K327A nor GST-Syt1[246-422]T329A bound the 
triply-phosphorylated cluster-2 peptide. This corroborates that this cluster of charged 
and polar amino acids in the C2B domain of Syt1 mediates the physical interaction 
with phosphorylated SV2A cluster-2. 
This knowledge of the binding interface between the two proteins will be invaluable 
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for further structural and functional studies of the SV2A/Syt1 interaction. It will be 
extremely informative if the structure of the C2B domain of Syt1 complexed with the 
SV2A cluster-2 triply-phosphorylated peptide can be determined. This should provide 
a rationale of the molecular basis of this selectivity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  181 
5.5   The use of pHluorins for optical measurements of 
presynaptic acitivity 
 
Chemical synaptic transmission between neurons is a major means of communication 
mediating information flow in the brain. Monitoring of synaptic events during 
behavioural or cognitive tasks would ultimately provide important understanding of 
the link between collective neuronal network function and the demands placed upon 
cellular machinery. Clear interpretations of electrically recorded synaptic events in 
intact or semi-intact neuronal networks are, however, hampered by several problems. 
First, the complexity of the neural circuit is such that responses from single synaptic 
sites are often hard to extract, and second, electrical filtering properties of the 
dendrites strongly shape synaptic responses recorded in the postsynaptic neuron. In 
addition, postsynaptic electrical recordings usually obscure many of the underlying 
cell biological and molecular events that support presynaptic function. The advent of 
new optical recording techniques (Denk and Svoboda, 1997) in combination with 
advances in fluorescent molecular probes (Tsien, 1998) together are poised to provide 
new levels of information about the functioning of multicellular neuronal networks 
and the underlying cellular and molecular machinery that govern their behaviour. 
Recently, a novel approach that uses pH-sensitive green fluorescent protein (GFP) has 
been applied to visualise secretion at synaptic terminals (Miesenbock et al., 1998). 
Because this is a genetically encoded reporter, it holds significant promise for future 
studies in a number of genetic systems, including drosophila, nematode, zebrafish, 
and mouse. 
 
The functional basis of pH-based sensors of synaptic activity is diagrammed in Figure 
5.7. Synaptic vesicles are specialised endosomes that maintain an acidic lumen 
resulting from the activity of a vacuolar H+-ATPase (Nelson, 1992). This activity is 
required to establish an electromotive force that, in turn, drives neurotransmitter 
uptake from the cytosol into the vesicle (Liu et al., 1999). Measurements of synaptic 
vesicle lumen pH indicate that it has a resting value of ~ 5.6 (Miesenbock et al., 
1998). Following fusion with the plasma membrane during action potential firing, the 
lumenal surface of the synaptic vesicle abruptly switches to the more alkaline pH of 
the extracellular environment (pH ~ 7.4). Miesenbock and coworkers used a histidine-
based combinatorial mutagenesis strategy combined with a pH-dependent selection 
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screen to obtain new variants of GFP that enable measurements of synaptic vesicle 
exocytosis. These new GFPs were termed pH-sensitive green fluorescent protein-
based sensors (pHluorins). pHluorins targeted to the synaptic vesicle lumen (synapto-
pHluorin) enabled measurements of dynamic changes in pH of vesicle lumen 
resulting from exocytosis and endocytosis of synaptic vesicles during presynaptic 
activity. The net fluorescence change observed during action potentials therefore 
reflect a net balance of externalised pHluorin, which is brightly fluorescent, and the 
endocytosed and reacidified vesicles, which are dark.  
 
 
Figure 5.7. Exocytosis relieves the proton-dependent quenching of ecliptic-pHluorin fluorescence. 
The pHluorin molecule is attached to the lumenal aspect of VAMP. At the resting pH of 5.6 within 
vesicles, the fluorescence signal from pHluorin is completely quenched. During firing of action 
potentials, the vesicles undergo fusion with the plasma membrane leading to the externalisation of 
pHluorin to pH of 7.4. This relieves the proton-dependent quenching and causes an increase in 
fluorescence. The fluorescence signal then recovers following endocytosis by reacidification of 
vesicles. 
 
5.5.1 Hippocampal neurons preparation, transfections and pHluorin 
imaging of neurons 
 
To investigate the role of SV2A phosphorylation and the impact of the phospho-
dependent association of SV2A and Syt1 on SV trafficking, optical imaging of 
pHluorin-tagged SV2A and Syt1 proteins was carried out in collaboration with Dr. 
Sarah Gordon from Professor Michael Cousin’s laboratory (University of Edinburgh).  
A chimeric reporter cDNA construct consisting of a signal-sequence-tagged pHluorin 
fused to the lumenal domain of mouse SV2A (SV2A-pH) was generated by inserting 
superecliptic pHluorin into the first intra-vesicular loop of mouse SV2A (between 
amino acid 197 and 198) (Figure 5.8B). Three further SV2A-pH constructs were 
generated; one with mutations to the cluster-1 phosphorylation sites to alanine 
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(Ser42Ala, Ser45Ala and Ser47Ala), another with mutations to the cluster-2 
phosphorylation sites to alanine (Ser80Ala, Ser81Ala and Thr84Ala), and one with all 
six phosphorylation sites mutated to alanine (Ser42Ala, Ser45Ala and Ser47Ala, 
Ser80Ala, Ser81Ala and Thr84Ala).  
Another chimeric reporter cDNA construct consisting of a signal-sequence-tagged 
pHluorin fused to the lumenal domain of rat synaptotagmin 1 (Syt1-pH)  was kindly 
provided by Prof. Michael Cousin. SV2A-binding defective mutants of Syt1 were 
generated by mutating the three key amino acids (K327, T329 and K332) in the C2B 
domain of Syt1 to alanines. Those three key residues K327, T329 and K332 in the 
human Syt1 sequence correspond to residues K326, T328 and K331 in the rat protein 
sequence (see alignment in Figure 4.20). Those three residues were individually 
mutated to alanines to generate three independent cDNA constructs and a fourth 
construct with all three residues mutated to alanine was also generated. 
 
Figure 5.8. The use of Syt1-pH and SV2A-pH to monitor SV traffic. A) Because SVs are an acidic 
compartment, the Syt1-pHluorin reporter does not fluoresce before exocytosis but does once exposed 
on the cell surface. After endocytosis, this fluorescence is rapidly quenched by reacidification of the 
vesicle. Thus each exocytic event increases the fluorescence and each endocytic event reduces it. B) 
SV2A-pH was generated by inserting superecliptic pHluorin (green circle) into the first intra-vesicular 
loop of mouse SV2A (between amino acid 197 and 198). 
 
Firstly, to establish the consequence of ablating the phosphorylation of SV2A and 
secondly the effect of disrupting the phospho-dependent association of SV2A with 
Syt1 in SV endocytosis, the traffic of the SV2A-pHluorin and Syt1-pHluorin wild-
type and mutant proteins was monitored in primary hippocampal cultures derived 
from wild-type mice.  
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Syt1-pHluorin reports the traffic of Syt1 to and from the cell surface during SV 
exocytosis and endocytosis, by virtue of the pHluorin tagged to the luminal domain of 
Syt1 (Figure 5.8A). Its dynamic presence at the cell surface is reported by either 
increases (exocytosis) or decreases (endocytosis) in its signal, due to its fluorescence 
being quenched by the acidic environment within SVs. Similarly, SV2A-pHluorin 
reports the traffic of SV2A to and from the cell surface during SV exocytosis and 
endocytosis, by virtue of the pHluorin tagged to the luminal domain of SV2A (Figure 
5.8B). 
 
5.6   Results 
 
5.6.1 Effect of ablating the phosphorylation of SV2A on its trafficking 
In cultured primary hippocampal neurons, SV proteins, including SV2A and Syt1, 
undergo constitutive cycling between SVs and the presynaptic plasma membrane. A 
quantitative assessment of the consequence of abolishing the phosphorylation of 
SV2A at cluster-1 and cluster-2 sites in SV endocytosis was performed by mutating 
those residues to alanine.  
Neurons in culture were transfected with SV2A-pHluorin reporters and were 
visualised at 500 nm (all >525 nm emission). Four different constructs were used for 
transfections: SV2AWT-pHluorin, SV2AS42A,S45A,S47A-pHluorin, SV2AS80A,S81A,T84A-
pHluorin, and SV2AS42A,S45A,S47A,S80A,S81A,T84a-pHluorin (SV2A6XA-pHluorin). 
All the four SV2A-pHluorin chimeras were properly targeted to presynaptic vesicles, 
as electrical stimulation with 300 action potentials (APs) at 10 Hz gave rise to a 
stimulation-dependent SV2A-pHluorin fluorescence increase at synaptic boutons with 
similar characteristics as described before for pHluorin-tagged synaptobrevin 
(Miesenbock et al., 1998, Sankaranarayanan and Ryan, 2001). The pH dependence of 
the fluorescence was utilised to monitor the effect of mutating cluster-1 and cluster-2 
phosphorylation sites within the presynaptic compartment of living neurons by using 
a simple acid quenching-dequenching protocol. Acid quenching resulted in a near 
complete loss of fluorescence, whereas alkalinisation of the vesicular lumen with 
NH4Cl produced a maximum intensity signal at synaptic boutons, indicating that the 
transient fluorescence increase after stimulation was due to exocytotic externalisation 
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of SV2A-pHluorin.  
The kinetics of SV2A-pHluorin exo-endocytosis indicated that SV2A-pHluorin can 
serve as a faithful reporter of SV2A recycling at presynaptic nerve terminals. This 
system was then used to assess the effect mutating the phosphorylation sites in living 
neurons both at steady state and under stimulating conditions. 
A robust stimulation-dependent increase in SV2A-pHluorin fluorescence occurred in 
the hippocampal cultures, indicating that the reporters were efficiently delivered to 
the cell surface by SV exocytosis. SV2AWT-pHluorin fluorescence decayed back to 
baseline with first order kinetics (Figure 5.9).  
Remarkably, the three SV2A-pHluorin constructs harbouring phosphosite mutations 
produced similar responses; the endocytic rates remained largely unchanged (Figure 
5.9A-D) with small differences in retrieval rate (i.e. relative speed of reinternalisation 
of SV2A-pHluorin molecules). This indicates that SV2A phosphorylation is 
dispensable for its normal trafficking. 
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Figure 5.9. Mutation of SV2A phosphorylation sites are fully dispensable for proper SV2A 
trafficking. SV retrieval kinetics in WT neurons by recording SV2A-pHluorin fluorescence during and 
after field stimulation applied at 10 Hz for 30 s. (A) SV2AS42A,S45A,S47A-pHluorin retrieval in WT 
neurons (purple line, purple bar) shows similar retrieval efficiency as compared to SV2AWT-pHluorin 
retrieval in WT neurons (blue line, blue bar). (B-D) SV2AS80A,S81A,T84A-pHluorin (green line, green bar) 
and  SV2A6XA-pHluorin (red line, red bar) both display very little difference in retrieval efficiency as 
compared to SV2AWT-pHluorin retrieval in WT neurons (blue line, blue bar). All the four curves are 
plotted on the same graph in D. Data shown is mean ± SEM of five independent experiments. 
 
 
5.6.2 Effect of disrupting the binding of SV2A to Syt1 on the recycling of 
Syt1 
 
A quantitative assessment of the consequence of ablating the phospho-dependent 
association of SV2A with Syt1 in SV endocytosis was performed by mutating the 
three key residues, which are critical for the binding of SV2A cluster-2, in the C2B 
domain of Syt1.  
Neurons in culture were transfected with pHluorin reporters and were visualised at 
500 nm (all >525 nm emission). Five different constructs were used for transfections: 
Syt1WT-pHluorin, Syt1K326A-pHluorin, Syt1T328A-pHluorin, Syt1K331A-pHluorin and 
Syt1K326A+T328A+K331A-pHluorin. 
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All the five Syt1-pHluorin chimeras were properly targeted to presynaptic vesicles, as 
electrical stimulation with 200 action potentials (APs) at 10 Hz gave rise to a 
stimulation-dependent Syt1-pHluorin fluorescence increase at synaptic boutons. The 
pH dependence of the fluorescence was utilised to monitor the effect of mutating 
those three residues on syt1-pHluorin distribution within the presynaptic compartment 
of living neurons by using a simple acid quenching-dequenching protocol. As 
observed with SV2A-pH, acid quenching resulted in a near complete loss of 
fluorescence, whereas alkalinisation of the vesicular lumen with NH4Cl produced a 
maximum intensity signal at synaptic boutons, indicating that the transient 
fluorescence increase after stimulation was due to exocytotic externalisation of Syt1-
pHluorin.  
The kinetics of Syt1-pHluorin exo-endocytosis indicated that Syt1-pHluorin can serve 
as a faithful reporter of Syt1 recycling at presynaptic nerve terminals. This system 
then used to assess the effect mutating the three key residues, which abrogate Syt1’s 
interaction with SV2A in the C2B domain on Syt1 recycling in living neurons both at 
steady state and under stimulating conditions. 
A robust stimulation-dependent increase in Syt1-pHluorin fluorescence occurred in 
the hippocampal cultures, indicating that the reporters were efficiently delivered to 
the cell surface by SV exocytosis. Syt1WT-pHluorin fluorescence decayed back to 
baseline with first order kinetics (Figure 5.10). The three Syt1-pHluorin constructs 
harbouring single mutations yielded similar responses; the endocytic events remained 
largely unchanged with small differences in retrieval rate (i.e., relative speed of 
reinternalisation of Syt1-pHluorin molecules). However, retrieval of the Syt1-
pHluorin harbouring mutations in all three residues was significantly accelerated 
(Figure 5.10A), indicated by the increased speed of SV protein retrieval.  
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Figure 5.10. Mutation of SV2A binding site in the C2B domain of Syt1 accelerates SV retrieval. 
SV retrieval kinetics in WT neurons by recording Syt1-pHluorin fluorescence during and after field 
stimulation applied at 10 Hz for 20 s. (A) Syt1 K326A+T328A+K332A -pHluorin retrieval in WT neurons (red 
line, red bar) is faster than Syt1WT-pHluorin retrieval in WT neurons (blue line, blue bar) as post-
stimulation rate of fluorescence decay is higher. (B-D) Syt1K326A-pHluorin (green line, green bar), 
Syt1T328A-pHluorin (purple line, purple bar) and Syt1K331A-pHluorin (light blue line, light blue bar) all 
display very little difference in retrieval efficiency as compared to Syt1-pHluorinWT retrieval in WT 
neurons (blue line, blue bar). Data shown is mean ± SEM of nine independent experiments. 
 
5.6.3 Discussion 
 
The role of SV2A phosphorylation was studied via mutagenesis and optical imaging 
of pHluorin-tagged proteins in cultured neurons from wild-type mice. Surprisingly, 
these experiments revealed that phosphorylation is completely dispensable for the 
proper trafficking and retrieval of SV2A. However, the simultaneous mutation of the 
three residues in the C2B domain of Syt1 responsible for binding SV2A 
phosphocluster-2 increases the rate of SV endocytosis. This is the first direct 
functional evidence of a molecular role for phospho-dependent SV2A/Syt1 interaction 
in SV trafficking. 
 
A potential confounding factor in this interpretation is that the same three residues are 
responsible for binding inositol hexaphosphate (IP6) (Joung et al., 2012), an inhibitor 
of SV exocytosis. Furthermore, several proteins, such as clathrin adaptor protein-2 
(AP2) (Zhang et al., 1994), soluble NSF attachment protein (β-SNAP) (Schiavo et al., 
1995), SNAP-25, and N-type calcium channels (Schiavo et al., 1997), bind to 
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different sites in the C2B domain. The mutation of those three residues could 
arguably affect the ability of the C2B domain to bind any of those molecular 
effectors, which could lead to the accelerated endocytic rate observed. 
 
 
5.6.4 Synaptotagmin 1 promotes both vesicle fusion and recycling 
 
In an active nerve terminal, exocytosis and endocytosis proceed at a frenzied pace. 
Each action potential releases ≈0.5% of the total supply of synaptic vesicles in the 
terminal (Ryan and Smith, 1995), and, with some neurons firing at a rate of 50 Hz or 
greater, synapses would lose the ability to secrete neurotransmitter within seconds if 
they could not reform and refill synaptic vesicles. Endocytosis is the principal means, 
and perhaps the only means, by which the used vesicles are recovered and recycled 
into the releasable vesicle pool (Jarousse and Kelly, 2001). Moreover, the rate of 
endocytosis is tightly coupled to the rate of exocytosis. In a resting terminal, 
endocytosis rates are low, but activity can increase this rate enormously to preserve 
the balance of exocytosis and endocytosis and thereby preserve the sizes of the nerve 
terminal and vesicle pool. A temporally linked balance of exo- and endocytosis 
maintains the supply of synaptic vesicles in the nerve terminal. How the rate of 
endocytosis is regulated, however, remains obscure. 
Synaptotagmin 1 has been established as a significant contributor to exocytosis of 
synaptic vesicles (Sudhof and Rizo, 1996). However, Syt1 has an important role to 
play in promoting the efficient endocytosis of synaptic vesicles. This protein is thus of 
consequence to both sides of the vesicle cycle at nerve endings.  
Nicholson-Tomishima and Ryan (2004) have compared exocytotic and endocytic 
rates in cortical cultures from wild-type and Syt1 knockout mice using synaptobrevin-
pHluorin (a fusion protein of synaptobrevin tagged with pHluorin at its lumenally 
exposed C-terminus). For comparable levels of exocytosis, the synapses lacking 
synaptotagmin were substantially slower to recover their vesicles. 
This evidence that Syt1 is necessary for rapid endocytosis of synaptic vesicles fits 
nicely with another study, in which a different approach was taken to test the 
involvement of Syt1 in endocytosis at the fly neuromuscular junction (Poskanzer et 
al., 2003). In this study, synaptobrevin-pHluorin was also used as a reporter of 
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exocytosis and endocytosis. The authors found that the rate of endocytosis was slower 
when Syt1 was inactivated. The conclusions of both studies were quite parallel and 
support an evolutionarily conserved and direct role of Syt1 in accelerating 
endocytosis. 
These studies mesh well with earlier work. In particular, Syt1 has been shown to bind 
the clathrin–adaptor complex AP2 (Zhang et al., 1994). The binding of this complex 
is a mechanism by which domains of plasma membrane recruit clathrin and cargo 
proteins and thereby begin membrane invagination (Traub, 2003). The site of the 
interaction has been mapped to the C2B domain of Syt1, and this interaction can 
enhance the recruitment of both the AP2 complex and clathrin to liposomes (Haucke 
et al., 2000). The AP2 complex, however, also binds to inositol phospholipids on the 
membrane, and thus Syt1 was not expected to be a requisite step for AP2 recruitment 
to the membrane. Rather, Syt1 may assist in concentrating the clathrin apparatus at 
sites of recycling vesicles or may help AP2 to gather other synaptic vesicle proteins 
including SV2A. This model is consistent with the fact that endocytosis persisted in 
mice lacking Syt1 but was kinetically slower (Nicholson-Tomishima and Ryan, 
2004). 
Endocytosis of Syt1 is also regulated by the AP2µ related protein, stonin 2 (Diril et 
al., 2006), which selectively associates with Syt1 and no other SV proteins. Stonin 2 
is required for the complex formation between AP2 and Syt1. Kononenko et al. 
(2013) compared the SV retrieval kinetics in wild-type and stonin 2 knock-out 
neurons by recording Syt1-pHluorin fluorescence during and after field stimulation. 
SV retrieval was significantly faster in stonin 2 KO neurons (Kononenko et al., 2013), 
an observation that echoes the accelerated rate of endocytosis with the SV2A-binding 
defective Syt1. Since SV2A also influences the endocytosis of Syt1, stonin 2 and 
SV2A could be components of a unique common mechanism for Syt1 endocytosis or 
they could operate via different pathways; and that remains to be determined. 
The tight functional coupling between SV2A and Syt1 is a critical step in the SV 
cycle. SV2A impacts on the endocytosis of Syt1 because peptides corresponding to 
the endocytosis domain of SV2A increase the binding of Syt1 to AP2 clathrin 
adaptors (Haucke and De Camilli, 1999). Moreover, synaptic vesicles isolated from 
SV2A KO mice contain lower levels of Syt1 than wild-type mice (Yao et al., 2010). 
SV2A thus plays a major role in regulating the amount of the Syt1 protein in synaptic 
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vesicles. SV2A may help concentrate clathrin adaptors in a way that insures the 
inclusion of Syt1 in vesicles. 
The SV2A-Syt1 interaction may influence the modulation of one or both proteins' 
actions. The SV2A/Syt1 complex may assist in concentrating the clathrin apparatus at 
sites of recycling vesicles or may help AP2 to gather other synaptic vesicle proteins. 
Disruption of this interaction could cause the repartitioning of SV2A and Syt1 to the 
active zones of neuronal membranes, which may in turn induce compensatory AP-1-
mediated SV reformation from bulk endosomes to maintain the supply of synaptic 
vesicles. Increased bulk endocytosis and endosomal SV reformation may underlie the 
observed accelerated kinetics of SV protein retrieval, although other mechanisms, 
such as bypassing an otherwise rate-limiting step of the SV2A/Syt1 interaction, 
cannot be ruled out (Kononenko et al., 2013). 
SV2A is essential for normal neurotransmission. In its absence, synaptic release 
probability decreases, a result that leads to a severe seizure phenotype and premature 
death (Crowder et al., 1999, Janz et al., 1999). The functional lesion in synapses 
lacking SV2A occurs after vesicle docking (Custer et al., 2006) and before the 
formation of tightly-associated SNARE complexes (Xu and Bajjalieh, 2001), 
indicating that SV2A contributes to the process that renders vesicles competent for 
calcium-stimulated fusion.  In the absence of SV2A, Syt1 trafficking to synaptic 
vesicles becomes more random (Yao et al., 2010), leading to fewer vesicles with 
enough of the calcium sensor to trigger calcium-stimulated fusion. This could trigger 
compensatory endocytosis, which could produce the accelerated endocytic phenotype 
observed with the SV2A-binding defective Syt1. The role of SV2A and Syt1 in 
endocytosis can potentially explain the hyperexcitability and hypersynchrony that are 
the hallmarks of epileptic brain circuits observed in SV2A knockout mice. 
 
5.6.5 Conclusions 
 
By optical imaging of pHluorin-tagged SV2A in cultured neurons from wild-type 
mice, the phosphorylation of SV2A at cluster-1 and cluster-2 was found to play no 
measureable role in the normal trafficking and recycling of SV2A. Remarkably, 
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ablating the SV2A binding site in the C2B domain of Syt1 significantly enhances the 
rate of Syt1 endocytic retrieval. 
 
The C2B domain of Syt1 engages several different proteins including clathrin adaptor 
protein-2 (AP2) and mutations of those critical residues could arguably affect the 
ability of the C2B domain to bind any of these molecular effectors. This is a potential 
confounding factor in the interpretation of the data. Another caveat is that the 
trafficking of pHluorin-tagged SV2A and Syt1 were monitored in hippocampal 
neurons from wild-type mice and the wild-type proteins may be masking the effect of 
the exogenous proteins in those neurons. 
 
To control for off target effects of endogenous SV2A, small hairpin RNA (shRNA) 
that efficiently knocks down SV2A has been generated. shRNA-resistant SV2A 
constructs bearing alanine mutations at cluster-1 and cluster-2 have also been made. 
Repeat experiments involving the coexpression of the rescue constructs with SV2A-
shRNA are currently underway. Further insights in the role of SV2A phosphorylation 
and in the functional significance SV2A/Syt1 phosphospecific interaction can be 
garnered by monitoring the traffic of Syt1 in neurons expressing SV2A 
phosphomutants in SV2A-deficient neurons. 
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6 Conclusions and perspectives 
 
6.1  In vivo validation of SV2A as a physiological TTBK2 substrate 
 
In conclusion, the work I have presented in this thesis postulate the first lines of 
evidence that TTBK2 operates at a distinct step in the synaptic vesicle trafficking 
cycle. I have demonstrated by immunoprecipitation of the endogenous TTBK2 
protein from brain homogenates that it networks with a number of synaptic vesicle 
proteins including SV2A, which it potently phosphorylates in vitro. Subsequent 
phosphopeptide mapping revealed that SV2A is phosphorylated at two clusters of 
three highly-conserved residues by TTBK2.  
 
The complete characterisation of this novel kinase-substrate relationship requires one 
crucial piece of scientific evidence. The one remaining challenge is to establish 
conclusively that SV2A is a physiological TTBK2 substrate in vivo. To validate the 
phosphorylation of SV2A by TTBK2 in vivo at the relevant sites, a set of criteria has 
to be satisfied. This can be achieved by a number of experimental strategies including 
the demonstration that the phosphorylation of the endogenous substrate is reduced at 
the relevant site(s) in cells by treatment with specific pharmacological inhibitors of 
the kinase. Another potential way to validate the substrate in vivo is by showing that 
phosphorylation does not occur in cells and tissues of mice that do not express the 
kinase, or in cells from knock-in mice that express a catalytically inactive mutant of 
the kinase. All these strategies require the monitoring of the levels of phosphorylation 
at the relevant sites and thus phosphospecific antibodies are very valuable tools for 
the in vivo validation of the kinase-substrate relationship. 
 
The in vivo validation of SV2A phosphorylation by TTBK2 has thus far been 
logistically hindered by the lack of key reagents and tools. The generation of 
appropriate phospho-specific antibodies that are able to specifically recognize the two 
SV2A clusters of phosphorylation has proved to be difficult due to the close 
proximity of the phosphorylation sites. Moreover, as TTBK2 is not a well-studied 
kinase, specific inhibitors have not been developed yet. Finally, we have found that 
mice homozygous for the SCA11 mutation are embryonically lethal and so are 
complete TTBK2 gene knockouts.  
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Nevertheless, the validation may alternatively be accomplished by the depletion of the 
TTBK2 protein in neurons by RNAi (RNA interference) or shRNA (short-hairpin 
RNA). Due to the lack of sensitive phosphospecific antibodies, changes in 
phosphorylation levels may be monitored by mass spectrometry. It is also noteworthy 
that as synaptic vesicle traffic is a process only occurs in neurons, it will be 
imperative that the validation is performed in primary neuronal cultures. 
 
 
6.2  Investigation of brain developmental defects in SCA11 homozygous 
mouse embryos 
 
As data was gathered on TTBK2 over the course of the project, a number of key 
questions were raised. One such important question to be tackled is the mechanism 
causing developmental defects and embryonic lethality in the homozygous SCA11 
knockin mice. Homozygous E10-TTBK2fmly1/fmly1 embryos were developmentally 
delayed, lacking prominent subdivisions of the developing brain, and were smaller 
than wild-type littermates. Early embryonic lethality caused by genetic mutations 
have led to great insights into the genetic control of fundamental biological processes, 
including cell division, cell death, cell fate, differentiation, and morphogenesis. Thus, 
the discovery of an early embryonic lethal phenotype is an exciting opportunity for 
novel insights into the genetic control of biological processes with important 
implications for our understanding of fundamental mechanisms of neurogenesis in 
embryonic development. 
 
An analysis of the mutant phenotype requires specialised embryological and 
analytical tools. The normal patterns of the wild-type and mutant TTBK2 gene in 
wild-type, heterozygous and homozygous mouse embryos will provide clues in the 
analysis of the lethal phenotype by pinpointing the tissue in which the mutation is 
likely to have its primary effect. TTBK2 expression patterns can be established by in 
situ hybridisation for mRNA or immunohistochemistry for the protein. Abnormal 
embryos can be assessed in comparison with their control littermates, which allow the 
comparison of differences in the developmental timing within and between litters. 
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Morphological assessment of embryos during the post-implantation period can be 
insightful and can be accomplished by dissection or by fixation and sectioning of 
embryos within the uterus. Following dissection, embryonic and placental samples 
can be fixed for further analysis either as whole mounts or sections for cell death and 
proliferation assays, gene or protein expression, or evaluation of detailed 
morphological and histological features. In parallel, signs of cerebellar atrophy and 
Purkinje cell loss can be studied in the heterozygous mice by staining and 
quantification of cerebellar sections using high-resolution microscopy. 
 
 
 
6.3  Selective vulnerability of Purkinje cells in Spinocerebellar Ataxia 
 
The most intriguing aspect of the pathogenesis of SCA11 is that although TTBK2 is 
widely expressed in the central nervous system and various other tissues, the 
pathology is confined mainly to the cerebellar Purkinje cells. It would certainly be 
worthwhile to examine the molecular basis of this selective vulnerability of the 
Purkinje cells of the cerebellum.  
 
The issue of selective neuronal vulnerability is likely to be complex and influenced by 
a multitude of factors. I propose that among such contributing factors are the relative 
expression levels of TTBK2 in different neuronal cell populations. It is known that 
the levels of TTBK2 expression is higher in the cerebellar Purkinje cells than other 
neuronal cell populations. Therefore, if Purkinje cells express higher levels of TTBK2 
as other neurons, this could put them at increased risk for degeneration when the 
protein is mutated. Along the same lines, the levels of TTBK2’s interacting partners 
are likely contributors to the cell-specific vulnerabilities. For example, if SV2A or 
synaptotagmin 1 levels are slightly higher in vulnerable neurons, the toxic gain-of-
function effects of the TTBK2 mutant protein would be more pronounced in such 
neurons.  
 
There is also exploratory evidence that the SCA11 mutations markedly inhibit 
endogenous kinase activity. The aberrant phosphorylation of SV2A could potentially 
be a probable contributor to the progressive demise of Purkinje neurons. Because 
SV2A’s interactions with synaptotagmin1 and clathrin adaptor proteins are modulated 
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by phosphorylation, one possible mechanism of neurotoxicity is that anomalous 
phosphorylation SV2A may lead to alterations in those interactions that, in turn, 
impact on protein trafficking and/or endocytic reinternalisation, which may lead to the 
accumulation of inactive (unfolded) protein intermediates that may render synaptic 
terminals vulnerable to activity-dependent degeneration. Research must therefore be 
focused on investigating these hypothetical scenarios, as they are likely to provide 
insights into the fundamental neurodegenerative process in SCA11. 
 
6.4  New insights provided by the crystal structure of the C2B domain of Syt1 
and the cluster-2 phosphopeptide 
 
Since I completed my thesis work, the crystal structure of the C2B domain of 
synaptotagmin 1 complexed with the triply-phosphorylated cluster-2 peptide has been 
solved by Dr. Maximilian Fritsch (postdoc in the lab). The crystal structure has 
refined the binding interface between the two proteins and has exposed that Thr84 
residue of SV2A is the critical determinant of the interaction and the two residues 
mediating this interaction in the C2B domain are Lys326 and Lys328 (not Lys327 as 
originally predicted from the C2B-IP6 structure). Therefore, the key residues to target 
in the functional dissection of the SV2A/Syt1 interaction are Lys326 and Lys328. 
Planned pHluorin imaging experiments and SV2A shRNA rescue experiments (in 
collaboration with Prof. Mike Cousin’s lab) have been adjusted in the light of this 
relevant information.  
 
6.5  The mechanism of action of Levetiracetam 
 
Finally, Levetiracetam’s mechanism of action remains unknown. It is conceivable that 
one possible mechanism of Levetiracetam (LEV) action is that it modulates SV2A’s 
function by altering its phosphorylation by TTBK2, which in turn impacts on SV2A 
protein interactions. A direct implication of my findings would be to investigate the 
effect of LEV on SV2A phosphorylation by TTBK2 in vivo.  From the findings 
presented in this thesis, a model now exists that can be used to design experiments to 
test these hypotheses. Elucidating the mechanism by which LEV, SV2A and TTBK2 
cooperate to prevent seizures will undoubtedly open doors to the investigation of 
potential novel target proteins involved in the synaptic vesicle cycle. 
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